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A series of chelating, bidentate (C,N-) monomeric and dendritic ligands based on a 
poly(propyleneimine) dendritic scaffold were synthesized via a Schiff-base condensation 
reaction of the relevant amine and either naphthaldehyde or benzaldehyde. These reactions 
yielded air- and moisture-stable solids or oils. These compounds were isolated in good yields 
and characterized using standard spectroscopic and analytical techniques.  
 
The monomeric and dendritic ligands were reacted via a bridge-splitting reaction with the 
dimeric metal precursors, either [Ru(p-cymene)Cl2]2, [Rh(η5-C5Me5)Cl2]2  or [Ir(η5-
C5Me5)Cl2]2, generating a series of new mono- and polynuclear ruthenium(II), rhodium(III) 
and iridium(III) cyclometalated complexes. The naphthaldimine complexes were isolated as 
air- and moisture-stable solids, while the benzaldimine complexes were slightly hygroscopic 
and decomposed in solution over time. All the complexes were obtained in poor to good 
yields, and were fully characterized using 1H-, 13C-NMR and IR spectroscopies, as well as 
elemental analysis and mass spectrometry. The molecular structures of selected neutral 
mononuclear complexes were determined using single crystal X-ray crystallography. 
Selected transition metal complexes, based only on the naphthaldimine ligand, underwent 
reactivity studies with PTA to afford a series of cationic chelating bidentate (C,N-) 
complexes. These complexes were also isolated as air- and moisture-stable solids, in poor to 
good yields, and were fully characterized using 1H-, 13C-, 31P{1H}-NMR and IR 
spectroscopies, as well as elemental analysis and mass spectrometry. Further to this, a series 
of chelating bidentate (C,N-) cationic heterometallic rhodium(III) and iridium(III) complexes 
were synthesized based on the monomeric and dendritic naphthaldimine ligands, through the 
incorporation of a ferrocenyl-pyridine moiety. The desired complexes were obtained as air- 
and moisture-stable solids, in poor to moderate yields. These complexes were fully 
characterized using a series of spectroscopic and analytical techniques. 
 
The cytotoxicities of the mononuclear and dendritic ruthenium(II), rhodium(III) and 
iridium(III) complexes were evaluated against the cisplatin-sensitive (A2780) and cisplatin- 
resistant (A2780cisR) human ovarian cancer cells, as well as the non-cancerous human 




embryonic kidney (HEK) and KMST-6 cell line. The higher-generation metallodendrimers 
showed superior biological activity over the mononuclear analogues. The cationic complexes 
also showed increased activity over the neutral complexes, as well as the metallodendrimers 
showing the best activity, versus the mononuclear analogues. The cationic octanuclear 
ruthenium(II) and rhodium(III) metallodendrimers were found to be the most active, with 
IC50 values in the low micromolar range. These in vitro studies show a clear correlation 
between the size of the metallodendrimer and cytotoxicity, as well as between the charge on 
the complex and cytotoxicity. 
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Chapter 1: A Review of Ruthenium(II), Rhodium(III) and Iridium(III) Organometallic 
Complexes and their Anti-Cancer Properties 
1. Introduction 
1.1 Cancer and chemotherapy 
According to the WHO, there are more than 6 million deaths each year attributed to cancer.1 
Cancer is a disease known to affect any part of the human body due to the formation and 
accumulation of abnormal cells.1 The ability of these cells to invade and spread throughout 
the body is known as metastasis and is the leading cause of death from cancer.1 
Chemotherapy, radiation therapy, and immunotherapy2 are a few therapies that have been 
developed for the treatment and regulation of cancer, although there are many harsh side-
effects that are associated with these therapies.3 
Chemotherapy is not very selective to cancer cells as the chemotherapeutic drugs cannot 
always distinguish between cancerous and healthy cells, which cause undesirable side effects 
and systemic toxicity.4 For instance its mode of action is to kill cells that divide rapidly, 
which is characteristic of cancer cells, whereas certain healthy cells also divide rapidly, for 
example, cells in the bone marrow.3 Hence healthy cells can also be damaged in the process.  
Therefore these therapies require excessive doses which will cause side effects that are 
intolerable for the human body and causes more damage than the cancer itself.4 Organic 
compounds have been and are widely used in the pharmaceutical world, but there has been 
motivation for the development of metal-based drugs and drug delivery vehicles as potential 
anticancer treatments.5 A metal-based drug, cisplatin ((cis-diamminedichloro-platinum(II)) 
was discovered by Rosenberg6-8 in the 1960s for its use in anti-cancer treatment.6 
 
1.2 Clinical success of platinum-based drugs 
The most common metal-based drug that has been used for the past 30 years is cisplatin.9,10 
cisplatin, amongst other platinum-based drugs derived from cisplatin, have been used for the 
treatment of ovarian, testicular and other cancers.9 Besides cisplatin, carboplatin and 
oxaliplatin are platinum-based complexes that have also received global attention (Figure 
1.1).9, 10  








Figure 1.1: Three platinum-based anticancer drugs.9 
Carboplatin and oxaliplatin were designed based on cisplatin, with modifications that 
attempted to eliminate the side effects associated with cisplatin. As can be seen in Figure 1.1, 
the chloride ligands have been replaced by less labile ligands. This is because the toxicity of 
platinum-based drugs is related to the ease with which the leaving groups (chloride and 
ammonia) are aquated, i.e. the ease with which these groups are replaced with a water 
molecule once the molecule enters the cell.9 The slower the ligands are aquated, the less toxic 
the platinum-based drug, hence the presence of the less labile ligands on carboplatin and 
oxaliplatin. 
One of the targets of cisplatin is supposed to be DNA. It is suspected that cisplatin targets and 
binds cellular DNA once aquated, whereby it interferes with DNA replication and 
transcription, and to some degree interferes with RNA processing, therefore the cancerous 
cells cannot replicate and apoptosis occurs.9,10 
Besides the notable success of these platinum-based drugs, particularly cisplatin, as anti-
cancer drugs, they have their limitations.9 These include non-specific targeting of unhealthy 
as well as non-cancerous cells, dose-limiting side effects and drug resistance.9  
A series of platinum(IV) drugs have demonstrated increased stability and lipophilicity in 
vitro, versus their platinum(II) counterparts.10, 11 However, in vivo studies demonstrated the 
opposite effect. The platinum(IV) complexes showed little to no activity and hence these 
molecules have not advanced to clinical trials.10, 11 In the case of in vitro studies, the cells in 
monolayer cultures tend to be exposed to uniform conditions which is not analogous to the 
tumour microenvironment, whereas in vivo, the cells are exposed to a large concentration 
gradient as the drug diffuses from the blood vessels.10  
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1.3 Platinum-like drug candidates (Ruthenium, rhodium and iridium-based drug 
candidates) 
1.3.1 Ruthenium-based drug candidates 
In light of the issues associated with platinum-based drugs, ruthenium-based drugs have 
received considerable attention due to their variety of available oxidation states,12 similar 
ligand exchange abilities,12 better selective cytotoxicity toward cancer cells allowing them to 
overcome cisplatin resistance12-14 and their high affinity towards proteins making it easier for 








Figure 1.2: Structure of KP1019 and NAMI-A.14 
Two mononuclear ruthenium complexes have completed phase I clinical trials and are 
undergoing phase II trials, namely Indazolium trans-[tetrachlorobis(1H-
indazole)ruthenate(III)] (KP1019) and New Anti-tumour Metastasis Inhibitor-A (NAMI-A) 
(Figure 1.2).17 Their potential anticancer activity can be accredited to the affinity of Ru(III) 
for proteins which can selectively enter cancerous tissue.18 NAMI-A is not very toxic to 
cancer cells but it does show promising anti-metastatic activity.19 
Ruthenium complexes are able to mimic the behaviour of iron under physiological 
conditions, making them more susceptible to be taken up by cancer cells via endocytosis by 
means of attaching themselves to albumin or transferrin.12, 18, 20  The ability of ruthenium 
complexes to target cancer cells versus non-cancerous cells could be due to the fact that 
cancer cells have a high iron requirement and therefore express a large number of transferrin 
receptors on the cell surface. Therefore it has been proposed that there is cellular 
accumulation of ruthenium(III) in cancerous cells.12, 18, 20 Once the ruthenium anti-cancer 
Chapter 1  Literature Review 
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agent has entered the cell, it has been proposed that the pH and redox potential within the cell 
can act as drug release triggers.4 The speculated mode of action of ruthenium-based 
molecules is their ability to damage DNA and to some extent inhibit enzyme action.9,10,21,22 
The mononuclear complexes, NAMI-A and KP1019 (Figure 1.2), undergo in vivo reduction 
from ruthenium(III) to ruthenium(II) which is the suggested active species, as it is expected 
to bind and interfere with DNA. Therefore the ruthenium metal centre can be stabilized in the 
+2 oxidation state with coordinated arene ligands through pi-bonding.13, 18, 23 
 
Figure 1.3: General structure of Sadler et al.24 ruthenium(II)-arene complexes with promise 
for clinical trials.  
Since the discovery of the proposed metal active species, there has been a shift in focus 
towards ruthenium(II)-arene type complexes.20 Cationic complexes of the type [η-
(arene)RuCl(en)]PF6 (Figure 1.3)20, 24 have shown in vitro and in vivo anticancer activity 
against many cell lines, more specifically against secondary metastatic tumours.15, 24, 25 The 
arene-ring not only provides stabilization of the ruthenium in the +2 oxidation state but also 
provides a lipophilic face which can enhance molecular recognition and transport the 
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Dyson et al.25 synthesized and studied the anti-cancer activity of half-sandwich ruthenium-
(II)-arene-PTA (RAPTA) complexes (Figure 1.4a) which exhibited dose-dependent in vivo 
activity against secondary metastatic tumours.25 The success of these RAPTA-type 
compounds has been proposed to be because of their increased water solubility25 as well as 
demonstrating pH-dependent activity.22, 25 In an acidic environment, analogous to hypoxic 
cancerous cells, the nitrogen atom on the PTA ligand is protonated to the proposed active 
species and there is evidence of DNA damage.27, 28 At a pH similar to that of healthy cells, 
pH above 7, there is little to no DNA damage therefore making these compounds more 
selective towards cancer cells versus non-cancerous cells.22, 25, 27, 28  
Other ruthenium-(II)-arene complexes, that contain different functional groups, such as 
ethylenediamine in [(ƞ6-biphenyl)Ru(en)Cl][PF6] (Figure 1.4b), have shown IC50 values as 
low as carboplatin, when tested against the human ovarian cancer cell line A2780.26 
 
1.3.2 Rhodium-based drug candidates 
Metal-based chemotherapeutics containing rhodium(III) and iridium(III) have also sparked 
interest in the field of anticancer therapy.15 They possess similar properties to ruthenium 
where rhodium(III) complexes are isoelectronic to ruthenium(II).20, 29 Their reactivity can be 
adjusted from kinetically labile to inert, but recently it has been proposed that their activity is 
due to their kinetic inertness.20, 29 These rhodium and iridium complexes are also readily 
available and show high water solubility.30 
As previously mentioned rhodium(III) and ruthenium(II) are isoelectronic and therefore are 
worth looking at as potential anticancer agents. In one study, rhodium and ruthenium 
complexes were tested against the ovarian cancer cell line, A2780 and cisplatin-resistant 
A2780cisR.8, 14 The cluster complex [Rh3(µ3-S)2(ƞ5-C5Me5)3]2+ exhibited cytotoxicity similar 
to that of the ruthenium analogue, [Ru3(CO)9(PTA)3] indicating that rhodium(III) complexes 
can be considered for potential anticancer drugs.8, 14  
With the success of incorporating 1,3,5-triaza-7-phosphaadamantane (PTA) into 
ruthenium(II) mononuclear complexes, a group of rhodium(III)-arene complexes, [Rh(ƞ5-
C5Me5)(PTA)Cl2], showed similar cytotoxicities to the ruthenium analogue, against the HT29 
colon cancer cell line (Figure 1.5).15 








Figure 1.5: Rhodium(III) arene-PTA complex showing similar cytotoxicity’s to the 
ruthenium(II) analogues.15 
In this study, the focus is on bidentate-cyclometalated complexes. Meggers and co-workers 
developed a rhodium(III)-based bidentate cyclometalated complex to target protein kinase-C 
(PKC) active sites.31 PKC is important for the regulation of a variety of cellular functions. 
Therefore if the complex inhibits the activity of the enzymes, apoptosis may occur.32  
Complexes can be designed for a particular target and in this case a phenylquinoline motif 
was incorporated with the intention for these complexes (Figure 1.6) to be able to form 
hydrogen bonds with the ATP-binding site.31 This is ideal as protein kinases are responsible 
for dephosphorylating the ATP group and transferring it to other substrates for important 
metabolic pathways. This process will be inhibited by these complexes and apoptosis of 
cancerous cells may occur.31 The results showed that in the complex where R=H, an IC50 
value of 30 μM was obtained.31 
 
Figure 1.6: Rhodium(III) complexes as PKC inhibitors (where R = benzyl or H).31, 33  
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In a similar study, the intended target was the Janus kinase and signal transducers and 
activators of transcription (JAK-STAT) pathway, which is directly linked to the regulation 
and signalling of cell proliferation and apoptosis.34 Enzyme and cellular assays were 
performed using two charged cyclometalated rhodium(III) complexes (Figure 1.7) and each 







Figure 1.7: Rhodium(III) complexes as JAK-STAT pathway inhibitors.33, 35  
A rhodium(III) C,N-chelating mononuclear complex was synthesized and its anticancer 
activity was evaluated. These complexes showed good stability due to the 
pentamethylcyclopentadienyl (Cp*) ring and showed activity similar to that of cisplatin.20, 36  
This evidence demonstrates that rhodium(III) complexes have the potential to act as anti-
cancer agents, focussing on targeted pathways different to that of cisplatin. 
 
1.3.3 Iridium-based drug candidates 
As discussed above, targeting a variety of kinases important for pathways within the cell is 
vital in the design of potential anti-cancer complexes.31 VEGFR3 or FLT4 is a Fms-related 
tyrosine kinase 4 that plays a role in maintaining lymphatic vessels.37 Meggers and co-
workers designed and synthesized a series of iridium(III) pyridocarbazole complexes 
containing a 1,5-cyclooctadiene ligand and these complexes showed tyrosine kinase 
inhibition.38 All the complexes showed good activity with the iridium(III) complex in Figure 
1.8 showing the best activity with an IC50 value in the nanomolar range. This complex also 
did not show the toxicity associated with other metallodrugs.33, 38 









Figure 1.8: Iridium(III) pyridocarbazole complex showing tyrosine kinase inhibition.33, 35, 38  
In another study, a cationic cyclometalated iridium complex was studied as a potential 
tumour necrosis factor-α (TNF-α) inhibitor.39 TNF-α is a cytokine that regulates cell 
processes such as cell apoptosis and survival.40 In vitro results confirmed that the iridium 
complex (Figure 1.9) interferes with TNF-α binding in the TNF-α binding pocket, which is 
necessary for it to perform its functions.33 The authors proposed via molecular modelling 
analysis, that the complex coordinates to the binding pocket of the TNF-α dimer therefore 
preventing TNF-α from binding.33 Further studies confirmed that the inhibition was 
dependent on the iridium metal centre and its affinity for the binding pocket, making this 
complex a specific inhibitor of TNF-α.33 
 
Figure 1.9: Ir(III) complex as an inhibitor of the TNF-α cytokine.33, 35, 38, 39 
Sadler et al. synthesized a series of mononuclear iridium complexes and their cytotoxicity 
against the A2780 ovarian cancer cell line was examined.41 Three complexes with the general 
formula [Ir(ƞ5-C5Me5)(C^N)Cl] (Figure 1.10) exhibited IC50 values similar to that of 
cisplatin.41, 42 One iridium complex with the extended Cp* moiety exhibited an IC50 value of 
0.70±0.04 µM, which is lower than cisplatin.41, 42 There has been evidence that there is a 
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direct correlation between the cytotoxicity and the size of the ligands attached to the metal 
centre.22 It is proposed that the larger ligands are able to intercalate into DNA therefore 
disrupting the DNA structure.41 It was also proposed that the replacement of the N,N-
chelating ligand with the C,N-chelating ligand switches on biological activity.20, 42 Therefore 
there is promising evidence that iridium complexes can be used in biological applications, 
such as anticancer treatment.41, 42 
 
Figure 1.10: Iridium complexes showing in vitro activity against the A2780 human ovarian 
cancer cell line (cisplatin IC50 - 1.19±0.12 µM).41 
There is sufficient evidence that molecules that contain ruthenium, rhodium and iridium have 
shown in vitro and to some extent in vivo cytotoxicity against a variety of cancer cell   
lines.20, 33 There have been recent reviews on rhodium and iridium specifically.33,35 It is also 
speculated that these metal-complexes affect and bind DNA, RNA and other proteins in a 
different and improved mechanism in comparison to platinum-based drugs.22,41 However the 
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incorporation of multiple metal atoms has only been briefly looked into and so there is space 
for investigations into such complexes. The aim of this project is to incorporate all three 
transition metals in macromolecules such as dendrimers, as these molecules have the 
advantage of being morphologically similar to biological macromolecules, and therefore can 
be taken up into the human body relatively effortlessly. 
 
1.4 Multinuclear metal-based drug candidates for clinical applications 
1.4.1 Platinum-based drug candidates 
After the success of cisplatin, it was suggested that increasing the number of metal centres 
may increase the biological activity of the platinum complexes. 
 
Figure 1.11: Trinuclear cationic platinum(II) compound, BBR3464.44  
Synthesis of multinuclear complexes was initiated by Farrell et al.44 who synthesized the 
platinum complex BBR3464 ([μ-trans-Pt(NH3)2{trans-PtCl(NH3)2{NH2(CH2)6-
NH2}}2][NO3]) (Figure 1.11) which is a trinuclear complex that entered phase I clinical trials 
and the results showed that its in vitro activity was greater than that of cisplatin as well as 
showing a different mechanism of action by overcoming cisplatin-resistant mechanisms.43, 44 
From these results it has been established that multinuclear complexes show improved anti-
cancer activity versus the mononuclear analogues.44 
Platinum-based drugs have proven that the incorporation of metal centres into potential anti-
cancer drugs has a desirable effect. Unfortunately, platinum-based drugs have developed a 
variety of limitations such as toxic side effects and acquired resistance, hence the shift in 
focus away from platinum-based drugs towards other transition metal-based drugs.9, 17  
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1.4.2 Palladium-based drug candidates 
From what has been discussed so far, incorporating metals from the PGM series other than 
platinum has led to an increase in anti-cancer activity as well as potentially overcoming 
resistance. Palladium(II) is structurally and thermodynamically similar to platinum(II) 
therefore the incorporation of palladium(II) has been investigated.20 A series of dimeric 
palladium(II) complexes (Figure 1.12) showed promising antitumor activity by inhibiting 
cathepsin B which is an enzyme that is expressed in cancer cells, showing both in vitro and in 











Figure 1.12: Examples of C,N-palladium(II) complexes.20  
1.4.3 Osmium-based drug candidates 
Another such example is osmium, which has been incorporated into metalla-rectangles as 
potential multinuclear anti-cancer agents.46  One tetranuclear complex (Figure 1.13a) showed 
an IC50 value of 5.4 ± 0.6 μM, which was comparable with a series of ruthenium analogues 
(Figure 1.13b).46, 47 Osmium complexes tend to be less cytotoxic than ruthenium complexes 
and therefore there has been more focus on ruthenium complexes.46 




Figure 1.13: Multinuclear osmium and ruthenium metalla-rectangle (X = H) showing the 
highest in vitro activity.46  
1.4.4 Ruthenium-based drug candidates 
A series of multinuclear ruthenium analogues of the above mentioned compounds (Figure 
1.13b) were also synthesized and showed even more promising in vitro activity.47 These 
complexes showed a smaller range of IC50 values, from 6-50 μM whereas the osmium 
complexes showed a larger range from 5-223 μM.47 
Dinuclear complexes have also been investigated for their biological properties. A series of 
ruthenium dinuclear complexes (Figure 1.14) were synthesized based on the mononuclear 








Figure 1.14: Two dinuclear ruthenium(III) complexes showing similar activity to NAMI-A 
(where X=Na and L=bipy (4-4’-bipyridine) and pyz (pyrazine)).48  
Similarly to NAMI-A, the complexes in vitro activity was not promising even with an 
increase in the number of ruthenium atoms, although there was a correlation between the 
modification of the cell cycle with an increase in concentration of ruthenium uptake in 
tumour cells.48 They were therefore able to conclude that these two dinuclear complexes 
(Figure 1.14) were able to modify the cell cycle and behave similarly to that of NAMI-A, 
which is able to inhibit the growth of new metastases as well as the growth of already 
established metastases.49 
Dinuclear complexes have also been designed and synthesized with the purpose to target 
different pathways to that of cisplatin.50 A di-ruthenium(II) triple-stranded helicate was 
obtained based on a bis(pyridylimine) ligand with a hexafluorophosphate counterion and 
exhibited IC50 values better than ruthenium(III) complexes (Figure 1.15). The complexes 
were tested against two breast cancer cell lines (HBL100 and T47D) and exhibited IC50 
values of 22 and 53 μM, respectively, versus 4.9 and 28 μM for cisplatin, respectively. They 
also demonstrated that the helicate is able to bind and coil DNA.50 





Figure 1.15: X-ray crystal structure of a di-ruthenium(II) triple stranded helicate.50  
Increasing the number of metal atoms incorporated into an organic framework can potentially 
increase its anticancer and biological properties. These dinuclear complexes didn’t show 
activity as high as that of the tetranuclear complexes but ruthenium has shown great potential 
when incorporated into potential anti-cancer agents. 
 
1.5 Ferrocene-based anticancer drugs 
Since the discovery of platinum-based anticancer drugs there has also been an increasing 
interest in ferrocene-based complexes to be used as potential anti-cancer drugs.51 It is 
understood that the oxidised analogue of ferrocene, the ferrocenium ion (Figure 1.16), acts as 
the antitumor agent as it is proposed that this oxidised analogue generates active radicals 
which in turn form radical metabolites which are responsible for the damage in cancer 
cells.51,52 
 
 Figure 1.16: Active ferrocenium ion.53 
In addition to this, the ferrocenyl moiety contains two cyclopentadienyl rings in a sandwiched 
arrangement, which prevents the iron from forming further bonds with any nearby 
molecules.54 The oxidised ferrocenium ion seems to be more active than the ferrocene 
molecule. This could be due to solubility issues, but it has also been proposed that the 
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ferrocene is oxidised to the ferrocenium ion in vivo so the solubility of ferrocene may not be a 







Figure 1.17: Ferrocene derivatives of known anticancer drugs (a) tamoxifen and (b) 
cisplatin, respectively.51, 52 
Ferrocifen (Figure 1.17a) is a ferrocenyl derivative of tamoxifen (TAM), and has entered 
clinical trials and other related ferrocenyl derivatives are in clinical trials for malaria.52 
Ferrocene has also been incorporated in another well-known anti-cancer drug, cisplatin, in an 
attempt to develop dual action drugs (Figure 1.17b).36,52,40  
TAM (Figure 1.18) is an anti-oestrogen drug that has been used in the treatment of breast 
cancer.52 Its proposed mechanism of action is to inhibit the progression of tumours rather 
than eliminating them all together. This action is aided by the hydroxyl group which 
enhances recognition of the oestadiol receptor, which is an oestrogen receptor.52 This gives 
the potential drug more than one functionality which can be involved in the anticancer 
activity, which decreases the chances of developed resistance and increases the activity of the 
molecule.52 However in the case where it was coupled to cisplatin, it was found to be only 
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In conjunction with this particular study, there is evidence that organometallic tamoxifen 
derivatives have been prepared that show considerable promise, of which the ferrocenyl 
derivatives are ready for entry into clinical trials therefore evidence that the incorporation of a 
ferrocene derivative can enhance the anticancer activity.16 
 
1.6 Dendrimers in biology 
Dendrimers are a group of macromolecules that are well-defined, highly branched, three-
dimensional, globular polymers that consist of a central core with side chains that branch 
from it (Figure 1.19).55-57 The periphery of the dendrimer can be comprised of different 
functional groups, which plays an important role in determining the physical properties of 
dendrimers, such as those that make dendrimers better drug delivery agents.55-57  
 
Figure 1.19: General structure of dendrimers. 
Dendrimers possess properties such as high polyvalency, which means that a variety of 
targeting moieties, solubilising elements or drug molecules can be covalently attached to the 
periphery of the macromolecule to improve the performance of the drug carrier.58  
 
1.6.1 Synthesis of dendrimers - the convergent and divergent synthetic routes 
There are two main approaches to the synthesis of dendrimers. The first approach involves 
the initiation of synthesis at the core of the molecule and then progresses outwards, which is 
known as the divergent approach and was established by Tomalia et al.59 While Frechét et 
Chapter 1  Literature Review 
17 
 
al.60 introduced the convergent approach where synthesis starts off at the periphery of the 
molecule and progresses inward via a step addition of branching molecules which are finally 
attached to a central core (Figure 1.20). 
 
Figure 1.20: Two synthetic routes for dendritic macromolecules, (a) the divergent method 
and (b) the convergent method.61 
Both synthetic routes have their advantages and disadvantages, but they complement each 
other in that the convergent approach has advantages at lower molecular weights while the 
divergent approach has advantages in its ability to reach much higher molecular weights.62 
Both synthetic routes are used in the production of three main dendritic scaffolds, the 
poly(amido amine) (PAMAM), poly(propylenimine) (PPI) and poly(aryl ether) dendritic 
scaffolds. 
1.6.2 Dendritic Scaffolds 
1.6.2.1 PAMAM 
PAMAM dendrimers consist of polyamide branches stemming from a central amine or 
diaminoalkane (diaminobutane) core (Figure 1.21).63 They are synthesized via the divergent 
approach, irrelative of the fact that for higher generation dendrimers complete 
functionalization of the surface groups is difficult using this synthetic approach.60,61 Synthesis 
(a) 
(b) 
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of these dendritic scaffolds involves repeating steps of double Michael addition of methyl 
acrylate to the terminal primary amines of the dendritic core followed by aminolysis of the 
terminal esters with ethylenediamine.61  
 
Figure 1.21: Schematic of a PAMAM dendritic scaffold.64 
Tomalia et al.59, 65 first synthesised these PAMAM dendrimers and they  are the most widely 
used dendrimers for biological applications, i.e. as drug delivery vehicles.64 This is due to 
properties such as good water solubility, low immunogenicity and their ability to mimic the 
properties of mammalian globular proteins.64 In one particular study, PAMAM dendrimers 
did not elicit immune responses and exhibited low toxicity, especially when the periphery 
contained anionic or neutral groups, such as carboxylic or hydroxylic moieties.62 
One limitation to PAMAM dendrimers is that molecules based on carbonyl-containing 
connecting groups are susceptible to reaction conditions such as reduction, hydrolysis and 
nucleophilic attack.  
1.6.2.2 PPI  
The first dendrimer, polypropyleneimine (PPI), was synthesized by Vögtle et al.66 and is 
based on a diaminobutane (DAB) core, or any other primary or secondary amine core, with 
alkane branches that consist of amino groups as termini (Figure 1.22).67 Synthesis of PPI 
dendrimers requires repeating steps of double Michael addition of acrylonitrile to the 
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dendritic core via the divergent synthetic approach and then followed by the hydrogenation of 
the nitriles.67,68 
 
Figure 1.22: Figure of a PPI dendritic scaffold. 
The PPI dendritic scaffold has been chosen for this study due to various reasons. For 
example, PPI dendrimers exhibit better general solubility compared to similar linear 
analogues.57 This is advantageous as it can solubilise otherwise hydrophobic, non-soluble, 
anti-cancer drugs or moieties attached to the anti-cancer molecule.68 The amine terminated 
surface of PPI dendrimers allows for the periphery to be easily modified in order to develop 
molecules that are ideal for cancer diagnosis and therapy.64, 68 For example, the dendrimer 
can be functionalized with specific moieties to enhance access in physiological conditions.64 
This dendritic scaffold has also shown to be highly flexible with a homogenous density 
distribution.69 These polyamines are therefore desirable as potential anticancer molecule 
scaffolds, especially since similar amine terminated molecules, such as spermidine found in 
ribosomes, are present within living cells. Therefore these macromolecules can be recognized 
by the cell without being rejected as foreign agents.   
1.6.3 Properties of dendrimers 
In order to develop dendrimers for biomedical applications, there are certain key aspects that 
need to be considered.  
1.6.3.1 Charge and size 
In one study, the retention time of the PAMAM dendrimers within the human body was 
evaluated. The cationic PAMAM dendrimers (amine terminated) were expelled quickly from 
circulation, meanwhile a prolonged circulation time was observed with their anionic 
counterparts (carboxylic acid terminated) (Figure 1.23).70 This indicates that the charge on 
the dendrimers can affect the solubility and stability of dendrimers as potential anticancer 
drugs or drug delivery vehicles.71 The anionic PAMAM dendrimers also showed clearance 
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rates that decreased with increasing size, hence the size also influences drug delivery 
efficacy.70 
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1.6.3.2 Functional groups 
In the preparation of dendrimers, a suitable design of the ligand or end-group functionality 
has to be taken into consideration as it can determine properties such as water solubility and 
whether metal coordination is possible.71 In this study, Schiff base ligands (Figure 1.24) with 
nitrogen and carbon donor atoms will be acting as end-group functionalities. This is due to 
their ability to readily form mono- or bidentate complexes with transition metals and exhibit 
interesting chemical and biological properties.72 For example, the presence of the C,N-
chelation has shown to induce strong nucleobase binding and high hydrophobicity.72 
N
R
H R'  
Figure 1.24: Schematic diagram of a Schiff base ligand. 
1.6.3.3 EPR effect 
Besides the fact that certain macromolecules and metal-based macromolecules can be taken 
up via endocytosis,73-75 nanosized molecules are also able to exploit the Enhanced 
Permeability and Retention (EPR) effect (Figure 1.25).57, 73, 76, 77 This effect is attributed to 
the fact that the blood vessels in tumours are irregular in shape, dilated, leaky and therefore 
more permeable.20,77 The increased permeability of tumour cells allows larger molecules to 
enter the cancerous cells more effortlessly compared to non-cancerous cells, making them 
more selective.73 The enhanced permeability can therefore be exploited by macromolecular 
drug delivery vehicles. The EPR effect also allows molecules to accumulate in the tumour 
site due to poor lymphatic drainage in the cancerous tissue.73 




Figure 1.25: Schematic diagram of the EPR effect.78 
1.6.3.4 Specificity 
Once the molecule has reached the cancerous tissue, the rate and location of drug release 
needs to be controlled in order to avoid non-specific action of the molecule.78 The drug is 
usually covalently bound to the drug delivery vehicle and is released via chemical or 
enzymatic cleavage of hydrolytically labile bonds.56 Dendrimers have the low polydispersity 
which can ensure and monitor the drug release.57 This provides reproducible pharmacokinetic 
behaviour56 which means that the rates at which the drug action begins, the duration of the 
effect, the chemical changes of the substance in the body and the routes of excretion of the 
drug can all be determined with ease in contrast to that of linear polymers. 56,58 
 
1.6.3.5 Toxicity 
As with most treatments of any disease worldwide, toxicity is one of the most important 
aspects to consider as any treatment that is too toxic is not worthwhile.56,58, 79 The charge on 
metallodendrimers have been shown to play an important role in toxicity of drugs. Drug 
delivery vehicles that are positively charged generally show dose dependent toxicity while 
negatively charged or neutral dendrimers are less toxic and therefore more preferable.70,80 But 
this is not always the case as it has been reported that cationic macromolecules are able to 
interfere with the cell membrane which is an advantage as it can therefore assist in the 
transport of the macromolecules into the cancerous cells.80 Where there is an unfavourable 
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charge or a charge is required, it is possible to cap the molecules with counter-ions or neutral 
molecules to eliminate charge problems. For example, displacing a chloride counterion with a 
PF6- counterion to make a compound more stable or displace a chloride ligand coordinated to 
the metal centre with PTA to give a cationic versus a neutral complex.70,81 
  
Other factors include cytotoxicity,80 stability in solution73 and intact release of the active drug 
component once the macromolecule has been released into the cell.56 For example, the active 
agent needs to be soluble in physiological media in order to be able to reach the active site 
intact without decomposition.56,79 Therefore, in order to develop and synthesize 
metallodendrimers, all the above features need to be considered. 
 
1.7 Metallodendrimers as potential anticancer agents 
In light of the benefits associated with dendrimers as potential anticancer agents, there is no 
doubt that these molecules show promising biological properties. These can also be enhanced 
with the incorporation of metal centres to give metallodendrimers.43 Incorporating metal 
centres into these organic frameworks provides varied coordination and redox properties, as 
well as multinuclearity for biological recognition and improving the effectiveness of these 
potential chemotherapeutic drugs.43 There are only a handful of biometallodendrimers that 
have been synthesized successfully and undergone anticancer in vitro and in vivo studies.  
After the success of cisplatin, Jansen et al. synthesized the first tetranuclear platinum 
metallodendrimer based on the PPI dendritic scaffold, using the same general structure as 
cisplatin (Figure 1.26).82 The tetranuclear complex behaved similarly to the trinuclear 
BBR3464 with respect to DNA binding and showed moderate in vitro activity with IC50 
values ranging from 9-12 μM against a range of mouse leukaemia and human tumour cell 
lines.82 The cytotoxicity of the complex can be attributed to the charge and the high 
branching of the metallodendrimer.43, 82 




Figure 1.26: Tetranuclear PPI platinum metallodendrimer, based on cisplatin.82  
Another tetranuclear platinum metallodendrimer was synthesized based on the PPI dendritic 
scaffold with a fluorophenyl(ethylenediamine) moiety to increase the selectivity of this 
compound for breast tumours (Figure 1.27).43, 83 It showed an IC50 value of 5 μM comparable 
to that of cisplatin, 2 μM,  in the MCF-7 breast cancer cell line.43, 83 
 
Figure 1.27: Tetranuclear PPI platinum metallodendrimer showing good cytotoxicity against 
the human breast cancer cell line MCF-7. 83 
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Among the few non-platinum examples, a copper based PAMAM metallodendrimer showed 
in vitro cytotoxicity against leukaemia (MOLT-4), breast cancer (MCF-7) and Chang liver 
cell lines (Figure 1.28).84 The in vitro activity for the tetranucelar complex was better than 
that of cisplatin, (Figure 1.28).84 
 
Cell line IC50 (μM) cisplatin IC50 (μM) 
MOLT-4 11.1 ± 0.6 15.5 ± 4.2 
MCF-7 10.2 ± 1.5 not detected 
Chang liver 8.7 ± 0.7 73.5 ± 3 
Figure 1.28: PAMAM heptanuclear copper metallodendrimer with the respective IC50 
values.84  
In another study Rodrigues et al.81 prepared low-generation ruthenium metallodendrimers via 
the divergent approach based on a poly(alkylidenamine) dendritic scaffold (Figure 1.29). 
These poly(nitriles) are usually intermediates in the preparation of well-known PPI 
dendrimers, whereby repetitive steps of acrylonitrile is added to a diamine via a Michael 
reaction, followed by reduction to give the polyamine.81 These were then functionalised on 
the periphery with [Ru(ƞ5-C5H5)(PPh3)2]+ (Figure 1.29) or cis-[RuCl(dppe)2][PF6].81 A group 
of these metallodendrimers underwent degradation tests at 36˚C in order to determine their 
stability in DMSO solution.81 The metallodendrimers that contain the triphenyl phosphine 
(PPh3) ligands showed instability which could indicate a release of the [Ru(ƞ5-C5H5)(PPh3)2]+ 
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metallofragments that can possibly enter  and accumulate in the cancerous tissue.81 This 
however would need to be confirmed by in vitro studies. 
 
Figure 1.29: Poly(alkylidenamine) tetranuclear ruthenium metallodendrimer.81 
Ruthenium(II)-arene metallodendrimers have exhibited in vitro cytotoxicity against A2780 
and A2780cisR ovarian cancer cell lines (Figure 1.30).13,81 Two PPI metallodendrimers, 
DAB-[Ru(ƞ6-C6Me6)Cl]8 with a salicylaldimine or 2-pyridinecarboxaldimine surface ligand 
showed the best interactions with DNA and lower IC50 values in vitro in comparison to 
cisplatin.13 The cationic fourth generation salicylaldimine ruthenium metallodendrimer, with 
the p-cymene arene moiety, displayed the best antiproliferative results, with an IC50 value of 
0.8 ± 0.1 μM, compared to its neutral analogue which displayed a value of                           
2.9 ± 0.1 μM.13, 85, 86 This could be due to the negative charge associated with the DNA 
backbone therefore making binding of cationic complexes more favourable than anionic or 
neutral complexes.15 Besides the charge playing a key role in the activity, the results also 
concluded that there is a direct correlation between the increasing size of the 
metalldoendrimer and its DNA damage on interaction and cytotoxity.13, 85, 86 




Figure 1.30: A series of PPI ruthenium metallodendrimers (n = 4-32; R = p-cymene or 
HMB).85  
Lo et al. synthesized a series of iridium(III) metallodendrimers in order to further confirm 
that introducing metal complexes onto dendritic scaffolds can modify and even improve 
biological properties of these complexes.43, 87 Tetranuclear iridium(III) polypyridine 
complexes (Figure 1.31) with one of two C,N-chelating ligands, phenylpyridine and 
phenylquinoline, were tested against the HeLa cancer cell line in vitro.87 Both chelating 
ligands exhibited comparable IC50 values of 1.4-3.3 μM, which is better than their 
mononuclear analogues as well as cisplatin exhibiting values of and 26.4±2.0 μM, 
respectively.87  
 
Figure 1.31: Representative iridium(III)-phenylpyridine metallodendrimer showing 
promising in vitro cytotoxicity (IC50 = 3.3±0.1 μM).43  
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The increased cytotoxicity compared to mononuclear derivatives, was attributed to an 
increase in metal centres on the periphery of the metallodendrimer and the increase in charge 
on the complex.87,88 Besides showing good cytotoxicity, they were also able to demonstrate 
that the mononuclear and multinuclear complexes entered the cancerous cells via different 
pathways and that the multinuclear complexes bind to plasmid DNA in an electrostatic 
manner, whereas the mononuclear complexes did not.87,88  
 
1.8 Concluding remarks 
There have been limited biological investigations of metallodendrimers based on a variety of 
dendritic scaffolds, especially PAMAM and PPI scaffolds. With the known limitations 
associated with platinum-based compounds, there has been a shift in focus to ruthenium as 
well as rhodium and some iridium compounds. There is evidence that both neutral and 
cationic complexes based on the PPI scaffold have the ability to exhibit good biological 
activity. Within our research group there has also been investigations into cyclometalated 
rhodium(III) and iridium(III) complexes which show promising in vitro results and other 
investigations has shown that these complexes may be able to target different enzymatic 
pathways as anti-cancer agents.  
 
1.9 Aims and Objectives 
1.9.1 Aims 
The aim of this project was to modify a PPI dendritic scaffold on the periphery with two 
Schiff base C,N-chelating moieties, allowing incorporation of different metal centres, 
ruthenium(II), rhodium(III) and iridium(III). This was to determine whether the aryl moiety 
and incorporation of different metal centres influences the cytotoxicity of these compounds 
and whether there is a correlation between size and cytotoxicity. A phosphorous moiety was 
incorporated in order to create a series of cationic analogues, as well as the incorporation of a 
ferrocenyl moiety to produce heterometallic complexes, therefore obtaining an effect of 
charge and heteronuclearity on cytotoxicity. The aim of the project was to determine whether 
the complexes show in vitro activity, further tests would need to be done in order to 
determine the drug-target and mode of action.   




1.9.2.1 Ligand synthesis 
Naphthaldimine and benzaldimine C,N-chelating ligands (Figure 1.32) were synthesized and 
characterized. The synthesis was achieved by reacting propylamine or DAB-(NH2)n (n=4 or 
8) with naphthaldehyde and benzaldehyde via a Schiff-base condensation reaction. The 
ligands were characterized using a variety of spectroscopic and analytical techniques. 
 
Figure 1.32: Naphthaldimine and benzaldimine monomeric and dendritic ligands. 
1.9.2.2 Neutral metal complex synthesis 
Ruthenium(II), rhodium(III) and iridium(III) metal complex analogues (Figure 1.33) of the 
above ligands were synthesized and characterized. The synthesis was achieved by metallation 
of the ligand with [MCl2(L)]2 (where M = Ru, Rh, Ir; L = p-cymene or Cp*). The metal 
complexes were characterized using a variety of spectroscopic and analytical techniques. 
 Figure 1.33: Neutral ruthenium, rhodium and iridium cyclometalated complexes. 
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1.9.2.3 Cationic and heterometallic complex synthesis 
The synthesis of cationic derivatives (Figure 1.34) was achieved by displacement of the 
chloride with a phosphorous donor ligand, PTA. This was followed by salt metathesis with 
NaPF6 to obtain a hexafluorophosphate counterion. The cationic metal complexes were 
characterized using a variety of spectroscopic and analytical techniques. 
 
Figure 1.34: Cationic ruthenium, rhodium and iridium cyclometalated complexes. 
Heterometallic ferrocenyl - ruthenium(II), rhodium(III) and iridium(III) cationic analogues 
(Figure 1.35) were synthesized and charzterized. The synthesis was achieved by 
displacement of the chloride with a nitrogen-ferrocenyl ligand on the metal centre to obtain a 
cationic complex. This was followed by salt metathesis with NaPF6 to obtain a 
hexafluorophosphate counterion. The cationic metal complexes were characterized using a 
variety of spectroscopic and analytical techniques. 
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 Figure 1.35: Cationic heterometallic ferrocenyl-rhodium and iridium cyclometalated 
complexes. 
1.9.2.4 Biological testing 
The cytotoxicity studies of each ligand and metal complex was carried out by myself and 
collaborators at the Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique 
Fédérale de Lausanne (EPFL), Switzerland as well as at the University of the Western Cape 
(UWC). The cytotoxicity was studied against the human ovarian A2780 and A2780cisR 
cancer cell lines and the HEK or KMST-6 non-cancerous cell lines, to test for selectivity. A 
comparison between size of the complexes and the cytotoxicity was evaluated, as well as 
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Chapter 2: Synthesis and Characterization of the Mono- and Polynuclear Neutral 
Ruthenium(II), Rhodium(III) and Iridium(III) Cyclometalated complexes based on 
Naphthaldimine and Benzaldimine Schiff Base Ligands 
 
2.1 Introduction 
Dendrimers, such as poly(propyleneimine) (PPI) (Figure 2.1) dendrimers are large 
macromolecules that can be constructed to a desired size.1-5 They have been found to be 
useful in biological applications such as chemotherapeutics6 due to their multivalency which 
means they are able to interact with multiple, specific receptors for biological recognition. 
This factor improves the selective activity of these molecules which could in turn reduce 
toxicity and side effects.7 
 
 
Figure 2.1: Structures of the first- and second-generation PPI dendritic scaffolds. 
Since the discovery of cisplatin, the incorporation of metal centres has become of increasing 
biological interest.8, 9 With the limitations associated with cisplatin, the use of platinum group 
metals, other than platinum, has become more prevalent. For example, ruthenium(II)10, 
rhodium(III)11, 12 and iridium(III) 3, 13, 14 complexes have displayed antitumour activity. 
 
Ruthenium-arene complexes, for example, have shown an array of applications such as 
antiviral15, antibacterial16, antimalarial and anticancer agents.10 There has also been 
investigation into nitrogen directed metallations17,18 as potential DNA binding agents using 
palladium and platinum which showed IC50 values as low as 1.1 μmol/L.19  
 




Our research group has focussed on ruthenium(II) PPI metallodendrimers therefore this 
project is an extension to previous work by focussing on the same dendritic scaffold but 
introducing new metals. There have been a few reports on rhodium(III) and iridium(III) 
cyclometalated complexes as potential kinase and protein inhibitors. For example one 
rhodium(III) cyclometalated complex showed an IC50 value as low as 30μM (Figure 2.2a).20 
A well as an iridium(III) cyclometalated complex which showed promising tumour necrosis 






Figure 2.2: Rhodium(III) (a) and iridium(III) (b) complexes as a protein kinase-C and TNF-
α inhibitors, respectively. (where R = benzyl or H).20, 22 
Multivalency is increased further by the presence of multiple metal centres. For example a 
series of tungsten-functionalized metallodendrimers were synthesized based on the 
diaminobutane (DAB) dendritic scaffold and studies showed that they were able to cleave 
DNA in com[arison to the mononuclear analogues, giving these multinuclear complexes good 
biological properties.23  
(a) (b) 





Figure 2.3: Multinuclear tungsten-functionalized metallodendrimer.23  
 
With only very few examples of cyclometalated complexes as anticancer agents, we sought to 
develop a series of neutral cyclometalated multinuclear complexes as potential anti-cancer 
agents in order to incorporate multinuclearity as well as nitrogen-directed cyclometallation. 
Herein we discuss the synthesis and characterization of bidentate C,N-ligands, monomeric 
and dendritic, as well as the neutral ruthenium(II), rhodium(III) and iridium(III) mono- and 
polynuclear cyclometalated complexes based on these ligands. 
 
2.2 Synthesis of the naphthaldimine and benzaldimine monomeric ligands 2.1 and 2.2 
Two organic bidentate C,N-ligands (2.1 & 2.2) were synthesized by reacting propylamine 
with either naphthaldehyde or benzaldehyde, respectively, in a Schiff-base condensation 
reaction (Scheme 2.1) adapted from the work done by Mungwe et al.24 The ligands differed 
from one another by the presence of a more extended phenyl group in the naphthaldehyde 
series of ligands compared to that of the benzaldehyde series. The extended phenyl group is 
incorporated as it can play a role in DNA intercalation13 which could modify the anticancer 
activity of the naphthaldimine series of compounds versus the benzaldimine compounds.13 
Both ligands were stirred in ethanol at room temperature overnight. The naphthaldimine 
ligand (2.1) was obtained as a yellow-brown solid in a moderate yield of 62%, while the 
benzaldimine ligand (2.2) was obtained as a brown-red oil, in a good yield of 82%. Both 
ligands are soluble in most organic solvents, such as DCM, chloroform, acetone and ethanol. 





Scheme 2.1: Synthesis of naphthaldimine and benzaldimine monomeric ligands (2.1 & 2.2). 
 
2.2.1 1H-NMR and 13C{1H}-NMR spectroscopy 
Both ligands (2.1 & 2.2) were characterized by 1H- and 13C{1H}-NMR spectroscopy. In the 
1H-NMR spectra of each ligand (2.1 & 2.2) that there is formation of the Schiff base. A 
doublet is observed at 8.43 and 8.28 ppm for 2.1 and 2.2, respectively, corresponding to the 
imine proton due to long range coupling to the proton at position 5. The aromatic protons for 
the naphthaldimine and benzaldimine rings appear at typical chemical shifts associated with 
aromatic protons between 7.40 and 8.50 ppm (Figure 2.4). Another notable feature (see 
Figure 2.4) is the downfield positioning of the triplet corresponding to the protons at position 
3, being adjacent to the electron-withdrawing imine nitrogen, seen at 3.65 and 3.60 ppm for 
each ligand (2.1 & 2.2), respectively. This is in comparison to the resonances of the protons 
at position 1 and 2, appearing further upfield between 0.98 and 1.78 ppm. This was also 
confirmed by using 2D-NMR techniques such as HSQC and COSY. As can be seen in 
Figure 2.4, the COSY shows the spin-spin coupling between the aliphatic protons at position 
1,2 and 3, as well as long distance coupling of the imine proton at position 4 with the proton 
at position 3, also adjacent to the imine nitrogen. Hence the splitting observed for the imine 
doublet. 
In the 13C{1H}-NMR spectra, the chemical shifts for the aliphatic carbons appear between 
11.0-64.0 ppm, while the aromatic carbon atoms are further downfield, between 124.0-160.0 
ppm. The imine carbon peak appears the furthest downfield at 160.0 ppm for the monomeric 
ligands (2.1 & 2.2) confirming the Schiff-base condensation reaction.  





Figure 2.4: Representative COSY spectra of the naphthaldimine monomeric ligand (2.1). 
2.2.2 Infrared (IR) spectroscopy 
The IR spectra of each ligand was recorded as KBr pellets and shows the presence of an 
imine absorption band at 1640 and 1646 cm-1 for ligand 2.1 & 2.2, respectively. This 
confirms the presence of an imine bond and in turn the formation of the Schiff base ligand.  
2.2.3 Electron Ionization Mass Spectrometry (EI-MS) 
The mass spectrum of the naphthaldimine ligand (2.1) has a fragmentation peak which 
corresponds to the loss of the propyl group and the nitrogen atom. In the mass spectrum of 
2.2, there is a molecular ion peak corresponding to the molecular mass of the desired product 
as well as a fragmentation peak corresponding to the loss of an ethyl group of the aliphatic 








Table 2.1: Mass spectrometry data for monomeric ligands 2.1 and 2.2. 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
2.1 197.28 141.01 [M-C3H7N]+ 
2.2 147.22 147.08 [M]+ 
 147.22 118.02 [M-C2H5]+ 
 
2.3 Synthesis of the naphthaldimine and benzaldimine dendritic ligands 2.3-2.6 
Following the synthesis of the monomeric ligands, a series of first- and second-generation 
PPI dendritic ligands were synthesized (Scheme 2.2) by reacting the appropriate aldehyde 
with the first- and second-generation poly(propylene amine) dendritic scaffold, DAB-dendr-
(NH2)4-G1 or DAB-dendr-(NH2)8-G2, via a similar Schiff-base condensation reaction as the 
model monomeric ligand synthesis.24 Through these reactions a series of 
poly(propyleneimine) dendritic ligands were obtained, with their spherical structure giving 
these molecules improved physical and chemical properties as potential anticancer-agents.25 
The dendritic ligands (2.3-2.6) were stirred in ethanol for 72-96 hours. To decrease the 
reaction time, a microwave reaction can also be performed in ethanol at 70oC for 30-45 





















Scheme 2.2: Synthesis of the first- and second-generation C,N-chelating PPI dendritic 
ligands based on naphthaldimine (2.3 & 2.5) and benzaldimine (2.4 & 2.6). 
The reactions proceeded over 72 and 96 hours, respectively for the first- (2.3 & 2.4) and 
second-generation (2.5 & 2.6) dendritic ligands, in order to ensure full functionalization of 
the periphery. For the first-generation dendritic ligands (2.3 & 2.4), the microwave reaction 
time was 30 minutes, while for the second-generation dendritic ligands (2.5 & 2.6) the 
microwave reaction took place over for 30-45 minutes. The first- and second-generation 
naphthaldimine dendritic ligands (2.3 & 2.5) were obtained as white solids, in moderate 
yields of 67 and 42%, respectively. The benzaldimine analogues (2.4 & 2.6) were obtained as 
yellow oils in moderate yields of 52% and 45%, respectively. All the dendritic ligands are 
soluble in DCM, chloroform, ethanol and acetone. 
 
2.3.1 1H-NMR and 13C{1H}-NMR spectroscopy 
All four dendritic ligands (2.3-2.6) were characterized by 1H- and 13C{1H}-NMR 
spectroscopy. In the 1H-NMR spectra of all four dendritic ligands (2.3-2.6) there is the 
presence of a doublet in each spectrum ranging between 8.25-8.40 ppm, corresponding to the 
imine proton and indicative of the formation of the Schiff base imine bond. The aromatic 
protons for the naphthaldimine and benzaldimine rings appear at typical chemical shifts 
associated with aromatic protons between 7.30 and 8.40 ppm (Figure 2.5). 
The core protons at position 1 and 2 appear at different shifts in comparison to one another as 
the protons at position 2 are adjacent to the electron-withdrawing nitrogen atoms of the DAB-
core. The protons at position 1 appear furthest upfield at 1.49, 1.43, 1.33 and 1.38 ppm for 
each dendritic ligand 2.3-2.6, respectively. While the protons at position 2 are further 
downfield at 2.46, 2.41, 2.37 and 2.41 ppm, respectively (Figure 2.5). Another key feature in 




the 1H-NMR is the downfield position of the triplet corresponding to the protons on the 
carbon atom adjacent to the imine nitrogen (position 5 for G1 and position 8 for G2) 
appearing at 3.68, 3.62, 6.58 and 3.61 ppm for each dendritic ligand (2.3-2.6), respectively 
(Figure 2.5). This was also confirmed by using 2D-NMR techniques such as HSQC and 
COSY. The COSY of the dendritic ligands show similar trends found in the COSY of the 
monomeric ligands, whereby there is coupling between the aliphatic protons of the dendritic 
arms and between the core protons. There is also long distance coupling of the imine proton 
at position 9 with the proton at position 8, hence the splitting observed for the imine proton in 
the 1H-NMR spectra. 
 
Figure 2.5: Representative 1H-NMR spectrum of the benzaldimine G2 dendritic ligand (2.6). 
In the 13C{1H}-NMR spectra of the dendritic ligands (2.3-2.6) the resonances for the aliphatic 
carbons appear between 24.0-60.0 ppm, while the aromatic carbon atoms were further 
downfield, between 124.0-160.0 ppm. The imine carbon peak appears the furthest downfield 
at 161.0 ppm for all the dendritic ligands (2.3-2.6) similar to the monomeric ligands (2.1 & 
2.2), confirming Schiff-base formation.  
 
2.3.2 Infrared (IR) spectroscopy 
To further confirm that the Schiff-base condensation reaction occurred and that all the PPI 
peripheral arms were fully functionalised, IR spectroscopy was used. The IR spectra of all 




four dendritic ligands (2.3-2.6) were recorded as KBr pellets and each spectrum shows the 
presence of an imine absorption band ranging between 1639 and 1646 cm-1.  
 
2.3.3 Low Resolution Electrospray Ionization Mass Spectrometry (ESI-MS) 
All four dendritic ligands (2.3-2.6) exhibit base peaks in the mass spectra (Table 2.2). As can 
be seen in Table 2.2, dendritic ligands 2.3 2.5 and 2.6 form adducts with methanol, while 
ligand 2.4 forms an adduct with water and methanol (see Table 2.2). 
Table 2.2: Mass spectrometry data for dendritic ligands 2.3-2.6. 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
2.3 869.21 322.20 [M+3H++3MeOH]3+ 
2.4 668.97 272.20 [M+3H3O++MeOH]3+ 
2.5 1878.64 408.20 [M+5H++MeOH]5+ 
2.6 1478.16 773.80 [M+2H++2MeOH]2+ 
 
2.4 Synthesis of the mononuclear cyclometalated naphthaldimine and benzaldimine 
complexes 2.7-2.12 
Before synthesizing the half sandwich ruthenium(II), rhodium(III) and iridium(III) 
complexes, the appropriate metal dimer precursors were synthesized by reacting the 
appropriate metal salt (MCl2.nH2O) with α-phellandrene in the case of ruthenium or 
pentamethylcyclopentadiene in the case of rhodium and iridium (Scheme 2.3).25, 26  
 
Scheme 2.3: Synthesis of the ruthenium(II), rhodium(III) and iridium(III) metal precursors. 




The monomeric ligands (2.1 & 2.2) were cyclometalated using one of three metallic dimers, 
[Ru(p-cymene)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2], in methanol or ethanol 
(Scheme 2.5) for two hours to produce a series of mononuclear complexes (2.7-2.12). The 
synthetic method followed was a similar method used by Govender et al.27 Sodium acetate 
was used for the selective C-H activation of the ortho-proton as previously reported results28 
show that acetate can stimulate the cyclometallation of imines with ruthenium, rhodium or 
iridium metal salts at room temperature.28 Ortho CH-activation can be attributed to the 
directing effect of the imine bond on the metal centre. The proposed mechanism of the 
reaction is shown in Scheme 2.4. It is suggested that NaOAc acts as an intramolecular base 
and facilitates the break-up of the dimer and exchange of the chloride ligand (Scheme 2.4).28 
There are two likely mechanisms for the C–H activation step to occur; oxidative addition of 
the aryl C–H bond followed by reductive elimination (Scheme 2.4 - via D1).28 The alternative 
route is said to first involve the electrophilic attack of the metal on the arene (Scheme 2.4 - 
via D2) followed by loss of a proton.28 
 
Scheme 2.4: Proposed mechanism of reaction for the cyclometallation of imines.28  
The ruthenium(II) naphthaldimine (2.7) and benzaldimine (2.10) complexes were obtained as 
golden-brown solids in moderate to poor yields of 65 and 25%, respectively. The 
ruthenium(II) naphthaldimine (2.7) and benzaldimine (2.10) complexes were obtained as 
golden-brown solids in moderate to poor yields of 65 and 25%, respectively. In general, the 
ruthenium dimer showed a poor reactivity with the benzaldimine ligands and often produced 
unstable compounds. The rhodium(III) (2.8 & 2.11) and iridium(III) (2.9 & 2.12) complexes 




were obtained as orange solids in moderate yields ranging between 51-71%. All the 
mononuclear complexes are soluble in methanol, ethanol, DCM and chloroform. The 
iridium(III) complexes (2.9 & 2.12) tend to be less soluble or sparingly soluble compared to 
the ruthenium(II) and rhodium(III) complexes. 
 
Scheme 2.5: Synthesis of the ruthenium(II), rhodium(III) and iridium(III) C,N–chelating 
naphthaldimine and benzaldimine mononuclear complexes (2.7-2.12). 
2.4.1 1H-NMR and 13C{1H}-NMR spectroscopy 
All the mononuclear complexes were characterized by 1H- and 13C{1H}-NMR spectroscopy. 
The 1H-NMR spectra of all six complexes (2.7-2.12) have a characteristic imine singlet 
between 7.99 and 8.96 ppm, indicating the imine bond is still intact. There is also a shift of 
the imine singlet in each metal complex when compared to imine resonance observed in the 
naphthaldimine (2.1) and benzaldimine (2.2) metal-free ligands. This confirms the 
coordination of the metal centre to the imine nitrogen. As expected, the aromatic protons for 
the phenyl rings appear between 7.00 and 8.44 ppm, which are typical chemical shifts for 
aromatic protons (Figure 2.6a & b). In the 1H-NMR spectra of the ruthenium complexes (2.7 
& 2.10) there is a loss of two-fold symmetry of the p-cymene moiety which results in the 
methyl protons of the isopropyl group exhibiting two doublets in the range of 0.81-1.10 ppm 
(Figure 2.6b). A septet is also observed at 2.49 ppm assigned to the single proton of the 
isopropyl group (Figure 2.6b). The aromatic protons of the p-cymene moiety display four 
separate doublets in the range 4.84-5.70 ppm, as opposed to two doublets in the free metal-
dimer (Figure 2.6b). This is because the p-cymene moiety now has less freedom of rotation 




and therefore all four aromatic protons appear in different environments. In some cases two 
of the signals overlap and seem to appear as one peak. Complexes 2.8, 2.9, 2.11 and 2.12 
exhibit a singlet at about 1.70 ppm corresponding to the methyl protons of the 
pentamethylcyclopentadienyl (Cp*) moiety. In all six complexes (2.7-2.12), two sets of 
resonances are observed for each –CH2 group of the propyl chain. This can be attributed to 
the diastereotopic nature of the protons induced by the chiral metal centre, now coordinated 
in a C,N-bidentate fashion to the naphthaldimine and benzaldimine ligands. In order to 
confirm the assignments made from the 1H- and 13C{1H}-NMR, 2D-NMR techniques were 
used such as HSQC and COSY. 
 
Figure 2.6: Representative 1H-NMR spectrum of the rhodium(III) naphthaldimine (2.8) and 
ruthenium(II) benzaldimine (2.10) mononuclear complexes. 
(a) 
(b) 




13C{1H}-NMR spectroscopy shows characteristic imine carbon peaks for each metal complex 
(2.7-2.12) at about 145.0 ppm, further upfield when compared to the imine carbon shift in the 
metal-free ligands (2.1 & 2.2) which appears at about 160.0 ppm. This is expected as the 
imine nitrogen is now coordinated to a metal centre. There is back donation occurring 
between the imine nitrogen and metal centre, therefore more electron density lies on the 
imine functional group (see Figure 2.7).  The chemical shifts for the aliphatic carbon atoms 
appear between 11.0-68.0 ppm, while the aromatic carbon atoms appeared furthest 
downfield, between 101.0-178.0 ppm. The aromatic carbons on the p-cymene ligand appear 
between ~70.0-100.0 ppm in the ruthenium complexes (2.7 & 2.10), while the CH3 
substituents on the Cp* moiety in complexes 2.8 2.9 2.11 and 2.12, appear at ~9.00 ppm. 
 
2.4.2 Infrared (IR) spectroscopy 
IR spectroscopy was used to determine whether the imine bond was still intact and to confirm 
the coordination of the metal centre to the imine nitrogen atom of the ligands (2.1 & 2.2). The 
IR spectra of all six complexes (2.7-2.12) were recorded as KBr pellets and show the 
presence of an imine absorption band ranging between 1602 and 1614 cm-1. These values 
indicate a shift in the imine absorption band in each metal complex (2.7-2.12) to a lower 
frequency, when compared to the imine absorption bands for the metal-free ligands (2.1 & 
2.2) with values of 1640 and 1646 cm-1, respectively. This shift is expected and it confirms 
the coordination of the metal centre to the imine nitrogen as there is back donation from the 
metal centre’s filled d-orbital into the empty π*-antibonding orbital of the imine nitrogen. 
This increases the electron density on the nitrogen and in turn increases the electron density 
on the carbon-nitrogen imine bond and hence the imine absorption bands occur at lower 
frequencies in the complexes. This is known as the synergistic effect (Figure 2.7).29 
 
Figure 2.7: Molecular orbital diagram illustrating the synergistic effect.29 




2.4.3 Electron Ionization Mass Spectrometry (EI-MS) 
The mass spectrum of the each complex (2.7-2.12) show base peaks corresponding to the 
molecular ion without the chloride ion, [M-Cl]+.  
 
2.4.4 X-ray crystallography 
The structures of complexes 2.7, 2.8, 2.11 and 2.12 were confirmed by single-crystal X-ray 
diffraction whereby single crystals of each complex was grown from a methanol/hexane 
mixture30 (Figure 2.8). This characterization technique confirms the characteristic pseudo-
tetrahedral “piano-stool” geometry with a η5-coordination of the Cp* to the rhodium (2.8 & 
2.11) and iridium (2.12) metal centres and a η6-coordination of the p-cymene arene-ring to 
the ruthenium centre (2.7). This coordination forms the ‘seat’ of the piano stool and the other 
two ligands form the ‘legs’ of the stool (Figure 2.8). 
 
Figure 2.8: X-ray molecular structure of (a) ruthenium(III) (2.7); (b): rhodium(III) 









Complexes 2.8, 2.11 and 2.12 crystallize with the monoclinic space group P21/n. The 
distances between the metal centres and the aromatic carbon atoms range between 2.15 and 
2.27 Å. The bond lengths between the metal centres and the chloride ligands are similar for 
both rhodium(III) complexes (2.8 & 2.11) with values of 2.39 and 2.40 Å, respectively. The 
iridium(III) complex (2.12) has a metal-Cl bond length of 2.40 Å. The distance between the 
metal centres and the carbon coordinated to the metal centre, are between 2.03 Å and 2.04 Å, 
which are considerably shorter than the metal-N bond lengths, ranging between 2.09 and 2.10 
Å. In all three complexes 2.8, 2.11 and 2.12, the angle around the metal centre from the 
carbon coordinated to the metal centre to the nitrogen atom lies between 78.25° and 78.96° 
(Table 2.3). The rhodium(III) (2.8 & 2.11) and iridium(III) (2.12) complexes showed similar 
geometric parameters to each other and to similar related mononuclear iridium complexes 
reported in the literature.14 The ruthenium(II) naphthaldimine complex (2.7) is also 

















Table 2.3: Crystallographic parameters with selected bond lengths and bond angles for the 
ruthenium(II)  (2.7) and rhodium(III) naphthaldimine and rhodium (2.11) and iridium (2.12) 
benzaldimine mononuclear complexes. 
Chemical formula 
 
C24H27ClNRu C24H29ClNRh C20H27ClNRh C20H27ClIrN 
Formula weight (g/mol) 466.01 469.86 419.79 509.11 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic 
Space group P21/c P21/n P21/n P21/n 
a (Å) 13.776 8.4123(4) 8.2170(3) 8.2604(3) 
b (Å) 7.796 12.7708(5)  17.1415(9)  17.0360(6) 
c (Å) 20.725 26.8982(12)  13.1453(6)  13.0692(4) 
α (°) 90.00 90.00 90.00 90.00 
ß (°) 116.78 94.9730(10)  90.306(3)  90.0180(10) 
ɣ (°) 90.00 90.00 90.00 90.00 
V (Å^3) 1987.1 2878.8(2)  1851.51(15)  1839.15(11) 
Z 4 4 4 4 
T (K) 293(2) 173(2)  173(2) 173(2) 
Bond Distances (Å) 
M(1)-C(11) or Ru(1)-C(1) 2.279(2) 2.256(3) 2.243(2) 2.239(2) 
M(1)-C(12) or Ru(1)-(C2) 2.257(2) 2.275(3) 2.279(2) 2.277(2) 
M(1)-C(13) or Ru(1)-C(3) 2.163(2) 2.166(3) 2.174(2) 2.174(2) 
M(1)-C(14) or Ru(1)-C(4) 2.168(2) 2.167(3) 2.157(2) 2.151(3) 
M(1)-C(15) or Ru(1)-C(5) 2.161(2) 2.159(3) 2.159(2) 2.167(3) 
M(1)-Cl(1) or Ru(1)-Cl(1) 2.4027(6) 2.3984(8) 2.3943(6) 2.4047(6) 
M(1)-N(1) or Ru(1)-N(1)  2.0692(18) 2.097(3) 2.091(2) 2.086(2) 
M(1)-C(1) or Ru(1)-C(6) 2.176(2) 2.030(3) 2.032(2) 2.038(2) 
Ru(1)-C(11) 2.036(2)    
Bond Angles(°) 
C(1)-M(1)-N(1) 78.20(8) 78.96(12) 78.93(9) 78.25(9) 
C(1)-M(1)-Cl(1) 84.98(6) 86.01(8) 86.37(7) 85.82(7) 
 




The ruthenium(II) naphthaldimine complex (2.7) crystallizes with the monoclinic space 
group P21/c, with the distances between the ruthenium centre and the arene aromatic carbons 
ranging between 2.16 and 2.28 Å. The bond length between the ruthenium metal centre and 
the chloride ligand is 2.40 Å. The distance between the ruthenium and the carbon atom 
coordinated to the metal centre is 2.04 Å, which is considerably shorter than the ruthenium-N 
bond length of 2.07 Å. The angle around the metal centre from the carbon atom coordinated 
to the metal centre to the nitrogen atom lies at 78.20° (Table 2.3).   
 
2.5 Synthesis of the cyclometalated naphthaldimine and benzaldimine G1 & G2-
metallodendrimers 2.13-2.24 
The first- and second-generation dendritic ligands (2.3-2.6) were reacted with either the 
[Ru(p-cymene)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2]2 dimer in a 1:2 ratio for the 
first-generation metallodendrimers (2.13-2.16) or 1:4 ratio for the second-generation 
metallodendrimers (2.19-2.24). The cyclometalation was done in the presence of sodium 
acetate (Schemes 2.6 & 2.7). A similar general synthetic method was used for the metallation 
of the monomeric ligands27, except the metallation of the dendritic ligands required stirring in 
ethanol or methanol for 24-48 hours.  
 
Scheme 2.6: Synthesis of ruthenium(II), rhodium(III) and iridium(III) tetranuclear C,N-
chelating naphthaldimine (2.13-2.15) and benzaldimine (2.16-2.18) metallodendrimers. 




The ruthenium(II) naphthaldimine and benzaldimine metallodendrimers (2.13, 2.16, 2.19 & 
2.22) were obtained as green-brown solids. The first-generation ruthenium(II) 
metallodendrimers  (2.13 & 2.16) were obtained in moderate to good yields of 99 and 65%, 
respectively, while the second-generation ruthenium metallodendrimers (2.19 & 2.22) were 
obtained in poor yields of about 32%. The rhodium(III) (2.14, 2.17, 2.20 & 2.23) and 
iridium(III) (2.15, 2.18, 2.21 & 2.24) metallodendrimers  were obtained as orange solids in 
yields ranging between 29 and 80%. All the metallodendrimers (2.13-2.24) are soluble in 
methanol, ethanol, DCM and chloroform. The low yields of the second generation complexes 
can be attributed to functionalization of 8 arms therefore a longer period of time was required 
but due to results obtained in the early synthesis attempts, the reaction could not proceed for 
too long without decomposition of the products. 
 
Scheme 2.7: Synthesis of ruthenium(II), rhodium(III), and iridium(III) octanuclear C,N-
chelating naphthaldimine (2.19-2.21) and benzaldimine (2.22-2.24) 
metallodendrimers. 
2.5.1 1H-NMR and 13C{1H}-NMR spectroscopy 
In the 1H-NMR spectra of all the metallodendrimers (2.13-2.24) there is a shift of the imine 
singlet compared to the resonance observed in the 1H-NMR spectra of the metal-free 
dendritic ligands (2.3-2.6). This result confirms that the imine bond is still intact and that 




there is coordination of the metal centre to the imine nitrogen. The imine proton is observed 
furthest downfield in the 1H-NMR spectra between 8.00-8.45 ppm (Figures 2.9 & 2.10). IR 
spectroscopy was used to further confirm coordination of the metal centre to the dendritic 
ligands (2.3-2.6).  
 
Figure 2.9: Representative 1H-NMR spectra of the iridium(III) naphthaldimine (2.15) and 
rhodium(III) benzaldimine (2.17) G1 metallodendrimers. 
The aromatic protons for the naphthaldimine and benzaldimine phenyl rings of 
metallodendrimers 2.13-2.24 appear between 7.00 and 8.45 ppm, in the expected region for 
aromatic protons. The ruthenium complexes (2.13, 2.16, 2.19 & 2.22) exhibit a loss of two-
fold symmetry of the p-cymene moiety in the 1H-NMR spectra, which results in the methyl 
protons of the isopropyl group exhibiting two broad peaks between 1.20 and 1.75 ppm. There 
is an additional broad peak observed between 1.80 and 2.80 ppm assigned to the single 
proton of the isopropyl group. The aromatic protons of the p-cymene moiety display four 
separate peaks in the range 4.60-5.80 ppm, as opposed to two peaks in the metal-free dimer. 
This is because the p-cymene moiety now has less freedom of rotation and therefore all four 
aromatic protons appear in different environments, but in some cases two of the signals 
overlap and seem to appear as one peak, especially with the broadening of the peaks in the 
metallodendrimers. The rhodium(III) (2.14, 2.17, 2.20, 2.23) and iridium(III) (2.15, 2.18, 
2.21 & 2.24)  metallodendrimers exhibit a broad singlet between 1.56 and 1.68 ppm 
corresponding to the methyl protons of the pentamethylcyclopentadienyl (Cp*) moiety 
(Figures 2.9 & 2.10). 
 
 






Figure 2.10: Representative 1H-NMR spectra of the rhodium(III) naphthaldimine (2.20) and 
iridium(III) benzaldimine (2.24) G2 metallodendrimers. 
In all the metallodendrimers (2.13-2.24), two broad peaks are observed at about 3.89-4.20 
ppm corresponding to the –CH2 group adjacent to the imine nitrogen. This can be attributed 
to the diastereotopic nature of the protons induced by the chiral metal centre, now 
coordinated in a C,N-bidentate fashion to the dendritic ligands. In the rhodium(III) complexes 
(2.14, 2.17, 2.20 & 2.23) the peak appears as two broad signals which are expected as these 
two protons are in different environments due to diastereotopicity. If one proton is replaced 
with another functional group it would generate a set of diastereomers, being adjacent to the 
chiral metal centre. This can also be due to the fact that rhodium(III) is NMR active. Whereas 
in the ruthenium(II) (2.13, 2.15, 2.19 & 2.22) and iridium(III) (2.15, 2.17, 2.21 & 2.24) 
complexes the peaks overlap to appear as one broad peak.  
The peaks observed in the 1H-NMR spectra of all the metallodendrimers appear as broadened 
peaks. The broadening of the peaks is due to the fact that each peak represents four times as 
many protons for each one of the four metallodendritic arms and therefore on the NMR-time 
scale the peaks average out to a broadened peak. These assignments were made in 
conjunction with 2D-NMR techniques such as HSQC and COSY. 
The 13C{1H}-NMR spectra exhibit imine carbon peaks downfield in each spectra ranging 
between 142.1 and 147.0 ppm for all 12 metallodendrimers (2.13-2.24). The chemical shifts 
for the aliphatic carbons of each metallodendrimer (2.13-2.24) appear between 9.00-60.0 
ppm, while the aromatic carbon atoms appear furthest downfield between 123.0-176.0 ppm. 
The aromatic carbons on the p-cymene ligand appear between ~70.0-100.0 ppm in complexes 




2.13 2.16 2.19 and 2.22, while the carbons on the Cp* ligand in complexes 2.14, 2.15, 2.17, 
2.18, 2.20, 2.21, 2.23 and 2.24 appear at ~9.00 ppm.  
2.5.2 Infrared (IR) spectroscopy 
IR spectroscopy was used to determine whether the imine bond was still intact and to confirm 
the coordination of the metal centre to the imine nitrogen atom of the dendritic ligands (2.3-
2.6). The IR spectra of all twelve metallodendrimers (2.13-2.24) were recorded as KBr pellets 
and each complex exhibited a shifted imine absorption band to a lower frequency ranging 
between 1600-1610 cm-1, compared to the metal-free dendritic ligands (2.3-2.6) with imine 
absorption bands at 1639, 1643, 1639 and 1646 cm-1, respectively. 
2.5.3 High Resolution Electrospray Ionization Mass Spectrometry (ESI-MS) 
The MS spectra of the ruthenium(II) (2.13) and rhodium(III) (2.14) naphthaldimine G1 
metallodendrimers show base peaks corresponding to the loss of chloride ligands as well as 
exhibiting molecular ion peaks (Table 2.4). The rhodium(III) benzaldimine (2.17) G1 
metallodendrimer exhibits a molecular ion peak only in the mass spectrum, while the MS of 
the G1 metallodendrimers 2.15 & 2.16, show base peaks corresponding to the loss of the 
chloride ligands (Table 2.4). Metallodendrimer 2.18 exhibits a base peak in the mass 
spectrum corresponding to an adduct with two protons (Table 2.4). 
Table 2.4: Mass spectrometry data for G1 metallodendrimers (2.13-2.18). 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
2.13 1948.15 613.8303 [M-3Cl-]3+ 
  1948.4221 [M]+ 
2.14 1959.52 1923.4847 [M-Cl-]+ 
  1959.4465 [M]+ 
2.15 2316.78 1122.4001 [M-2Cl-]2+ 
2.16 1474.91 407.1664 [M-4Cl-]4+ 
  544.2101 [M-3Cl-]3+ 
  842.1741 [M-2Cl-]2+ 
2.17 1759.30 1759.4011 [M]+ 
2.18 2116.54 1059.3232 [M+2H+]2+ 
 




The mass spectra of each G2 metallodendrimer (2.19-2.24) exhibit base peaks corresponding 
to the loss of the chloride ligands (Table 2.5). 
Table 2.5: Mass spectrometry data for G2 metallodendrimers (2.19-2.24). 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
2.19 4036.53 466.15 [M-8Cl-]8+ 
  974.24 [M-4Cl-]4+ 
2.20 4059.27 640.93 [M-6Cl-]6+ 
2.21 4773.79 761.74 [M-6Cl-]6+ 
  1152.39 [M-4Cl-]4+ 
2.22 3636.05 569.01 [M-6Cl-]6+ 
  873.22 [M-4Cl-]4+ 
2.23 3658.83 574.22 [M-6Cl-]6+ 
  696.23 [M-5Cl-]5+ 
2.24 4373.31 589.23 [M-7Cl-]7+ 




A series of new naphthaldimine and benzaldimine C,N-bidentate chelating ligands (2.1-2.6) 
were synthesized in good yields. New ruthenium(II), rhodium(III) and iridium(III) 
mononuclear (2.7-2.12), tetranuclear (2.13-2.18) and octanuclear (2.19-2.24) complexes were 
synthesized by reacting the ligands with the appropriate metal dimer precursor,  [Ru(p-
cymene)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2]2 and obtaining the desired products 
in a variety of yields, decreasing with the increase in metallodendrimer generation. The 
rhodium(III) and iridium(III) complexes tended to be easier to synthesize and purify, as well 
as being generally more stable than the ruthenium(II) complexes. All the ligands and 
complexes were successfully characterized by 1H-NMR, 13C{1H}-NMR and IR spectroscopy, 
as well as mass spectrometry. Four of the mononuclear metal complexes were also 
characterized using X-ray crystallography. 
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Chapter 3: Synthesis and Characterization of Mono- and Polynuclear Cationic 
Homometallic and Heterometallic Cyclometalated Complexes  
 
3.1 Introduction 
One of the main classes of bioorganometallic compounds that has been developed is the 
RAPTA series of complexes, with the general formula Ru(η6-arene)(PTA)Cl2 containing the 
phosphaadamantane ligand, 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA).1-7 These 
RAPTA compounds, specifically RAPTA-C (Figure 3.1), have shown poor in vitro 
cytotoxicity, but were shown to exhibit antitumour8 and antimetastatic2 behaviour in vivo. 
PTA is an amphiphilic ligand which is soluble in water and other organic solvents. It is 
proposed that this ligand can provide easy transport of macromolecules within the body and 
across lipophilic cell membranes.9 
 
Figure 3.1: Structure of the anticancer ruthenium(II) complex: RAPTA-C. 
For RAPTA complexes there is a synergistic effect between the mechanism of action of both 
the organic unit and the inorganic unit.9 The ruthenium(II)-arene subunit has the potential to 
coordinate to biomolecules within the body and there is evidence that it binds to proteins such 
as histones versus the DNA back-bone itself.10 Dyson et al. synthesized a series of 
napthalimide-tagged ruthenium(II) arene complexes and tested the in vitro anti-cancer 
activity of these complexes.9 Three complexes (Figure 3.2) showed good activity against the 
A2780 and A2780cisR cancer cell lines, exhibiting IC50 values ranging between 2.31-8.53 
μM for the cisplatin-sensitive strain, A2780, and 2.28-9.09 μM for the cisplatin-resistant 
strain, A2780cisR.9 
 




Figure 3.2: Structure of the naphthalimide-tagged RAPTA-type complexes.9 
Therefore by incorporating an organic subunit, such as the naphthaldimine moiety, this could 
act as a DNA-intercalator.9 With the binding abilities of the inorganic ruthenium(II)-arene 
sub-unit to nucleosome histones and the possible intercalation of the naphthaldimine organic 
moiety, the cytotoxic effect of the compound could be enhanced compared to cisplatin which 
intercalates with DNA only.9 Hence the motivation to incorporate PTA into ruthenium(II), 
rhodium(III) and iridium(III) naphthaldimine complexes in this project is to improve the 
ampiphilic character and due to the fact that these target metastatic tumors. 
Incorporating ferrocene into organometallic compounds has also attracted much interest in 
bioorganometallic chemistry, for application as anti-cancer drugs.11, 12 This can be attributed 
to its lipophilicity, stability toward air and moisture, non-toxicity, small size, aromaticity and 
its redox behaviour.12-14 As has been discussed previously, the biological activity of the 
ferrocene moiety can be attributed to its ability to generate free radical metabolites which 
then induces oxidative DNA damage.15 The low formal potential of ferrocene in water 
renders it vulnerable to biological oxidation-reduction processes, and it is the oxidised 
analogue of ferrocene that is said to act as the antitumour agent.14, 15 
Therefore incorporating ferrocene into organometallic frameworks could improve the 
biological activity of these compounds.12 Ferrocifen16, 17 (Figure 3.3) is one such example 
which is a ferrocenyl derivative of the well-known anticancer drug tamoxifen, and has shown 
higher anticancer activity compared to its precursor compounds.12 
 








Figure 3.3: Ferrocifen, the ferrocenyl derivative of the known anticancer drug, tamoxifen.11  
Since the success of cationic complexes which have shown improved anti-cancer activity, 
compared to their neutral analogues, there is an increasing interest in developing cationic 
complexes as potential anti-cancer agents. 
 
3.2 Reactions with PTA 
3.2.1 Synthesis of the cationic naphthaldimine mononuclear complexes 3.1-3.3 
The synthesis of the cationic complexes followed a similar method to the synthesis of the 
neutral complexes, adopting a method used by Govender et al.18, whereby the naphthaldimine 
ligand (2.1) was metallated with one of the metallic dimeric precursors in the presence of 
sodium acetate for the selective C-H activation of the alpha proton in order for 
cyclometalation to occur.19 The cationic series of complexes was synthesized only with the 
naphthaldimine ligand (2.1) due to the fact that the benzaldimine complexes were less stable 
and exhibited decomposition over time and in solution. In this case, the neutral precursors 
were not isolated. The reaction mixture was filtered through Celite followed by the addition 
of PTA, which was stirred for a further 30-60 minutes, in order to replace the chloride ligand 
with the more water-soluble PTA phosphorous-donor ligand. This, in turn,, generates the 
corresponding cationic complexes (Scheme 3.1). Hexafluorophosphate was finally added at 
0oC in order to replace the chloride counterion with a more stable counterion (Scheme 3.1).20  
 




Scheme 3.1: Synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) C,N–
chelating naphthaldimine mononuclear complexes (3.1-3.3). 
The ruthenium(II) naphthaldimine cationic complex (3.1) was obtained as a red-brown solid 
in a poor yield of 15%, while the rhodium(III) and iridium(III) naphthaldimine complexes 
(3.2 & 3.3) were obtained as yellow-orange solids in moderate yields ranging between 34 and 
47%. All the mononuclear complexes are soluble in acetone, methanol, ethanol, DCM, 
chloroform and only sparingly soluble in water. All the cationic mononuclear complexes 
(3.1-3.3) were characterized using  1H-, 13C- and 31P{1H}-NMR spectroscopy. 
 
3.2.1.1 1H-, 13C{1H}- and 31P{1H}-NMR spectroscopy 
The 1H-NMR spectrum of each complex (3.1-3.3) displays a characteristic imine singlet 
upfield at 8.61, 8.73 and 8.85 ppm, respectively, indicating that the imine bond is still intact. 
The aromatic protons for the naphthaldimine ring appear at typical aromatic chemical shifts 
between 7.44 and 8.40 ppm (Figure 3.4). The PTA protons appear between 3.64 and 4.36 
ppm in the 1H-NMR spectra of each cationic complex (3.1-3.3). 
 
 











Figure 3.4: Representative 1H-NMR spectrum of the ruthenium(II) naphthaldimine cationic 
mononuclear complex (3.1). 
In the 1H-NMR spectrum of the cationic ruthenium(II) complex (3.1), there is a loss of two-
fold symmetry of the p-cymene moiety which results in the methyl protons of the isopropyl 
group exhibiting two sets of doublets at 1.07 and  1.26 ppm (Figure 3.4). There is also 
evidence of a septet observed at 2.51 ppm assigned to the single proton of the isopropyl 
group. The aromatic protons of the p-cymene moiety display four separate doublets in the 
range 5.86-6.10 ppm, as opposed to two doublets in the ruthenium(III)-dimer. This can be 
attributed to the p-cymene moiety having less freedom of rotation or that the ruthenium(II) 
centre is chiral and therefore all four aromatic protons appear in different environments. In 
some cases two of the signals overlap and appear as a broad doublet. 
Complexes 3.2 and 3.3 exhibit a singlet at 1.91 and 2.00 ppm, respectively, in the 1H-NMR, 
corresponding to the methyl protons of the pentamethylcyclopentadienyl (Cp*) moiety 
(Figure 3.5). In all three complexes (3.1-3.3), two sets of resonances are observed for each –
CH2 group of the propyl chain at about ~4.00 ppm. This can be attributed to the diasterotopic 
nature of the protons induced by the chiral metal centre.  
These assignments were made and confirmed using 2D-NMR techniques such as HSQC and 
COSY, whereby the COSY shows the spin-spin coupling between proton 1 and 2, as well as 
between 2 and 3 of the propyl chain as well as between the PTA protons (Figure 3.5). 
 




Figure 3.5: Representative COSY spectrum of the rhodium(III) naphthaldimine cationic 
mononuclear complexes (3.2). 
In the 13C{1H}-NMR spectra the imine carbon resonances appear downfield at about ~175.0 
ppm for each metal complex (3.1-3.3). The chemical shifts for the aliphatic carbons appear 
between 10.4-72.5 ppm, while the aromatic carbon atoms appear furthest downfield, between 
119.9 and 147.1 ppm. The aromatic carbons on the p-cymene ligand of the ruthenium 
complex (3.1) appear between 86.3 and 92.6 ppm, while the carbons on the Cp* moiety in 
complexes 3.2 and 3.3, appear at 9.01 and 8.71 ppm, respectively.  
In the 31P{1H}-NMR spectrum of each complex (3.1-3.3), a septet is observed at -144.0 ppm 
which corresponds to the hexafluorophosphate counterion. This septet is observed due to the 
coupling of the phosphorous to all six fluorine atoms. The spectra of the ruthenium(II) and 
iridium(III) complexes (3.1 & 3.3), display a singlet at  -39.9 and    -79.5 ppm, respectively, 
which corresponds to the PTA coordinated to the metal centre. A doublet is observed in the 
spectrum of the rhodium(III) complex (3.2) at -44.9 ppm, with a coupling constant of -45 Hz, 
as rhodium is NMR-active and confirms that there is coupling between the rhodium(III) 
metal centre and the P-donor ligand of the PTA moiety.   
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3.2.1.2 Infrared (IR) spectroscopy 
The IR spectra of all three complexes (3.1-3.3) were recorded as KBr pellets and show the 
presence of imine absorption bands ranging between 1602 and 1607 cm-1. These values 
indicate a shift in the imine absorption band from 1640 cm-1 for the metal-free ligand (2.1) to 
lower frequencies for each cationic metal complex (3.1-3.3). This shift is expected as it 
confirms the coordination of the metal centres to the imine nitrogen due to metal-nitrogen 
back donation, as previously discussed.  
Table 3.1: IR spectroscopy data for the cationic mononuclear complexes (3.1-3.3) versus the 
data obtained for the corresponding neutral analogues (2.7-2.9). 
Complex Cationic complex (cm-1) Neutral complex (cm-1) 
Ru(II)  1602 (3.1) 1611 (2.7) 
Rh(III) 1607 (3.2) 1610 (2.8) 
Ir(III) 1602 (3.3) 1603 (2.9) 
 
The imine absorption band in the IR spectra of each cationic complex (3.1-3.3) is consistent 
with that of the neutral complexes (2.7-2.9) (Table 3.1).  
 
3.2.1.3 Electron Ionization Mass Spectrometry (EI-MS) 
The mass spectra of each complex (3.1-3.3) show fragmentation peaks corresponding to the 
loss of a hexafluorophosphate counterion as well as the PTA moiety corresponding to the 
molecular ion [M-( PF6+PTA)]+.  
 
3.2.2 Synthesis of the cationic naphthaldimine G1 & G2 metallodendrimers 3.4-3.9 
The synthesis of the G1 and G2 cationic metallodendrimers was similar to the synthesis of 
the cationic mononuclear complexes (3.1-3.3),18 whereby PTA was added to the reaction 
mixture after cyclometalation and finally sodium hexafluorophosphate was added at 0oC in 
order to replace the chloride ligand (Scheme 3.2 & 3.3).20  




Scheme 3.2: Synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) C,N–
chelating G1 naphthaldimine metallodendrimers (3.4-3.6). 
The ruthenium(II) naphthaldimine G1 and G2 cationic complexes (3.4 & 3.7) were obtained 
as yellow-brown solids in moderate yields of approximately 40%, while the rhodium(III) (3.5 
& 3.6) and iridium(III) (3.8 & 3.9) metallodendrimers were obtained as yellow-orange solids 
in poor to moderate yields. All the cationic metallodendrimers (3.4-3.9) are soluble in 
acetone, methanol, ethanol, DCM and chloroform and sparingly soluble in water. 
  
Scheme 3.3: Synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) C,N–
chelating G2 naphthaldimine metallodendrimers (3.7-3.9). 
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3.2.2.1 1H-, 13C{1H}- and 31P{1H}-NMR spectroscopy 
The imine singlet in both the first- and second-generation metallodendrimers (3.4-3.9) is 
observed upfield in each 1H-NMR spectrum between 8.57 and 8.84 ppm. This result confirms 
that the imine bond is still intact (Figures 3.6 & 3.7).  
The core protons of the metallodendrimers appear in similar ranges far upfield, with the 
ruthenium(II) complexes (3.4 & 3.7) having their core protons generally more upfield than 
the rhodium(III) (3.5 & 3.6) and iridium(III) (3.8 & 3.9) complexes. The core protons of the 
ruthenium(II) G1 (3.4) and G2 (3.7) metallodendrimers appear between 0.71 and 2.44 ppm, 
while the core protons of the rhodium(III) (3.5 & 3.8) and iridium(III) (3.6 & 3.9) 















Figure 3.6: Representative 1H-NMR spectra of the cationic rhodium(III) (3.5) and 
iridium(III) (3.6) naphthaldimine G1 metallodendrimers. 
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For all six metallodendrimers (3.4.-3.9), the aromatic protons for the naphthaldimine phenyl 
ring appear between 7.29 and 8.58 ppm, which is the expected region for aromatic protons. 
The cationic ruthenium complexes (3.4 & 3.7) exhibit a loss of two-fold symmetry of the p-
cymene moiety as well as the aromatic protons of the p-cymene moiety in each ruthenium 
complex displaying four separate peaks in the 1H-NMR spectra between 4.95 and 5.86 ppm. 
These trends are observed in the model cationic mononuclear complex (3.1) due to 
diastereotopicity and loss freedom of rotation of the p-cymene moiety. However in the 
metallodendrimers two of the p–cymene resonances overlap and appear as one peak due to 
broadening of the peaks. The Cp* methyl protons in the rhodium(III) (3.5 & 3.8) and 















Figure 3.7: Representative 1H-NMR spectra of the cationic rhodium(III) (3.8) and 
iridium(III) (3.9) naphthaldimine G2 metallodendrimers. 
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In the spectra of all six metallodendrimers (3.4-3.9), two sets of broad resonances are 
observed between 3.91 and 4.13 ppm corresponding to the –CH2 group adjacent to the imine 
nitrogen, which can be attributed to the diasterotopicity of the protons induced by the now 
chiral metal centre. The proton signals associated with the PTA moiety appear in the region 
3.58-4.64 ppm for all six metallodendrimers (3.4-3.9). 
The spectra obtained from 13C{1H}-NMR spectroscopy exhibit imine carbon resonances 
downfield between 174.70 and 177.50 ppm for each cationic G1 and G2 metallodendrimer 
(3.4-3.9). The aliphatic carbon atoms resonate at chemical shifts between 9.32 and 62.35 ppm 
for the rhodium(III) (3.5 & 3.8) and iridium(III) (3.6 & 3.9) metallodendrimers, while for the 
ruthenium(II) metallodendrimers (3.4 & 3.7) the aliphatics range further downfield between 
18.21 and 72.86 ppm. The aromatic carbons of the p-cymene moiety appear between 79.73 
and 94.72 ppm, while the carbons of the Cp* moiety in the rhodium(III) (3.5 & 3.8) and 
iridium(III) (3.6 & 3.9) metallodendrimers, appear at about ~9.00 ppm. The carbon atoms 
associated with the PTA moiety in each metallodendrimer (3.4-3.9) appear between 49.79 
and 72.00 ppm. All the NMR spectroscopy assignments were made using 2D-NMR 
techniques such as HSQC and COSY whereby similar trends were found for the 
metallodendrimers as the model cationic mononuclear complexes, except for the presence of 
the core protons. 
 In the 31P{1H}-NMR spectrum of each metallodendrimer (3.4-3.9), a septet is observed at     
-144.0 ppm which corresponds to the hexafluorophosphate counterion. The spectra of the 
ruthenium(II) (3.4 & 3.7) and iridium(III) (3.6 & 3.9) complexes displays a singlet at about -
30.0 and -79.1 ppm, respectively, while a doublet is observed in the spectra of the 
rhodium(III) (3.5 & 3.8) complexes at about -44.0 ppm. These resonances correspond to the 
coupling of the metal centre to the PTA moiety, and further attest to only one phosphorous 
containing compound.   
 
3.2.2.2 Infrared (IR) spectroscopy 
In the IR spectra of each cationic metallodendrimer (3.4-3.9), there has been a shift of the 
imine absorption band to a lower frequency compared to that of the metal-free ligands (2.3 & 
2.5), which have imine absorption bands at 1639 cm-1 which confirms the coordination of the 
metal centres to the dendritic ligands in a C,N-bidentate fashion. 
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Table 3.2: IR spectroscopy data for the cationic metallodendrimers (3.4.-3.9) versus the data 
obtained for the corresponding neutral analogues (2.13-2.15) and (2.19-2.21). 
Complex Cationic complex (cm-1) Neutral complex (cm-1) 
Ru(II)-G1 1600 (3.4) 1604 (2.13) 
Rh(III)-G1 1613 (3.5) 1609 (2.14) 
Ir(III)-G1 1604 (3.6) 1602 (2.15) 
Ru(II)-G2 1603 (3.7) 1602 (2.19) 
Rh(III)-G2 1609 (3.8) 1610 (2.20) 
Ir(III)-G2 1602 (3.9) 1600 (2.21) 
 
As with the model mononuclear complexes, the IR imine absorption band of each cationic 
complex corresponds to the analogous neutral complexes. (Table 3.2) 
 
3.2.2.3 High Resolution Electrospray Ionization Mass Spectrometry (ESI-MS) 
All six metallodendrimers (3.4-3.9) show base peaks without several or all of the PF6 
counterions and PTA moieties. The ruthenium G1 metallodendrimer (3.4) shows a base peak 
corresponding to the loss of the PF6 counterions as well as forming an adduct with water. The 
rest of the metallodendrimers (3.5-3.9) exhibit base peaks corresponding to the loss of all or a 
few of the PF6 counterions and PTA moiety (Table 3.3). 
Table 3.3: Mass spectrometry data for the cationic metallodendrimers (3.4.-3.9). 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
3.4 3014.81 626.1612 [M-4PF6+4H2O]4+ 
3.5 3026.20 533.2226 [M-4PF6-2PTA]4+ 
3.6 3383.44 1391.4447 [M-2PF6-2PTA]2+ 
3.7 6169.85 585.1436 [M-8PF6-2PTA)]8+ 
3.8 6192.63 587.1556 [M-8PF6-2PTA]8+ 
3.9 6907.11 1215.4901 [M-4PF6-PTA)]4+ 
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3.3 Reactions with ferrocenyl-pyridine 
3.3.1 Synthesis of the cationic heterometallic-ferrocenyl mononuclear complexes 3.10 & 
3.11 
An additional series of cationic compounds were synthesized by incorporating a ferrocenyl 
moiety in order to obtain a series of heterometallic complexes. The chloride ligand 
coordinated to the metal centre was displaced by a ferrocenyl-pyridine nitrogen-donor ligand, 
making these complexes cationic. The ferrocenyl moiety used was 4-ferrocenyl-pyridine, 
with the pyridine-nitrogen acting as the nitrogen donor ligand to be coordinated to the 
rhodium(III) or iridium(III) metal centre. The synthesis used followed the procedure outlined 
by Imrie et al.11 whereby bromoferrocene was reacted with magnesium, in the presence of 
1,2-dibromoethane acting as a catalyst, to form a Grignard reagent.11 This was then reacted 
with 4-bromopyridine in the presence of a nickel catalyst (Scheme 3.4).11 
 
Scheme 3.4: Synthetic procedure for 4-ferrocenyl-pyridine.11 
The cyclometalation of the naphthaldimine monomeric ligand 2.1 followed the same 
procedure used throughout this project using only the rhodium(III) and iridium(III)-Cp* 
dimeric precursors.19 The ruthenium(II) p-cymene analogues were attempted but were 
obtained as impure solids, with the 1H-NMR spectra exhibiting a mixture of products. This 
could be attributed to the incomplete cyclometalation occuring. After cyclometalation, the 
reaction mixture was filtered through Celite followed by the addition of the ferrocenyl-
pyridine, which was stirred for a further 30-60 minutes. Sodium hexafluorophosphate was 
finally added at 0oC in order to replace the chloride counterion with a more stable counterion 
(Scheme 3.5).20  




Scheme 3.5: Synthesis of the heterometallic rhodium(III) and iridium(III) C,N–chelating 
mononuclear complexes (3.10 & 3.11). 
 
The heterometallic mononuclear complexes (3.10 & 3.11) were obtained as dark red solids in 
moderate yields ranging between 28 and 38%. All the mononuclear complexes are soluble in 
acetone, methanol, ethanol, DCM and chloroform. 
 
3.3.1.1 1H-NMR and 13C{1H}-NMR spectroscopy 
In the 1H-NMR spectra of each complex (3.10 & 3.11), the imine singlet appears downfield 
between 8.74 and 8.91 ppm. This is an indication that the imine bond is still intact. The 
ferrocenyl protons on the substituted and unsubstituted Cp rings appear in similar regions, 
further upfield between 3.98 and 4.89 ppm while the naphthaldimine aromatic protons appear 








Figure 3.8: Representative 1H-NMR spectrum of the heterometallic rhodium(III) 
naphthaldimine mononuclear complex (3.10). 
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In the 1H-NMR spectra, a singlet is observed for the protons of the Cp* moiety and a triplet 
for the –CH2 group adjacent to the imine nitrogen, at similar resonances found in the neutral 
(2.8 & 2.9) and cationic (3.2 & 3.3) analogues. These assignments were made and confirmed 
using 2D-NMR techniques such as HSQC and COSY. As can be seen in Figure 3.9, the 
COSY of the iridium(III) heterometallic complex (3.11) shows the spin-spin coupling 
between the protons 1 and, as well as 2 and 3 of the propyl chain, coupling between the 












Figure 3.9: Representative COSY spectrum of the heterometallic iridium(III) naphthaldimine 
mononuclear complex (3.11). 
The 13C{1H}-NMR spectra display resonances corresponding to the imine carbon peaks 
downfield at about ~175.0 ppm for each metal complex (3.10 & 3.11). The resonances for the 
aliphatic, aromatic and Cp* moiety carbons appear at similar resonances to that of the neutral 
(2.8 & 2.9) and cationic (3.2 & 3.3) analogues. In between these resonances, the ferrocenyl 
aromatic protons appear between 67.4 and 71.7 ppm.  
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3.3.1.2 Infrared (IR) spectroscopy 
The IR spectra of both complexes (3.10 & 3.11) were recorded as KBr pellets and show the 
presence of imine absorption bands at 1611 cm-1. These values indicate a shift in the imine 
absorption band from 1640 cm-1 for the metal-free ligand (2.1) to lower frequencies for each 
heterometallic complex (3.10 & 3.11). This shift is expected as it confirms the coordination 
of the metal centres to the imine nitrogen due to metal-nitrogen back donation, as previously 
discussed.  
Table 3.4: IR spectroscopy data for the heterometallic complexes (3.10 & 3.11) versus the 
data obtained for the corresponding neutral analogues (2.8 & 2.9). 
Complex Cationic complex (cm-1) Neutral complex (cm-1) 
Rh(III) 1611 (3.10) 1610 (2.8) 
Ir(III) 1611 (3.11) 1602 (2.9) 
 
As can be seen in Table 3.4), the neutral and heterometallic complexes have similar imine 
absorption band values.  
 
3.3.1.3 Electron Ionization Mass Spectrometry (EI-MS) 
The mass spectra of each mononuclear complex (3.10 & 3.11) show fragmentation peaks 
without the hexafluorophosphate counterions and ferrocenyl-pyridine ligand. The 
rhodium(III) complex (3.10) also shows the loss of the Cp*moiety (Table 3.5).  
 
Table 3.5: Mass spectrometry data for the heterometallic mononuclear complexes (3.10 & 
3.11). 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
3.10 842.49 295.05 [M-PF6-(Fc-py)-Cp*]2+ 
3.11 931.80 519.10 [M-PF6-(Fc-py)]+. 
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3.3.2 Synthesis of the cationic heterometallic-ferrocenyl G1 and G2 metallodendrimers 
3.12-3.15 
Once the model mononuclear complexes (3.10 & 3.11) had been synthesized, the first- and 
second-generation metallodendrimers (3.12-3.15) were then synthesized to obtain a series of 
polynuclear-heterometallic complexes. The same reaction protocol was using cyclometalation  
and chloride displacement was followed as for the mononuclear analogues (3.1-3.3) (Scheme 
3.6 & 3.7).19  
 
Scheme 3.6: Synthesis of the heterometallic rhodium(III) and iridium(III) C,N–chelating G1 
naphthaldimine metallodendrimers (3.12 & 3.13). 
All four poly-heterometallic complexes (3.12-3.15) were obtained as red-orange solids in 
moderate yields between 24 and 51%, and are soluble in acetone, methanol, ethanol, DCM 
and chloroform. 
Scheme 3.7: Synthesis of the heterometallic rhodium(III) and iridium(III) C,N–chelating G2 
naphthaldimine metallodendrimers (3.14 & 3.15). 
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3.3.2.1 1H-NMR and 13C{1H}-NMR spectroscopy 
The resonances observed in the 1H-NMR spectra of the poly-heterometallic complexes 
appear as broadened signals due to chemical equivalence of the polymeric compounds on the 
NMR timescale. In the 1H-NMR spectra of the heterometallic metallodendrimers (3.12-3.15) 
the imine resonance appears downfield between 8.49 and 8.74 ppm. This result confirms that 
the imine bond is still intact (Figure 3.10). The naphthaldimine aromatic protons of the 
metallodendrimers appear in similar ranges downfield between 7.18 and 8.29 ppm, while the 
ferrocenyl protons for each heterometallic metallodendrimer (3.12-3.15) appear between 3.94 
and 4.83 ppm. 
In the 1H-NMR spectra of the heterometallic metallodendrimers (3.12-3.15), a singlet is 
observed at ~1.70 ppm for the Cp* moiety and a broad singlet between 3.87 and 4.46 ppm for 
the –CH2 group adjacent to the imine nitrogen, similarly to the model mononuclear 
complexes (3.10 & 3.11). All the NMR spectroscopy assignments were made using 2D-NMR 
techniques such as HSQC and COSY, whereby the aliphatic protons, including the core 
protons, showed spin-spin coupling. The same is observed for the aromatic protons and the 
ferrocenyl moiety. 
The 13C{1H}-NMR spectra exhibit imine carbon peaks downfield between 174.96 and 177.18 
ppm for each heterometallic first- and second-generation metallodendrimer (3.12-3.15). The 
chemical shifts for the aliphatic carbons appear between 7.91 and 71.9 ppm, while the 
aromatic carbons appear further downfield between 121.5 and 158.8 ppm. The carbons on the 
Cp* moiety appear at about ~8.30 ppm. The carbon atoms associated with the ferrocenyl-
pyridine moiety appear between 67.8 and 72.0 ppm.  
 
3.3.2.2 Infrared (IR) spectroscopy 
It is evident in the IR spectra of each heterometallic complex (3.12-3.15) that the imine 
absorption bands are at lower frequencies compared to the metal-free dendritic ligands (2.3 & 
2.5) with an imine absorption band at 1639cm-1, which confirms the coordination of the metal 
centres to the dendritic ligands. (Table 3.6).  
 
 
Chapter 3  Cationic & Heterometallic Complexes 
80 
 
Table 3.6: IR spectroscopy data for the heterometallic metallodendrimers (3.12-3.15) versus 
the data obtained for the corresponding neutral analogues (2.14, 2.15, 2.20 & 2.21). 
Complex Heterometallic complex (cm-1) Neutral complex (cm-1) 
Rh(III)-G1 1610 (3.12) 1609 (2.14) 
Ir(III)-G1 1610 (3.13) 1602 (2.15) 
Rh(III)-G2 1608 (3.14) 1600 (2.20) 
Ir(III)-G2 1610 (3.15) 1600 (2.21) 
 
For certain cases, such as the rhodium(III) G1 metallodendrimer (3.12), the cationic and 
neutral complexes exhibit almost identical imine absorption bands.  
 
3.3.2.3 High Resolution Electrospray Ionization Mass Spectrometry (ESI-MS) 
All four metallodendrimers (3.12-3.15) exhibit the presence of base peaks in the mass 
spectra. The base peaks present in the mass spectra of complexes 3.12 and 3.15 correspond to 
the loss of all or several PF6 counterions as well as the loss of the ferrocenyl-pyridine moiety 
(Table 3.9). The base peaks correspond to complexes 3.13 and 3.14 form adducts with 
methanol and formic acid, respectively, as well as the loss of the PF6 counterions (Table 3.7). 
Table 3.7: Mass spectrometry data for the heterometallic metallodendrimers (3.12-3.15). 
Complex Calculated M (g/mol) Molecular fragment (m/z) Assignment 
3.12 3450.06 653.8500 [M-4PF6-(Fc-py)]4+ 
3.13 3807.30 1058.3701 [M-3PF6+MeOH]3+ 
3.14 7040.32 782.2932 [M-8PF6+HCO2H]8+ 
3.15 7754.82 1058.3744 [M-6PF6-2(Fc-py)]6+ 
 
3.4 Conclusions 
A series of cationic mononuclear and polynuclear dendritic ruthenium(II), rhodium(III) and 
iridium(III) complexes were obtained through reactivity studies with PTA, which presented a 
succession of air-stable chelating, bidentate C,N-donor ruthenium(II), rhodium(III) and 
iridium(III) metallodendrimers. These new complexes were fully characterized using 
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spectroscopic and analytical techniques, i.e. 1H-NMR, 13C{1H}-NMR, IR spectroscopy and 
mass spectrometry.  
Furthermore a series of cationic heterometallic complexes were also succesfully synthesized 
by incorporating a ferrocenyl-pyridine moeity. Only the rhodium(III) and iridium(III) 
analogues were synthesized for this series of compounds. This was the case as 
cyclometalation involves the intramolecular C-H activation via a process involving attack of 
an electrophilic metal centre on the C-H bond of the desired ligand, in this case the 
naphthaldimine ligand.21 Therefore the arene ligand attached to the ruthenium centre needs to 
be less π–electron donating, while the ligand needs to be more electron rich, in order for 
successful cyclometalation to occur. It has been shown previously that [Ru(HMB)Cl2]2 lends 
itself more to cyclometalation than [Ru(p-cymene)Cl2]2 as the benzene ring is a weaker π-
electron donor, compared to the p-cymene ligand.22, 23 However the rhodium(III) and 
iridium(III)-ferrocenyl heterometallic complexes were synthesized successfully and fully 
characterized using spectroscopic and analytical techniques. 
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Chapter 4: In Vitro Antitumour Evaluation of Multinuclear Ruthenium(II), 
Rhodium(III)and Iridium(III) Metallodendrimers 
 
4.1 Introduction 
Ruthenium-based compounds currently in clinical trials are NAMI-A and KP1019 (Figure 
4.1).1, 2 It is proposed that ruthenium is more active in the +2 oxidation state and it is 
understood that ruthenium(III) is reduced to ruthenium(II) in vivo.2 Therefore there has been 
a shift in focus from ruthenium(III) to ruthenium(II)-arene compounds, with the π-








Figure 4.1: Structure of ruthenium(III) anti-tumour drugs KP1019 and NAMI-A.3 
The ruthenium-arene unit has desirable amphiphilic properties such as the hydrophobic 
nature of the arene ligand with the hydrophilic nature of the ruthenium metal centre. The 
halide ligand is very labile and undergoes hydrolysis in an aqueous environment.4 It has also 
been proposed that ruthenium(II)-arene complexes undergo aquation in vivo leading to 
reactive cationic species (Figure 4.2).5 Aquation is believed to be the key aspect in the 
biological activity of certain ruthenium-arene and cyclometalated complexes as it has been 
proposed that the aquated cationic complex could bind covalently to DNA acting as DNA 
binding agents or DNA-intercalators of the planar moiety into the DNA double helix. 4 
 
 




Figure 4.2: Schematic of the proposed aquation that occurs in vivo.5  
There are only a handful of examples of rhodium(III) and iridium(III) complexes showing 
promising anticancer activity. Sadler et al.6 synthesized a series of mononuclear 
cyclometalated iridium complexes and evaluated their cytotoxicity against the A2780 ovarian 
cancer cell line.6 The complexes (Figure 4.3) exhibited IC50 values of 2.14 ± 0.50µM and 
0.70 ± 0.04µM, respectively, compared to cisplatin with an IC50 value of 1.19 ± 0.12µM.6, 7 
They proposed, besides the possibility of DNA intercalation, the presence of the C,N-








Figure 4.3: Iridium cyclometalated complexes showing good in vitro activity.6 
Ruthenium RAPTA-type compounds show in vivo anticancer activity and rhodium 
derivatives have also been synthesized.8, 9 The rhodium analogues showed comparable in 
vitro activity to the related ruthenium(II) compounds, against the T47D breast carcinoma, 
A549 lung carcinoma and HT29 colon carcinoma cell lines.10 Therefore there is promising 
evidence that rhodium and iridium complexes can be used in biological applications, such as 
anticancer treatment.6, 7 
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Multinuclearity is said to improve biological recognition and cytotoxicity of potential 
chemotherapeutic drugs.11 There are only a handful of ruthenium(II) biometallodendrimers, 
and even fewer containing rhodium(III) and iridium(III) that have been synthesized and 
undergone anticancer in vitro and in vivo studies.12 
Jansen et al.13 synthesized the first tetranuclear platinum metallodendrimer by incorporating 
the cisplatin moiety onto the PPI dendritic scaffold (Figure 4.4).13 The tetranuclear complex 
showed moderate in vitro activity with IC50 values ranging from 9-12 μM against a range of 
mouse leukaemia and human tumour cell lines.13 The cytotoxicity of the complex can be 
attributed to the charge and the polynuclearity of the metallodendrimer.11, 13  
 
Figure 4.4: Tetranuclear PPI platinum metallodendrimer showing moderate in vitro 
activity.13  
A supramolecular assembly with ruthenium(II) arene corners linked by polypyridyl spacers 
were synthesized. Their anticancer activity was evaluated against human ovarian cancer cells 
and the complexes displayed activities similar to cisplatin (Figure 4.5) .14, 15 




Figure 4.5: Ruthenium-arene molecular assembly tested for anti-cancer activity.14  
Multinuclearity13 has shown to improve cytotoxicity of biorganometallic complexes, as well 
as the incorporation of ruthenium(II)-arene16, 17 and cyclometalated6, 7, 18-20 moieties. 
Therefore this study focusses on combining cyclometalated ruthenium(II)-arene, rhodium(III) 
and iridium(III) complexes with multinuclear scaffolds, namely metallodendrimers. 
 
This chapter describes the in vitro biological activity of the synthesized ligands (2.1-2.6), as 
well as the ruthenium(II), rhodium(III) and iridium(III) neutral (2.7-2.24) and cationic (3.1-
3.9) complexes (Figure 4.6). These complexes were tested against the cisplatin-sensitive 
(A2780) and cisplatin-resistant (A2780cisR) human ovarian cancer cell lines, as well as the 































Figure 4.6: Monomeric and dendritic ligands 2.1-2.6, neutral 2.7-2.24 and cationic 3.1-3.9 
ruthenium(II), rhodium(III) and iridium(III) complexes which were tested for anticancer 
activity. 
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4.2 Ligands versus complexes 
The ligands and complexes were compared following their biological evaluation in the 
cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell line, as well as the non-
cancerous KMST-6 human skin tissue or HEK human embryonic kidney cell line. The 
naphthaldimine and benzaldimine ligands were tested against the respective cells (Table 4.1 
& Figure 4.7). The ligands showed moderate activity with no specificity towards the 
cancerous versus non-cancerous cells. This indicates that these will be toxic as anticancer 
agents, whereas the metal complexes show more specificity towards cancerous versus non-
cancerous cells. Therefore the incorporation of metal centres into these organic frameworks 
may increase the specificity and antiproliferative activity. 
Table 4.1: IC50 values of the naphthaldimine & benzaldimine ligands (2.1-2.6). 
Compound ref. IC50 A2780 (μM) IC50 A2780cisR (μM) IC50 HEK (μM) 
2.1 68.4±1.8 79.3 78.8±1.7 
2.2 18.0±2.0 10.5 18.4±2.4 
2.3 5.5±0.5 NA 4.2±0.5 
2.4 60.0±4.4 40.0 75.4±3.4 
2.5 17.3±11.3 NA 11.7±8.9 
2.6 30.5±0.5 5.80 14.3±4.1 
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4.3 Influence of the number of metal centres (n = 4,8) 
There is sufficient evidence that ruthenium, rhodium and iridium complexes have shown 
potential in vitro anticancer activity.12 Therefore as a preliminary study, the synthesized 
complexes were also tested in vitro to see whether they do show potential anticancer activity. 
Table 4.1 shows the IC50 values for the mononuclear (2.7-2.9), first- (2.13-2.15) and second- 
generation (2.19-2.21) naphthaldimine complexes. Comparison of their biological activity 
based on the number of metal moieties shows that with an increase in generation size there is 
an increase in cytotoxicity in most cases. 
Table 4.2: IC50 values of the neutral naphthaldimine complexes, comparing size and 
cytotoxicity. 
Naphthaldimine compound No. of metals A2780 A2780cisR HEK 
Ruthenium(II)  (IC50 μM) (IC50 μM) (IC50 μM) 
2.7 1 9.9 ± 1.3 8.2 ± 2.5 NA  
2.13 4 19.6 ± 1.2 18.97 ± 1.3 NA 
2.19 8 8.1 ± 0.8 <1.56 5.2 ± 1.1  
Rhodium(III)     
2.8 1 13.4 ± 2.4 19.0 ± 1.2 52.9 ± 67.9 
2.14 4 104.4 ± 15.0 105.4 ± 8.2 126.5 ± 178.9 
2.20 8 8.0 ± 0.5 3.11 4.5 ± 0.5 
Iridium(III)     
2.9 1 20.1 ± 13.6 19.0 ± 8.5 72.4 ± 91.1 
2.15 4 29.7 ± 0.1 28.1 ± 2.0 NA 
2.21 8 13.7 ± 0.1 3.0 5.0 ± 1.2  
cisplatin 1 1.5 25  
 
The second-generation complexes (2.19-2.21) with 8 metal centres each, show the best 
activity with IC50 values ranging between 8.0 and 13.7 μM, compared to their analogous 
mononuclear and first-generation complexes (Table 4.2). An unusual trend is noticed when 
comparing the mononuclear (2.7-2.9) and first-generation (2.13-2.15) complexes, there is a 
decrease in activity on going from the mononuclear complex to the first-generation complex. 
Without certainty, it may be attributed to back-folding of some of the repeat units in the first-
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generation metallodendrimers, compared to the mononuclear and second-generation 
complexes due to greater steric bulk at the periphery which reduces ‘back folding’.21 
Therefore it can be proposed that the metal centres situated on the periphery of the first-
generation metallodendrimers are not able to perform their respective biological activity due 
to this supposed ‘back folding’. Further work needs to be done, for example synthesizing and 
testing third- and fourth-generation metallodendrimers, in order to confirm this hypothesis. 
However, the second generation complexes, with the most metal centres (n=8), still show the 
best activity therefore confirming that with an increase in size and number of metals, there is 
an increase in cytotoxicity, which correlates with previously published work.22  
Another key feature observed is that the mononuclear and first-generation complexes show 
selectivity towards cancer cells over healthy cells, having lower IC50 values against the 
cancerous cells versus the non-cancerous HEK cells. However further biological tests would 
need to be performed in order to confirm this hypothesis as the error values obtained for the 
first-generation complexes are very large. This is not the case for the second-generation 
complexes, but the complexes do seem to be more selective for the cisplatin-resistant cell line 
versus the healthy HEK cells (Table 4.2). 
The rhodium(III) (2.20) and ruthenium(II) (2.19) second-generation metallodendrimers 
showed the best activity with IC50 values of 8.0 and 8.1 μM, respectively (Table 4.2). These 
values are approximately 5 times lower when compared to cisplatin (1.5μM) against the 
cisplatin-sensitive human ovarian cancer cell line, A2780. When comparing the IC50 values of 
the second-generation complexes (2.19-2.21) against the cisplatin-resistant ovarian cancer 
cell line, A2780cisR, the second generation complexes are far more active than cisplatin 
(25μM) with IC50 values as low as 1.56-3.00 μM. This could be attributed to these new 
complexes acting via a different mechanism of action compared to cisplatin and are therefore 
able to overcome cisplatin-resistant mechanisms.  
 
4.4 Influence of the metal centre – ruthenium(II) vs. rhodium(III) vs. iridium(III) 
The ruthenium centre has a p-cymene arene ligand, whereas the rhodium(III) and iridium(III) 
metal centres have a pentamethylcyclopentadienyl ligand. Bearing this is mind the 
ruthenium(II) (2.19) and rhodium(III) (2.20) second-generation complexes show comparable 
activity with the lowest IC50 values (Table 4.2 & Figure 4.8). When comparing the 
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rhodium(III) and iridium(III) complexes, in general, the rhodium(III) complexes show greater 
activity, with the exception of the rhodium(III) first-generation (2.14) complex (Table 4.2 & 
Figure 4.8). 
Figure 4.8: Graph illustrating the effect of the metal centre on the cytotoxicity of each 
neutral naphthaldimine complex 2.7-2.9, 2.13-2.15 & 2.19-2.21. 
 
4.5 Influence of the naphthaldimine versus the benzaldimine C,N-ligand 
The mononuclear (2.10-2.12), first- (2.16-2.18) and second- (2.22-2.24) generation 
benzaldimine complexes were compared following their biological evaluation in the 
cisplatin-resistant human ovarian cancer cell line and the non-cancerous KMST-6 human skin 
tissue cell line. This was due to contamination issues associated with the cisplatin-sensitive 
cell line, which could not be grown in order for accurate testing to occur.  
The ruthenium(II) benzaldimine complexes were the only complexes to show that an increase 
in generation size and number of metals lead to an increase in activity, indicated by a 
decrease in IC50 value from 22.3 to 15.5 μM (Table 4.3 & Figure 4.9). The rhodium(III) and 
iridium(III) benzaldimine series showed the opposite effect, whereby the biological activity 
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Another key feature observed is that the benzaldimine complexes show selectivity towards 
cancerous cells versus healthy cells, exhibiting high IC50 values against the non-cancerous 
cells (KMST-6) with values as high as 130.00 μM (Table 4.3). 
 
Table 4.3: IC50 values of the neutral benzaldimine series of complexes (2.10-2.12, 2.16-2.18 
& 2.22-2.24). 
Benzaldimine compound No of metals A2780cisR KMST-6 
Ruthenium(II)  (IC50 μM) (IC50 μM) 
2.10 1 22.3 ± 1.0 62.9 ± 41.2 
2.16 4 17.5 ± 6.0 28.5 ± 0.8 
2.22 8 15.5 ± 1.2 54.0 ± 1.2 
Rhodium(III)    
2.11 1 16.5 ± 3.5 58.1 ± 81.59 
2.17 4 76.0 ± 12.0 110.0 ± 0.3 
2.23 8 30.0 ± 2.0 130.5 ± 4.00 
Iridium(III)    
2.12 1 8.5 ± 0.8 41.5 ± 57.3 
2.18 4 67.0 ± 1.6 112.0 ± 1.3 
2.24 8 18.5 ± 0.45 96.0 ± 0.8 
 
Although the ruthenium(II) benzaldimine complexes showed an increase in activity with an 
increase in size, the second-generation ruthenium(II) metallodendrimer (2.22) still did not 
show the best activity. The iridium(III) mononuclear complex (2.12) showed the best 
antiproliferative activity within the benzaldimine series with an IC50 value of 8.5 μM (Table 
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Figure 4.9: Graph illustrating the effect of the Schiff base ligand on the cytotoxicity of each 
neutral complex. 
 
When comparing the activity of the neutral naphthaldimine versus the benzaldimine 
complexes, the activities of the mononuclear and first-generation complexes are comparable. 
The naphthaldimine second-generation complexes show better activity versus the second-
generation benzaldimine complexes (Table 4.3 & Graph 4.9). The naphthaldimine series 
also shows a direct correlation between size and cytotoxicity, whereas the activities of the 
benzaldimine complexes do not show any obvious trend (Table 4.3).  
 
4.6 Influence of the charge – neutral versus cationic complexes 
There is precedence in the literature that cationic complexes22 and complexes containing 
PTA8, 9, such as the RAPTA type complexes, show improved cytotoxicity. This is ascribed to 
the fact that PTA has shown to enhance the water solubility of organometallic complexes. As 
can be seen in Table 4.4 there is a direct correlation between size of the metallodendrimer, 
number of metal atoms and cytotoxicity. Going from the mononuclear complexes (3.1-3.3) to 
the first- (3.4-3.6) and then second-generation (3.7-3.9) complexes there is an increase in 
activity. The only exception being the first-generation rhodium(III) complex (3.5) which 
shows a decrease in activity going from the mononuclear (3.2) to the first-generation (3.5) 
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Table 4.4: IC50 values of the cationic naphthaldimine complexes comparing charge and 
cytotoxicity. 
Naphthaldimine compound No of metals A2780 A2780cisR HEK 
Ruthenium(II)  (IC50 μM) (IC50 μM) (IC50 μM) 
3.1 1 27.7 ± 0.6 NA 10.3 ± 1.1 
3.4 4 4.03 ± 1.13 5.48 5.00 ± 1.2 
3.7 8 1.35 ± 0.14 2.34 4.2 ± 0.5 
Rhodium(III)     
3.2 1 1.52 ± 0.05 1.49 ± 0.03 75.4 ± 3.4 
3.5 4 9.26 ± 0.72 4.90 18.4 ± 2.4 
3.8 8 2.10 ± 0.09 1.78 ± 0.56 4.5 ± 0.5 
Iridium(III)     
3.3 1 28.8 ± 2.2 45.6 14.3 ± 4.1 
3.6 4 3.59 ± 0.25 3.83 78.8 ± 1.7 
3.9 8 2.75 ± 0.01 1.61 ± 0.02 5.2 ± 1.1 
 
All three second-generation complexes (3.7-3.9) with 8 metal centres display the best 
cytotoxicity among the PTA-derivatives with IC50 values comparable to cisplatin, ranging 
between 1.35-2.75 μM. The first-generation complexes exhibited values of about ~5.00 μM 
while the mononuclear complexes varied from ~28.00 μM, with the exception of the 










Chapter 4  In Vitro Biological Results 
96 
 
Figure 4.10: IC50 values of the neutral versus cationic naphthaldimine series of complexes.  
 
The IC50 values of the neutral ruthenium(II), rhodium(III) and iridium(III) complexes were 
compared to the cationic PTA-derivatives (Table 4.4 & Figure 4.10). In general, all the 
cationic complexes (3.1-3.9) show better in vitro activity compared to their neutral analogues. 
For the second-generation cationic complexes there has been between a 4-10 fold increase in 
activity compared to the neutral complexes. This correlates with studies that state that the 
presence of a charge on a molecule can increase cytotoxicity, either by interaction with 




Following the synthesis of a series of new neutral and cationic dendritic ruthenium(II), 
rhodium(III) and iridium(III) multinuclear complexes based on a naphthaldimine and 
benzaldimine Schiff base ligand (2.7-2.24 & 3.1-3.9), their cytotoxicities against the cisplatin 
sensitive A2780 and cisplatin resistant A2780cisR human ovarian cancer cell lines, as well as 
the non-cancerous HEK and KMST-6 calls, were evaluated. 
A ruthenium(II), second-generation cationic cyclometalated C,N-chelating bidentate 
naphthaldimine octanuclear complex 3.7 showed the best antiproliferative activity with an 
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All the naphthaldimine complexes, neutral and cationic, showed better activity against the 
cisplatin resistant A2780cisR cell line, when compared to cisplatin. This was the case for all 
complexes except the cationic ruthenium(II) mononuclear and neutral rhodium first-
generation complexes. This is a promising result as it indicates that these complexes could act 
via a different mechanism of action to cisplatin and therefore overcome cisplatin-resistant 
mechanisms. 
The cationic naphthaldimine series of complexes showed greater activity than the neutral 
naphthaldimine series. This is expected as an increase in charge could allow for better uptake 
of the anticancer drug, as well as interact with molecules within the cell, facilitating in its 
biological anticancer activity. 
The naphthaldimine complexes show better and expected results versus the benzaldimine 
series, which could be due to the extended aromatic moiety in the naphthaldimine complexes 
which could play some sort of role in the anti-cancer activity of these complexes. 
In general the in vitro biological studies that were performed show preliminary results which 
need to be taken further in order to determine the full potential of these complexes as 
anticancer agents. Studies such as DNA-binding studies could be performed in order to 
determine the target of these complexes and whether they function via a different mode of 
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Chapter 5: Experimental Details 
General 
All reaction solvents were dried over Molecular Sieve Dehydrate Fluka with indicator and all 
samples were dried under vacuum. Naphthaldehyde, benzaldehyde, n-propylamine and 1,4-
diaminobutane poly(propyleneimine) tetraamine (DAB-dendr-(NH2)4-G1) were purchased 
from Aldrich; α-Phellandrene was purchased from Fluka; 1,4-diaminobutane 
poly(propyleneimine) octaamine (DAB-dendr-(NH2)8-G2) was purchased from SyMO Chem 
and used without further purification. Ruthenium(III), rhodium(III) and iridium(III) 
trichloride trihydrate was obtained as a generous donation from Johnson Matthey/Anglo 
Platinum. [Ru(p-cymene)Cl2)]21, [Rh(η5-C5Me5)Cl2]22 and [Ir(η5-C5Me5)Cl2]22 were prepared 
according to literature methods. 
Deuterated solvents were purchased from Aldrich. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Varian Unity XR400 spectrometer (1H: 399.95 MHz, 13C{1H}: 
100.58 MHz) or Varian Mercury XR300 spectrometer (1H: 300.08 MHz, 13C{1H}: 75.46 
MHz) or Bruker Ultrashield 400 Plus spectrometer (1H: 400.20 MHz, 13C{1H}: 100.60 MHz) 
at 30 oC with tetramethylsilane as an internal standard. Infrared (IR) absorptions were 
measured on a Perkin-Elmer Spectrum One FT-IR spectrometer as KBr pellets. 
Microanalysis for carbon, hydrogen and nitrogen were carried out using a Fisions EA 1108 
CHNS elemental analyser. For certain metallodendrimers, the analyses are outside acceptable 
limits, and are ascribed to the encapsulation of solvent molecules and other inorganic salts by 
dendritic compounds. Melting points were determined using a Büchi Melting Point (B-540) 
instrument and are corrected. Mass spectrometry was carried out at the University of 
Stellenbosch on a Waters API Quattro Micro triple quadrupole mass spectrometer. Data were 
recorded using low and high resolution Electrospray Ionisation (ESI) mass spectrometry in 










5.1 Synthesis of monomeric and dendritic ligands 
 
5.1.1 General synthesis of the naphthaldimine and benzaldimine Schiff-base monomeric  
ligands 2.1 & 2.23 
Propylamine (2.1: 1.00 mL, 12.2 mmol; 2.2: 1.00 mL, 12.2 mmol) was dissolved in ethanol 
(15.0 mL) followed by the dropwise addition of naphthaldehyde (2.1: 1.90 g, 12.2 mmol) or 
benzaldehyde (2.2: 1.23 mL, 12.2 mmol). The reaction mixture was allowed to stir for 24 
hours after which the solvent was removed on the rotary evaporator. The residue was 
dissolved in DCM (20.0 mL) and washed with water (15 x 10.0 mL). The organic layer was 
collected, dried over anhydrous MgSO4 and then filtered by gravity. The solvent was 
removed on the rotary evaporator to yield the desired products as a yellow-brown solid (2.1) 
or brown-red oil. (2.2) 
 
2.1: Yellow-brown solid. Yield = 1.48 g (62%). IR (KBr) ν(C=N) 1640 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.00 (t, 3H, H1); 1.78 (m, 2H, H2); 3.65 (t, 2H, H3); 7.51 (t, 2H, H7, 
H8); 7.86 (m, 3H, H6, H9, H10); 7.99 (m, 1H, H5); 8.04 (m, 1H, H11); 8.43 (d, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 11.89 (C1); 24.15 (C2); 63.64 (C3); 123.96 
(C5); 126.40 (C8); 127.00 (C7); 127.86 (C9); 128.42 (C10); 128.57 (C6); ); 129.61 (C11); 
133.19 (C14); 134.11 (C13); 134.67 (C12); 160.86 (C4). Melting point: 44-47oC. 
Elemental Analysis (%): Calc. For C14H15N (197.28): C, 85.24; H, 7.66; N, 7.10; Found: C, 




2.2: Brown-red oil. Yield = 1.48 g (82%). IR (KBr) ν(C=N) 1646 cm-1. 1H NMR (400 MHz, 
CDCl3) δ (ppm) =0.98 (t, 3H, H1); 1.76 (m, 2H, H2); 3.60 (t, 2H, H3); 7.41 (t, 3H, H6, H7, 
H8); 7.75 (d, 2H, H5, H9); 8.28 (d, 1H, H4).  




13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 11.82 (C1); 24.07 (C2); 63.51 (C3); 128.04 (C5, 
C9); 128.56 (C6, C7); 130.42 (C8); 136.42 (C10); 160.79 (C4).  
Elemental Analysis (%): Calc. For C10H13N (147.22): C, 81.59; H, 8.90; N, 9.51; Found: C, 
81.94; H, 8.39; N, 4.85. MS (ESI, m/z): 118.02 [M-C2H5]+. 147.08 [M]+. 
 
5.1.2 General synthesis of the naphthaldimine and benzaldimine G1 (2.3 & 2.4) and G2 
(2.5 & 2.6) Schiff-base dendritic ligands 
The PPI G1 (2.3: 0.120 mL, 0.373 mmol; 2.4: 0.196 g, 0.62 mmol) or G2 (2.5: 0.526 g, 
0.680 mmol; 2.6: 0.249 g, 0.322 mmol) dendritic scaffold was dissolved in ethanol (2.3: 10.0 
mL; 2.4: 15.0 mL; 2.5: 50.0 mL; 2.6: 25.0 mL) followed by the addition of naphthaldehyde 
(2.3; 0.237 g, 1.52 mmol; 2.5; 0.853 g, 5.46 mmol) or benzaldehyde (2.4: 0.260 mL, 2.55 
mmol; 2.6: 0.260 mL, 2.55 mmol). The reaction mixture was allowed to stir for 72-96 hours 
after which the solvent was removed on a rotary evaporator and the residue was dissolved in 
DCM (30.0 mL) and washed with a 7:3 water-brine mixture (15 x 30.0 mL). The organic 
layer was collected, dried over anhydrous MgSO4 and then filtered by gravity. The solvent 
was removed on a rotary evaporator to yield the desired products as white solids (2.3 & 2.5) 
or yellow oils (2.4 & 2.6).  
 
2.3: White solid. Yield = 0.216 g (67%). IR (KBr) ν(C=N) 1639 cm-1. 1H NMR (400 MHz, 
CDCl3) δ (ppm) = 1.49 (sep, 4H, Hcore); 1.89 (sep, 8H, H4); 2.46 (t, 4H, Hcore); 2.57 (t, 8H, 
H3); 3.68 (t, 8H, H5); 7.47 (m, 8H, H9, H10); 7.81 (t, 12H, H8, H11, H12); 7.95 (m, 8H, H7, H13); 
8.40 (d, 4H, H6). Melting point: 104-108oC. 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 25.25 (Ccore); 28.40 (C4); 51.74 (C3); 54.11 
(Ccore); 59.74 (C5); 123.88 (C13); 126.36 (C10); 126.97 (C9); 127.83 (C11); 128.41 (C8); 
128.57 (C12); 129.66 (C7); 133.14 (C16); 134.05 (C15); 134.64 (C14); 161.06 (C6). 




Elemental Analysis (%): Calc. For C60H64N6 (869.21): C, 82.91; H, 7.42; N, 9.67; Found: C, 
80.44; H, 6.78; N, 9.43. MS (ESI LR, m/z): 322.20 [M+3H++3MeOH]3+. 
 
2.4: Yellow oil. Yield = 0.314 g (76%). IR (KBr) ν(C=N) 1643 cm-1. 1H NMR (400 MHz, 
CDCl3) δ (ppm) = 1.43 (p, 4H, Hcore); 1.83 (p, 8H, H4); 2.41 (t, 4H, Hcore); 2.51 (t, 8H, H3); 
3.62 (t, 8H, H5); 7.38 (m, 12H, H8, H9, H10); 7.70 (dd, 8H, H7, H11); 8.26 (d, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 25.26 (Ccore); 28.42 (C4); 51.73 (Ccore); 54.11 
(C3); 59.71 (C5); 127.37 (C7); 127.67 (C11); 128.02 (C10); 128.55 (C9); 130.42 (C8); 136..67 
(C12); 160.96 (C6). Melting point: 134-137oC. 
Elemental Analysis (%): Calc. For C44H56N6 (668.97): C, 79.00; H, 8.44; N, 12.56; Found: 
C, 77.40; H, 7.70; N, 12.30. MS (ESI LR, m/z): 272.20 [M+3H3O++MeOH]3+. 
 
2.5: White solid. Yield = 0.842 g (66%). IR (KBr) ν(C=N) 1639 cm-1. 1H NMR (400 MHz, 
CDCl3) δ (ppm) = 1.33 (m, 4H, Hcore); 1.53 (m, 8H, H4); 1.80 (sep, 16H, H7); 2.37 (m, 20H, 
Hcore, H3, H5); 2.47 (t, 16H, H6); 3.58 (t, 16H, H8); 7.37 (m, 16H, H12, H13); 7.70 (m, 24H, 
H11, H14, H15); 7.86 (m, 16H, H10, H16); 8.36 (d, 8H, H9). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 24.75 (C4); 25.20 (Ccore); 28.48 (C7); 51.77 
(C6); 52.37 (C5); 53.40 (C3); 54.26 (Ccore); 59.79 (C8); 123.88 (C10); 126.34 (C13); 126.95 
(C12); 127.82 (C14); 128.39 (C11); 128.56 (C15); 129.67 (C16); 133.13 (C19); 134.05 (C18); 
134.62 (C17); 160.99 (C9). Melting point: 64-67oC. 
Elemental Analysis (%): Calc. For C128H144N14 (1878.64): C, 81.84; H, 7.73; N, 10.44; 
Found: C, 78.54; H, 7.54; N, 10.37. MS (ESI LR, m/z): 408.20 [M+5H++MeOH]5+. 





2.6: Yellow oil. Yield = 0.214 g (45%). IR (DCM) ν(C=N) 1646 cm-1. 1H NMR (400 MHz, 
CDCl3) δ (ppm) = 1.38 (m, 4H, Hcore); 1.57 (br sep, 8H, H4); 1.82 (sep, 16H, H7); 2.41 (m, 
20H, Hcore, H3, H5); 2.51 (t, 16H, H6); 3.61 (t, 16H, H8); 7.37 (m, 24H, H11, H12, H13); 7.69 
(dd, 8H, H10, H14); 8.25 (d, 8H, H9). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 24.68 (C4); 25.16 (Ccore); 28.42 (C7); 51.76 
(C6); 52.29 (C3); 52.37 (C5); 54.26 (Ccore); 59.72 (C8); 128.04 (C10, C14); 128.54 (C11, C12); 
130.42 (C13); 136.38 (C15); 160.93 (C9). 
Elemental Analysis (%): Calc. For C96H128N14 (1478.16): C, 78.00; H, 8.73; N, 13.27; 
Found: C, 74.44; H, 7.27; N, 13.12. MS (ESI LR, m/z): 773.80 [M+2H++2MeOH]2+. 
 
5.2 Synthesis of the neutral mononuclear and dendritic cyclometalated complexes: 
 
5.2.1 General synthesis of the cyclometalated ruthenium(II), rhodium(III) and iridium(III) 
naphthaldimine mononuclear complexes 2.7, 2.8 & 2.9. 
The naphthaldimine ligand (2.7: 0.0530 g, 0.269 mmol; 2.8: 0.0409 g, 0.207 mmol; 2.9: 
0.0408 g, 0.207 mmol), sodium acetate (2.7: 0.0443 g, 0.540 mmol; 2.8: 0.0339 g, 0.413 
mmol; 2.9: 0.0343 g, 0.418 mmol) and the [Ru(p-cymene)Cl2)]2 (0.0822 g, 0.134 mmol),  
[Rh(η5-C5Me5)Cl2]2 (0.0634 g, 0.102 mmol) or [Ir(η5-C5Me5)Cl2]2 (0.0810 g, 0.102 mmol) 
dimer were stirred together in DCM or methanol (20.0 mL) for 2 hours at room temperature. 
The reaction mixture was filtered through Celite, washing with DCM or methanol. The 
solvent was removed to obtain the crude product. This was then washed with diethyl ether to 
obtain the desired product as a golden brown (2.7), orange-red (2.8) or orange-brown (2.9) 
solid. The ruthenium(II) complex (2.7) was recrystallized from DCM, whereas the 
rhodium(III) (2.8) and iridium(III) (2.9) complexes were recrystallized from methanol and 
hexane by slow evaporation. 






2.7: Golden brown solid. Yield = 0.0790 g (63%). IR (KBr) ν(C=N) 1611 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.81 (d, 3H, H14); 1.10 (m, 6H, H1 & H14); 2.11 (m, 1H, H2); 
2.16 (s, 3H, H11); 2.24 (m, 1H, H2); 2.49 (sept, 1H, H13); 4.00 (m, 1H, H3); 4.21 (m, 1H, H3); 
4.84 (d, 1H, H12); 4.96 (d, 1H, H12); 5.64 (d, 1H, H12); 5.70 (d, 1H, H12); 7.27 (t, 1H, H7); 
7.44 (t, 1H, H8); 7.73 (t, 2H, H6 & H9); 7.90 (s, 1H, H5); 8.15 (s, 1H, H10); 8.45 (s, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 11.94 (C11); 18.90 (C1); 23.34 (C14); 30.80 
(C14); 68.20 (C1); 77.30 (C18); 79.43 (C12); 80.55 (C12); 89.93 (C12); 91.32 (C12); 101.20 
(C19, C20); 103.14 (C13); 123.61 (C16, C17); 126.51 (C6); 127.11 (C15); 128.7 (C5); 130.47 
(C7); 134.93 (C8); 136.21 (C9); 145.28 (C4); 171.72 (C3); 178.01 (C10). Melting point: 148-
150oC. 
Elemental Analysis (%): Calc. For C24H28ClNRu (467.01): C, 61.72; H, 6.04; N, 3.00; 
Found: C, 61.76; H, 6.16; N, 2.99. MS (ESI, m/z): 432.3 [M-Cl]+. 
 
2.8: Orange-red solid. Yield = 0.048 g (50%). IR (KBr) ν(C=N) 1610 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.01 (t, 3H, H1); 1.69 (s, 15H, Cp*); 1.93 (m, 1H, H2); 2.11 (m, 1H, 
H2); 3.72 (m, 1H, H3); 4.12 (m, 1H, H3); 7.29 (t, 1H, H7); 7.44 (t, 1H, H8); 7.74 (t, 2H, H6 & 
H9); 7.90 (s, 1H, H5); 8.06 (s, 1H, H10); 8.23 (s, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 11.75 (C2); 63.98 (C1); 95.70 (Cp*); 123.84 
(C6); 126.60 (C13); 127.06 (C7); 128.70 (C14); 129.16 (C9); 129.57 (C8); 130.50 (C10); 134.63 
(C12); 135.68 (C5); 145.21 (C4); 171.69 (C3); 192.35 (C11). Melting point: 168-170oC. 
Elemental Analysis (%): Calc. For C24H29ClNRh (469.86): C, 61.35; H, 6.22; N, 2.98; 
Found: C, 58.81; H, 6.16; N, 2.58. MS (ESI, m/z): 434.23 [M-Cl]+. 
 





2.9: Orange-brown solid. Yield = 0.08 g (71%). IR (KBr) ν(C=N) 1603 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.03 (t, 3H, H1); 1.80 (s, 15H, Cp*); 1.98 (m, 1H, H2); 2.12 (m, 1H, 
H2); 3.93 (m, 1H, H3); 4.11 (m, 1H, H3); 7.27 (t, 1H, H7); 7.42 (t, 1H, H8); 7.74 (t, 2H, H6 & 
H9); 8.01 (s, 1H, H5); 8.06 (s, 1H, H10); 8.44 (s, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 22.77 (C1); 65.23 (C2); 88.51 (Cp*); 123.50 
(C6); 126.57 (C13, C14); 127.07 (C7); 128.37 (C9); 128.83 (C8); 130.10 (C5); 132.06 (C10); 
136.60 (C12); 145.21 (C4); 171.69 (C11); 192.35 (C3). Melting point: 206-208oC. 
Elemental Analysis (%): Calc. For C24H29ClIrN (559.17): C, 51.55; H, 5.23; N, 2.50; 
Found: C, 50.83; H, 5.35; N, 2.63. MS (ESI, m/z): 524.4 [M-Cl]+. 
 
5.2.2 General synthesis of the cyclometalated ruthenium(II), rhodium(III) and iridium(III)  
naphthaldimine G1 metallodendrimers 2.13, 2.14 & 2.15. 
The naphthaldimine G1 dendritic ligand (2.13: 0.0439 g, 0.0505 mmol; 2.14: (0.0492 g, 
0.0566 mmol; 2.15: 0.0205 g, 0.0236 mmol), sodium acetate (2.13: 0.0169 g, 0.206 mmol; 
2.14: 0.0186 g, 0.227 mmol; 2.15: 0.0081 g, 0.0987 mmol) and the [Ru(p-cymene)Cl2]2 
(0.0613 g, 0.100 mmol), [Rh(η-C5Me5)Cl2]2 (0.0700 g, 0.113 mmol) or [Ir(η-C5Me5)Cl2]2 
(0.0376 g, 0.0472 mmol) dimer were stirred together in DCM or methanol (20.0 mL) 
overnight at room temperature. The ruthenium complex (2.13) was synthesized under argon. 
After which the reaction mixture was filtered through Celite and washed with DCM or 
methanol. The solvent was removed on a rotary evaporator to obtain the crude product. The 
solid was dissolved in a minimum amount of DCM and diethyl ether was slowly added to the 
solution down the side of the flask. A solid started to precipitate out and the suspension was 
placed in the fridge overnight. The solid was filtered under vacuum yielding the desired 
product as a green-brown (2.13), light yellow-orange (2.14) or light yellow-orange (2.15) 
solid. 
 





2.13: Green-brown solid. Yield = 0.0800 g (81%). IR (KBr) ν(C=N) 1604 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.72 (m, 8H, H4); 1.10 (m, 4H, Hcore); 1.49 (m, 24H, H16); 1.66 
(s, 12H, H13); 2.48 (m, 4H, Hcore); 2.50 (m, 8H, H3); 2.32 (m, 4H, H15); 3.47 (t, 8H, H5); 5.40 
(d, 8H, H14); 5.62 (d, 8H, H14); 7.39 (m, 8H, H9, H10); 7.58 (m, 4H, H8); 7.65 (m, 4H, H11); 
7.80 (m, 8H, H7, H12); 8.32 (s, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 22.00 (C16); 22.27 (Ccore); 25.04 (C13); 28.10 
(C4); 51.61 (C15); 53.01 (C3); 53.96 (Ccore); 59.68 (C5); 81.16-81.51; (C14); 122.97 (C19); 
123.85 (C7); 126.82 (C21,C22); 127.09 (C9); 127.83 (C10); 128.56 (C8); 129.10 (C11); 129.69 
(C12); 133.45 (C20); 133.97 (C18); 135.00 (C17); 142.12 (C6). Melting point: 124-128oC. 
Elemental Analysis (%): Calc. For C100H116Cl4N6Ru4 (1948.15): C, 61.65; H, 6.00; N, 4.31; 
Found: C, 57.95; H, 6.51; N, 6.50. MS (ESI HR, m/z): 613.83 [M-3Cl]3+; 1948.42 [M]+.  
 
2.14: Yellow-orange solid. Yield = 0.0605 g (52%). IR (KBr) ν(C=N) 1609 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 1.57 (m, 4H, Hcore); 1.61 (s, 60H, Cp*); 1.70 (m, 8H, H4); 2.20 
(br t, 8H, H3); 2.92 (m, 4H, Hcore); 3.96 (splitting of br m, 8H, H5); 7.30 (m, 8H, H8,H9); 7.43 
(m, 8H, H10,H11); 7.74 (m, 8H, H7,H12); 8.03 (s, 4H, H6). 




13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.35 (Cp*); 23.56 (C4); 24.64 (Ccore); 26.25 
(C3); 51.57 (Ccore); 59.72 (C5); 123.68 (C10); 123.74 (C15); 126.50 (C7); 126.93 (C9); 128.30 
(C8); 128.77 (C12); 130.48 (C11); 133.37 (C16); 135.60 (C14); 135.64 (C13); 145.66 (C6). 
Melting point: 220-224oC. 
Elemental Analysis (%): Calc. For C100H120Cl4N6Rh4 (1959.54): C, 61.29; H, 6.17; N, 4.29; 
Found: C, 63.17; H, 6.02; N, 4.93. MS (ESI HR, m/z): 1923.48 [M-Cl]+; 1959.44 [M]+. 
 
 
2.15: Yellow-orange solid. Yield = 0.0230 g (42%). IR (KBr) ν(C=N) 1602 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 1.50 (m, 8H, H4); 1.75 (m, 8H, Hcore); 1.65 (s, 60H, Cp*); 2.11 
(m, 4H, Hcore); 2.49 (br m, 8H, H3); 4.12 (m, 8H, H5); 7.26 (t, 8H, H10); 7.39 (t, 8H, H9); 7.73 
(t, 8H, H8 & H11); 8.02 (t, 8H, H7 & H12); 8.29 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.15 (Cp*); 25.64 (C4); 26.35 (Ccore); 28.16 
(Ccore); 51.60 (C3); 60.96 (C5); 122.87 (C15); 123.40 (C10); 126.47 (C8); 126.98 (C9); 128.88 
(C11); 130.09 (C12); 131.87 (C7); 136.60 (C13); 141.18 (C16); 141.37 (C14); 146.27 (C6). 
Melting point: 226-232oC. 
Elemental Analysis (%): Calc. for C100H120Cl4Ir4N6 (2316.78): C, 51.84; H, 5.22; N, 3.63; 
Found: C, 49.00; H, 5.31; N, 3.16. MS (ESI HR, m/z): 1122.40 [M-2Cl]2+. 
 
5.2.3 General synthesis of the cyclometalated ruthenium, rhodium and iridium 
naphthaldimine G2 metallodendrimers 2.19, 2.20 & 2.21 
The naphthaldimine G2 dendritic ligand (2.19: 0.120 g, 0.0639 mmol; 2.20: 0.109 g, 0.0579 
mmol; 2.21: 0.121 g, 0.0645 mmol), sodium acetate (2.19: 0.0424 g, 0.517 mmol; 2.20: 
0.0386 g, 0.470 mmol; 2.21: 0.0432 g, 0.527 mmol) and [Ru(p-cymene)Cl2]2 (0.158 g, 0.258 
mmol), [Rh(η5-C5Me5)Cl2]2 (0.144 g, 0.232 mmol) or [Ir(η5-C5Me5)Cl2]2 (0.205 g, 0.258 
mmol) dimer were stirred together in DCM or methanol (30.0 mL) for 24-48 hours at room 




temperature. After which the reaction mixture was filtered through Celite and washed with 
DCM or methanol. The solvent was removed on a rotary evaporator to obtain the crude 
product which was then dissolved in a minimum amount of DCM and diethyl ether was 
slowly added to the solution down the side of the flask until a solid starts precipitating out. 
The solid was filtered under vacuum yielding the desired product as a green-brown (2.19), 
red-orange solid (2.20) or red-orange (2.21) solid. 
 
2.19: Green-brown solid. Yield = 0.0602 g (23%). IR (KBr) ν(C=N) 1602 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.66 (m, 4H, Hcore); 0.94 (m, 8H, H4); 1.17-1.19 (br m, 88H, 
H7, H16, H19); 1.80 (br m, 8H, H18); 2.24-2.85 (m, 36H, Hcore, H3, H5, H6); 4.10 (br m; 16H, 
H8); 5.20-5.55 (m, 32H, H17); 7.17 (m, 8H, H12, H13); 7.36 (t, 4H, H14); 7.64 (t, 8H, H10, H11); 
7.94 (m, 4H, H15); 8.35 (s, 4H, H9).  
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 18.79 (C16); 21.00 (C1); 22.31 (C4); 23.37 
(C19); 23.95 (C7); 30.70 (C18); 51.49-58.88 (C2, C3, C5, C6).; 63.70 (C8); 79.46, 81.10, 89.75, 
91.84 (C17); 122.69 (C12, C13, C24).; 126.14 (C11); 127.07 (C14); 127.66 (C10); 128.76 (C15); 
130.23 (C25); 133.05 (C22); 133.96 (C21); 134.63 (C23); 135.98 (C20); 145.37 (C9). Melting 
point: 103-105oC. 




Elemental Analysis (%): Calc. for C208H248Cl8N14Ru8 (4036.53 g/mol): C, 61.89; H, 6.19; 
N, 4.86; Found: C, 56.04; H, 6.00; N, 4.52. MS (ESI HR, m/z): 407.16 [M-4Cl]4+; 544.21 
[M-3Cl]3+; 842.17 [M-2Cl]2+. 
 
2.20: Orange-yellow solid. Yield = 0.240 g (80%). IR (KBr) ν(C=N) 1610 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.8 (m, 4H, Hcore); 1.18 (m, 8H, H4); 1.56 (s, 120H, Cp*); 1.89 
(br m, 16H, H7); 2.20 (br m, 36H, Hcore, H3, H5, H6): 3.97 (splitting, 16H, H8); 7.20 (m, 16H, 
H12, H13); 7.34 (m, 8H, H11); 7.65 (m, 16H, H10, H14); 7.88 (m, 8H, H15); 7.93 (br s, 8H, H9). 
Melting point: 178-180oC. 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.41 (Cp*); 10.70 (Ccore); 12.80 (C4); 26.00 
(C7); 45.88 (C3); 51.83 (Ccore); 52.97 (C5); 54.16 (C6); 59.90 (C8); 93.20 (C18); 95.70 (C19); 
123.73 (C12); 125.0 (C13); 126.43 (C10); 126.91 (C11); 128.22 (C14); 128.83 (C15); 130.48 
(C17); 135.52 (C16); 143.36 (C9). Melting point: 183-188oC. 
Elemental Analysis (%): Calc. for C208H256Cl8N14Rh8 (4059.27 g/mol): C, 61.54; H, 6.36; 
N, 4.83; Found: C, 53.76; H, 6.36; N, 3.45. MS (ESI HR, m/z): 640.93 [M-6Cl]6+. 
 





2.21: Red-orange solid. Yield = 0.243 g (79%). IR (KBr) ν(C=N) 1600 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.40 (m, 4H, Hcore); 1.48 (m, 8H, H4); 1.60 (s, 120H, Cp*); 1.86 (br 
m, 16H, H7); 1.94 (br m, 36H, Hcore, H3, H5) 2.50 (br m, 16H, H6): 4.00 (br m, 16H, H8); 7.32 
(m, 16H, H12, H13); 7.65 (m, 8H, H11, H14); 7.93 (m, 16H, H10, H15); 8.45 (br s, 8H, H9). 
Melting point: 180-182oC. 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.17 (Cp*); 20.97 (Ccore); 24.33 (C4); 29.15 
(C7); 51.11-53.19 (Ccore, C3, C5, C6); 60.86 (C8); 126.43 (C12); 127.08 (C11); 127.65 (C13); 
128.99 (C10); 130.04 (C14); 131.9 (C15); 134.86 (C17); 136.55 (C16); 146.98 (C9). Melting 
point: 106-108oC. 
Elemental Analysis (%): Calc. for C208H256Cl8Ir8N14 (4773.79 g/mol): C, 52.33; H, 5.40; N, 









5.2.4 General synthesis of the cyclometalated ruthenium(II), rhodium(III) and iridium(III) 
benzaldimine mononuclear complexes 2.10, 2.11 & 2.12. 
The benzaldimine ligand (2.10: 0.0798 g, 0.542 mmol; 2.11: 0.0286 g, 0.194 mmol; 2.12: 
0.101 g, 0.688 mmol), sodium acetate (2.10: 0.0907 g, 1.12 mmol; 2.11: 0.0322 g, 0.392 
mmol; 2.12: 0.0590 g, 0.719 mmol) and the [Ru(p-cymene)Cl2]2  (0.155 g, 0.253 mmol),  
[Rh(η-C5Me5)Cl2]2 (0.0603 g, 0.0976 mmol) or [Ir(η-C5Me5)Cl2]2 (0.271 g, 0.340 mmol) 
dimer were stirred together in DCM or methanol (50.0 mL) for 2 hours at room temperature. 
The ruthenium complex (2.10) was synthesized under argon. After which the reaction 
mixture was filtered through Celite and washed with DCM or methanol. The solvent was 
removed on a rotary evaporator to obtain the crude product. The solid was washed with 
diethyl ether and placed in the freezer. A solid precipitated out, which was filtered under 
vacuum washing with cold diethyl ether to yield the desired product as an orange-gold (2.10), 
red-orange (2.11) or orange (2.12) solid. The rhodium(III) (2.11) and iridium(III) (2.12) 




2.10: Orange-gold solid. Yield = 0.0525 g (25%). IR (KBr) ν(C=N) 1602 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.8 (d, 3H, H12); 1.02 (t, 3H, H1); 1.06 (d, 3H, H12); 2.05 (m, 
1H, H2); 2.08 (s, 3H, H11); 2.15 (m, 1H, H2); 2.49 (m, 1H, H11); 3.94 (m, 1H, H3); 4.14 (m, 
1H, H3); 4.80 (d, 1H, H10); 4.94 (d, 1H, H10); 5.59 (d, 1H, H10); 5.63 (d, 1H, H10); 6.95 (t, 
1H, H6); 7.12 (t, 1H, H7); 7.40 (d, 1H, H5); 7.99 (s, 1H, H4); 8.12 (d, 2H, H8). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 18.89 (C9); 21.25 (C10); 22.96 (C1); 30.92 (C9); 
67.92 (C2); 79.72 (C11); 80.87 (C11); 89.79 (C11); 91.20 (C11); 101.44 (C16); 102.77 (C15); 
120.00 (C8); 122.20 (C5, C14); 128.44 (C7); 129.46 (C13); 138.96 (C6); 145.21 (C4); 171.62 
(C3). Melting point: 108-111oC. 
Elemental Analysis (%): Calc. For C20H26ClNRu (416.95): C, 57.61; H, 6.28; N, 3.36; 
Found: C, 56.99; H, 6.26; N, 3.39. MS (ESI, m/z): 382.2 [M-Cl]+. 






2.11: Red-orange solid. Yield = 0.0550 g (68%). IR (KBr) ν(C=N) 1614 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 0.99 (t, 3H, H1); 1.66 (s, 15H, Cp*); 1.89 (m, 1H, H2); 2.07 (m, 1H, 
H2); 3.66 (m, 1H, H3); 4.07 (m, 1H, H3); 7.00 (t, 1H, H6); 7.21 (t, 1H, H7); 7.40 (d, 1H, H5); 
7.76 (d, 1H, H8); 8.10 (d, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 11.73 (Cp*); 22.94 (C1); 63.71 (C2); 95.8 (C10); 
122.45 (C8); 127.88 (C7); 130.62 (C9); 135.87 (C6); 145.25 (C5); 145.69 (C4); 171.80 (C3). 
Melting point: 171-173oC. 
Elemental Analysis (%): Calc. For C20H27ClNRh (419.80): C, 57.22; H, 6.48; N, 3.34; 
Found: C, 56.96; H, 6.71; N, 2.80. MS (ESI, m/z): 384.2 [M-Cl]+. 
 
 
2.12: Orange solid. Yield = 0.0550 g (16%). IR (KBr) ν(C=N) 1605 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.00 (t, 3H, H1); 1.72 (s, 15H, Cp*); 1.88 (m, 1H, H2); 2.01 (m, 1H, 
H2); 3.86 (m, 1H, H3); 4.03 (m, 1H, H3); 6.97 (t, 1H, H6); 7.15 (t, 1H, H7); 7.50 (d, 1H, H5); 
7.75 (d, 1H, H8); 8.30 (S, 1H, H4). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 22.67 (C1); 64.78 (C2); 88.72 (Cp*); 121.82 
(C8); 127.98 (C7); 131.42 (C9); 134.62 (C6); 146.25 (C4); 168.19 (C5, C10); 174.34 (C3). 
Melting point: 178-181oC.  
Elemental Analysis (%): Calc. For C20H27ClIrN (509.11): C, 47.18; H, 5.35; N, 2.75; 









5.2.5 General synthesis of the cyclometalated ruthenium(II), rhodium(III) and iridium(III) 
benzaldimine G1 metallodendrimers 2.16, 2.17 & 2.18 
The benzaldimine G1 dendritic ligand (2.16: 0.107 g, 0.160 mmol; 2.17: 0.10 g, 0.15 mmol; 
2.18: 0.10 g, 0.16 mmol), sodium acetate (2.16: 0.0525 g, 0.640 mmol; 2.17: 0.05 g, 0.61 
mmol; 2.18: 0.05 g, 0.64 mmol) and [Ru(p-cymene)Cl2]2 (0.196 g, 0.319 mmol),  [Rh(η5–
C5Me5)Cl2]2 (0.19 g, 0.31 mmol) or [Ir(η5-C5Me5)Cl2]2 (0.25 g, 0.31 mmol)  dimer were 
stirred together in DCM or methanol (62.0 mL) for 24 hours at room temperature. After 
which the reaction mixture was filtered through Celite, washing with DCM or methanol. The 
solvent was removed on a rotary evaporator to obtain the crude product. The solid was 
dissolved in a minimum amount of DCM and diethyl ether was slowly added to the solution 
down the side of the flask. A solid started to precipitate out and the suspension was placed in 
the fridge overnight. The solid was filtered under vacuum yielding a green-brown (2.16) or 
red-orange (2.17, 2.18) solid. 
 
2.16: Green-brown solid. Yield = 0.180 g (64%). IR (KBr) ν(C=N) 1602 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 0.80 (m, 4H, Hcore); 1.05 (m, 8H, H4); 1.28 (m, 36H, H11, H14); 2.43 
(m, 12H, Hcore,H3); 2.83 (m, 4H, H13); 4.07 (br m, 8H, H5); 4.85, 4.99, 5.63 (br m, 16H, H12); 
6.96 (br m, 4H, H8); 7.13 (br m, 4H, H9); 7.39 (br m, 8H, H7, H10); 8.12 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 18.82 (Ccore); 20.95, 21.16 (C11,C14); 23.27 
(C4); 30.82 (Ccore,); 30.95 (C3); 51.59 (C13); 64.04 (C5); 83.47, 83.75, 89.67 (C12); 127.37 
(C17); 128.04 (C7); 128.44 (C18); 128.59 (C8); 128.79 (C9); 129.49 (C10); 129.74 (C16); 
129.97 (C15); 143.99 (C6). 




Elemental Analysis (%): Calc. For C84H108Cl4N6Ru4 (1747.91): C, 57.72; H, 6.23; N, 4.81; 
Found: C, 56.06; H, 7.41; N, 7.88. MS (ESI-HR, m/z): 842.17 [M-2Cl]2+, 544.21 [M-3Cl]3+, 
407.16 [M-4Cl]4+ 
 
2.17: Red-orange solid. Yield = 0.21 g (79%). IR (KBr) ν(C=N) 1607cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.60 (m, 4H, Hcore); 1.63 (s, 60H, Cp*); 2.20 (br m, 8H, H4); 2.68 
(br m, 4H, Hcore); 2.80 (br m, 8H, H3): 4.09 (splitting, 8H, H5); 6.98 (t, 4H, H9); 7.18 (t, 4H, 
H8); 7.43 (t, 4H, H10); 7.72 (d, 4H, H7); 8.23 (s, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.31 (Cp*); 23.09 (Ccore); 25.64 (C4); 51.49 
(C3); 53.41 (Ccore); 59.46 (C5); 122.43 (C9); 128.05 (C12); 128.24 (C10); 130.55 (C8); 131.00 
(C11); 135.84 (C7); 145.29 (C6). Melting point: 84-88oC. 
Elemental Analysis (%): Calc. for C84H112Cl4N6Rh4 (1759.30): C, 57.35; H, 6.42; N, 4.78; 
Found: C, 52.81; H, 7.02; N, 4.40. MS (ESI, m/z): 1759.40 [M]+. 
 
2.18: Red-orange solid. Yield = 0.17 g (50%). IR (KBr) ν(C=N) 1600 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.56 (m, 4H, Hcore); 1.62 (s, 60H, Cp*); 2.21 (br m, 8H, H4); 2.60 




(br m, 4H, Hcore); 2.72 (br m, 8H, H3); 3.97 (br s, 8H, H5); 6.90 (t, 4H, H9); 7.07 (t, 4H, H8); 
7.46 (m, 4H, H10); 7.66 (d, 4H, H7); 8.30 (s, 4H, H6). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.12 (Cp*); 25.77 (Ccore); 27.90 (C4); 51.29 
(C3); 53.53 (Ccore); 60.66 (C5); 121.73 (C9); 128.02 (C10); 130.27 (C11); 130.65 (C12); 131.34 
(C8); 134.57 (C7); 146.39 (C6). Melting point: 200-202oC. 
Elemental Analysis (%): Calc. for C84H112Cl4Ir4N6 (2116.54): C, 47.67; H, 5.33; N, 3.97; 
Found: C, 47.36; H, 5.27; N, 4.17. MS (ESI, m/z): 1059.32 [M+2H+]2+. 
 
5.2.6 General synthesis of the cyclometalated ruthenium(II), rhodium(III) and iridium(III) 
benzaldimine G2 metallodendrimers 2.22, 2.23 & 2.24. 
The G2 benzaldimine dendritic ligand (2.22: 0.0649 g, 0.0440 mmol; 2.23: 0.0379 g, 0.026 
mmol; 2.24: 0.0355 g, 0.0240 mmol), sodium acetate (2.22: 0.0577 g, 0.703 mmol; 2.23: 
0.0167 g, 0.200 mmol; 2.24: 0.0158 g, 0.193 mmol) and the [Ru(p-cymene)Cl2]2 (0.108 g, 
0.176 mmol), [Rh(η5-C5Me5)Cl2]2 (0.0617 g, 0.100 mmol) or  [Ir(η5-C5Me5)Cl2]2 (0.0762 g, 
0.0956 mmol) dimer were stirred together in methanol (20.0 mL) for 24-48 hours at room 
temperature. After which the reaction mixture was filtered through Celite, and washed with 
methanol. The crude ruthenium(II) complex (2.22) was dissolved in acetone and filtered by 
gravity. This was repeated with DCM, the solvent was removed on the rotary evaporator and 
the solid was washed with diethyl ether to give the desired product as a golden-brown solid 
(2.22). The crude rhodium(III) (2.23) and iridium(III) (2.24) complexes were dissolved in a 
minimum amount of DCM followed by an excess of diethyl ether whereby a solid 
precipitated out of solution. The solid was filtered under vacuum to give the desired products 
as a yellow (2.23) or orange-yellow (2.24) solid. 





2.22: Golden-brown solid. Yield = 0.140 g (88%). IR (KBr) ν(C=N) 1600 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 0.74 (br m, 4H, Hcore); 0.99 (br m, 8H, H4); 1.22 (br m, 72H, 
H14,H17); 1.59 (br m, 16H, H7); 1.96 (br m, 8H, H16); 2.40 (br m, 28H, Hcore, H3, H6); 3.74 (br 
m, 8H, H5); 4.01-4.11 (br m, 16H, H8); 4.75, 4.90, 5.32, 5.43 (br m, 32H, H15); 6.87 (br m, 
8H, H10); 7.04 (br m, 8H, H11); 7.32 (br m, 16H, H12,H13); 8.05 (br s, 8H, H9). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 18.86 (C16); 21.16 (Ccore); 22.22 (C14); 22.44 
(C17); 23.28 (C4); 30.92-31.48 (Ccore,C3,C6); 51.65 (C5); 64.07 (C8); 79.67, 81.45, 89.64, 
91.64 (C15); 100.81 (C21); 102.97 (C20); 122.09 (C10); 127.56 (C11); 128.46 (C12); 128.95 
(C13); 129.26 (C18); 138.98 (C19); 145.31 (C9). Melting point: 110-113oC. 
Elemental Analysis (%): Calc. For C176H232Cl8N14Ru8 (3636.05): C, 58.14; H, 6.43; N, 
5.39; Found: C, 56.79; H, 6.16; N, 4.88. MS (ESI-HR, m/z): 569.01 [M-6Cl]+, 873.22 [M-
4Cl]+. 





2.23: Yellow solid. Yield = 0.0800 g (58%). IR (KBr) ν(C=N) 1609 cm-1. 1H NMR (400 
MHz, CDCl3) δ (ppm) = 1.37 (m, 4H, Hcore); 1.57 (m, 8H, H4); 1.63 (s, 120H, Cp*); 1.81 (br 
m, 16H, H7); 2.41-2.50 (br m, 20H, Hcore, H3, H5); 2.94 (br m, 16H, H6); 3.90-4.01 (splitting 
of br m, 16H, H8); 7.38 (br m, 16H, H11, H12); 7.69 (br m, 16H, H10,H13); 8.26 (s, 8H, H9). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.34 (Cp*); 24.79 (Ccore); 28.47 (C7); 29.69 
(Ccore);  30.34 (C4); 51.8-52.19 (C3,5,6);  59.72 (C8);  126.95 (C10); 128.04 (C11); 128.57 
(C12); 129.48 (C13); 130.48 (C14); 136.39 (C15); 146.49 (C9). Melting point: 115-119oC. 
Elemental Analysis (%): Calc. for C176H240Cl8N14Rh8 (3658.83 g/mol): C, 57.78; H, 6.61; 
N, 5.36; Found: C, 52.48; H, 6.30; N, 4.84. MS (ESI-HR, m/z): 574.22 [M-6Cl]6+, 696.23 
[M-5Cl]5+. 
 




2.24: Orange-yellow solid. Yield = 0.0500 g (48%). IR (KBr) ν(C=N) 1600 cm-1. 1H NMR 
(400 MHz, CDCl3) δ (ppm) = 1.43 (m, 4H, Hcore); 1.61 (m, 8H, H4); 1.68 (s, 120H, Cp*); 
1.83 (br m, 16H, H7); 2.42 (br m, 20H, Hcore, H3, H5); 2.50 (br m, 16H, H6); 4.02 (br m, 16H, 
H8); 7.37 (t, 16H, H11, H12); 7.69 (d, 16H, H10,H13); 8.26 (s, 8H, H9). 
13C{1H}-NMR (100 MHz, CDCl3) δ (ppm) = 9.10 (Cp*); 24.62 (Ccore); 26.55 (C7); 28.39 
(Ccore); 29.68 (C4); 51.50-52.35 (C3,5,6); 59.70 (C8); 128.04 (C10); 128.56 (C11); 130.43 (C12); 
131.29 (C14); 134.60 (C13); 136.36 (C15); 145.96 (C9). Melting point: 121-123oC 
Elemental Analysis (%): Calc. For C176H240Cl8Ir8N14 (4373.31): C, 48.30; H, 5.53; N, 4.48; 
Found: C, 45.29; H, 6.25; N, 4.40. MS (ESI-HR, m/z): 589.23 [M-7Cl]7+, 693.31 [M-6Cl]6+. 
 
5.3 Synthesis of the cationic mononuclear and dendritic cyclometalated complexes 
containing PTA 
 
5.3.1 General synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) 
naphthaldimine mononuclear complexes 3.1, 3.2 & 3.3. 
The naphthaldimine monomeric ligand (3.1: 0.115 g, 0.581 mmol; 3.2: 0.0733 g, 0.372 
mmol; 3.3: 0.0739 g, 0.375 mmol) and sodium acetate (3.1: 0.0485 g, 0.591 mmol; 3.2: 
0.0301 g, 0.367 mmol; 3.3: 0.0309 g, 0.377 mmol) was suspended in DCM or methanol (15.0 
mL) followed by the addition of the [Ru(p-cymene)Cl2]2 (0.178 g, 0.291 mmol), [Rh(η-
C5Me5)Cl2]2  (0.114 g, 0.185 mmol) or [Ir(η-C5Me5)Cl2]2 (0.147 g, 0.185 mmol) dimer. The 
reaction mixture was allowed to stir for a couple of hours after which it was filtered through 
Celite. PTA (3.1: 0.0937 g, 0.596 mmol; 3.2: 0.0573 g, 0.365 mmol; 3.3: 0.0599 g, 0.381 
mmol) was added to the reaction mixture and allowed to stir for a further 30-40 minutes. The 
solvent was removed on a rotary evaporator; the residue was dissolved in a minimum amount 
of acetone and filtered through Celite. A minimum amount of methanol was added followed 
by the addition of the NaPF6 (3.1: 0.102 g, 0.604 mmol; 3.2: 0.0616 g, 0.367 mmol; 3.3: 
0.0642 g, 0.382 mmol). This was stirred at 0oC for about 30-40 minutes whereby a solid 
precipitated out of solution, which was then filtered under vacuum, washing with cold 
methanol and diethyl ether, to yield a orange-yellow (3.2) or light yellow (3.3) solid. The 
ruthenium(II) complex (3.1) did not precipitate out of solution therefore the solvent was 
removed on a rotary evaporator and the residue was dissolved in a minimum amount of DCM 




followed by the addition of an excess amount of diethyl ether, whereby a solid precipitated 
out of solution. This was filtered under vacuum to yield a red-brown (3.1) solid. 
 
3.1: Red-brown solid. Yield = 0.0651 g (15%). IR: (KBr pellets), ν/cm-1: 1602 (C=N), 801 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 0.72 (d, 3H, H11); 1.07 (d, 3H, H14); 
1.12 (t, 3H, H1); 1.26 (m, 6H, H14); 1.98, 2.16 (m, 2H, H2); 2.51 (sep, 1H, H13); 3.64 (d, 3H 
PTA); 4.05 (m, 2H, H3); 4.08, 4.20, 4.30 (d, 9H , PTA); 5.86 (m, 2H, H12); 5.92, 6.10 (d, 2H, 
H12); 7.44 (t, 1H, H8); 7.58 (t, 1H, H8); 7.85, (d, 1H, H9); 7.91 (d, 1H, H6); 8.26 (s, 1H, H5) 
8.28 (s, 1H, H10); 8.61 (s, 1H, H4). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 10.68 (C1); 18.85 (C11); 20.83, 22.70 (C14); 
24.09 (C2); 31.21 (C13); 51.51, 51.68 (PTA); 52.09-52.27 (C3); 68.81, 72.32, 72.39 (PTA); 
86.34,87.03,87.59, 92.55 (C12); 119.91 (C20); 121.83 (C19); 123.14 (C17); 124.72 (C7); 125.97 
(C9); 128.20 (C8); 129.02 (C6); 129.90 (C5); 130.74 (C15); 134.91 (C18); 138.16 (C10); 146.02 
(C16); 174.47 (C4). Melting point: 164-168oC. 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -39.96 (PTA); septet; -144.19 (PF6). 
Elemental Analysis (%): Calc. For C30H40F6N4P2Ru (733.68): C, 49.11; H, 5.50; N, 7.64; 
Found: C, 47.96; H, 6.03; N, 5.41. MS (EI, m/z): 429.05 [M-(PF6+PTA)]+. 
 
3.2: Orange-yellow solid. Yield = 0.122 g (47%). IR: (KBr pellets), ν/cm-1: 1607 (C=N), 843 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.15 (t, 3H, H1); 1.91 (s, 15H, Cp*); 




1.98 (m, 2H, H2); 3.97 (t, 2H H3) 3.68, 4.11, 4.27, 4.34 (d ,12H, PTA); 7.51, 7.63 (t, 2H, 
H7,H8); 8.01, 8.03 (d, 2H, H6,H9); 8.07 (s, 1H, H5); 8.36 (s, 1H, H10); 8.73 (s, 1H, H4).  
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 9.01 (Cp*); 10.66 (C1); 23.73 (C2); 49.77, 
49.92 (PTA); 63.95 (C3); 72.30, 72.36 (PTA); 125.34 (C7); 126.44 (C9); 128.47 (C8); 129.08 
(C6); 130.93 (C11); 131.07 (C13); 134.64 (C14); 134.68 (C5); 134.97 (C12); 135.54 (C10); 
174.59 (C4). Melting point: 240-242oC.  
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = doublet; -44.97 (PTA); septet; -144.24 (PF6). 
Elemental Analysis (%): Calc. For C30H41F6N4P2Rh (736.53): C, 48.92; H, 5.61; N, 7.61; 
Found: C, 48.25; H, 6.58; N, 7.16. MS (EI, m/z): 434.12 [M-(PF6+PTA)]+. 
 
3.3: Light yellow solid. Yield = 0.102 g (34%). IR: (KBr pellets), ν/cm-1: 1602 (C=N), 842 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.16 (t, 3H, H1); 2.00 (s, 15H, Cp*); 
2.05 (sex, 2H, H2); 3.65 (d, 3H PTA); 4.04 (m, 2H, H3); 4.08, 4.22, 4.36 (d, 9H, PTA); 7.49, 
7.60 (t, 2H, H7,H8); 7.95, 7.98 (d, 2H, H6,H9); 8.08 (s, 1H, H5); 8.40 (s, 1H, H10); 8.85 (s, 1H, 
H4).  
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.71 (Cp*); 10.45 (C1); 23.76 (C2); 48.60, 
48.82 (PTA); 65.94 (C3); 72.40, 72.47 (PTA); 124.93 (C7); 126.38 (C9); 128.52 (C8); 129.22 
(C6); 130.98 (C10); 130.61 (C11); 133.65 (C14); 133.68 (C5); 136.29 (C13); 147.10 (C12); 
177.44 (C4). Melting point: 186-188oC .  
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -79.47 (PTA); septet; -144.22 (PF6). 
Elemental Analysis (%): Calc. For C30H41F6N4IrP2 (825.84): C, 43.63; H, 5.00; N, 6.78; 
Found: C, 42.90; H, 5.26; N, 5.96. MS (EI, m/z): 524.19 [M-(PF6+PTA)]+. 
 
 




5.3.2 General synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) 
naphthaldimine G1 metallodendrimers 3.4, 3.5 & 3.6. 
The G1 naphthaldimine dendritic ligand (3.4: 0.101 g, 0.116 mmol; 3.5: 0.0693 g, 0.0797 
mmol; 3.6: 0.0145 g, 0.0167 mmol) and sodium acetate (3.4: 0.0394 g, 0.480 mmol; 3.5: 
0.0260 g, 0.317 mmol; 3.6: 0.0056 g, 0.0683 mmol) was suspended in methanol or ethanol 
(20.0 mL) followed by the addition of the [Ru(p-cymene)Cl2]2 (0.143 g, 0.233 mmol), [Rh(η-
C5Me5)Cl2]2 (0.0990 g, 0.160 mmol) or  [Ir(η-C5Me5)Cl2]2 (0.0266 g, 0.0334 mmol) dimer.  
The reaction mixture was allowed to stir overnight after which it was filtered through Celite. 
The PTA (3.4: 0.0761 g, 0.484 mmol; 3.5: 0.0489 g, 0.311 mmol; 3.6: 0.0110 g, 0.0700 
mmol) was added to the reaction mixture and allowed to stir for a further 30-40 minutes. The 
solvent was removed and the residue was dissolved in acetone and filtered through Celite. 
The solvent was removed again and a minimum amount of methanol was added followed by 
the addition of the NaPF6 (3.4: 0.0818 g, 0.487 mmol; 3.5: 0.0534 g, 0.318 mmol; 3.6: 
0.0119 g, 0.0708 mmol). This was stirred at 0oC for about 30-40 minutes, whereby a solid 
precipitated out, which was then filtered under vacuum, washing with cold ethanol and 
diethyl ether. The crude product was dissolved in acetone, filtered through Celite and 
repeated with DCM. The DCM was reduced and an excess of diethyl ether was added 
whereby a solid precipitated out of solution and filtered by gravity to give the desired product 
as a golden-brown (3.4), orange-yellow (3.5) or orange (3.6) solid. 
 
3.4: Golden-brown solid. Yield = 0.144 g (40%). IR: (KBr pellets), ν/cm-1: 1600 (C=N), 841 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 0.74 (s, 12H, H13); 0.97 (t, 4H, Hcore); 
1.18 (d, 24H, H16); 2.42 (br m, 20H, Hcore,H3,H4); 2.70 (sep, 4H, H15); 3.91 (br m, 8H, H5); 
4.32, 4.50 (d, 48H , PTA); 5.01 (br m, 4H, H14); 5.17 (br m, 4H, H14); 5.85 (br m, 8H, H14); 




7.29 (br m, 4H, H9); 7.46 (br t, 4H, H10); 8.07 (br m, 8H, H8,H11); 7.99 (br m, 4H, H7) 8.37 
(br m, 4H, H12); 8.72 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 18.21 (C13); 20.40 (C16); 22.86 (Ccore); 
30.15-31.00 (Ccore,C3,C4); 33.50 (C15); 51.50, 52.32 (PTA); 63.10 (C5); 72.33, 72.90 (PTA); 
79.73, 82.02, 88.36, 90.13 (C14); 123.66 (C9); 124.56 (C20); 126.18 (C8); 127.33 (C11); 
128.83 (C10); 129.17 (C7); 129.56 (C12); 130.45 (C17); 134.89 (C19); 137.05 (C18); 175.14 
(C6). 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -30.45 (PTA); septet; -144.14 (PF6). 
Elemental Analysis (%): Calc. For C124H164F24N18P8Ru4 (3014.81): C, 49.40; H, 5.48; N, 
8.36; Found: C, 47.29; H, 5.76; N, 5.36. MS (HR-ESI, m/z): 626.16 [M-4PF6+4H2O]4+. 
 
3.5: Orange-yellow solid. Yield = 0.0138 g (7%). IR: (KBr pellets), ν/cm-1: 1613 (C=N), 844 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.60 (m, 4H, Hcore); 1.72 (s, 60H, Cp*); 
2.30 (br m, 8H, H4) 3.20 (br m, 12H, Hcore,H3); 3.66-3.70 (m, 12H, PTA); 3.96 (br m, 8H, 
H5); 4.03-4.31 (m, 36H, PTA); 7.49 (br m, 4H, H11); 7.62 (br m, 4H, H9); 7.94-8.14 (br m, 
8H, H7,H8); 8.33 (br m, 4H, H10); 8.58 (br m, 4H, H12); 8.71 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 9.09 (Cp*); 9.60 (Ccore); 24.01 (C4); 
49.79,49.95 (PTA); 50.81-51.23 (Ccore,C3); 59.22 (C5); 72.33 (PTA); 123.92 (C11); 125.31 
(C14); 126.43 (C8); 127.28 (C9); 128.47 (C15); 128.80 (C16); 129.14 (C7); 130.54 (C13); 
131.06 (C12); 133.76 (C10); 174.85 (C6). Melting point: 201-204oC. 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = doublet; -44.32 (PTA); septet; -144.14 (PF6). 




Elemental Analysis (%): Calc. For C124H168F24N18P8Rh4 (3026.20): C, 49.22; H, 5.60; N, 
8.33; Found: C, 47.23; H, 6.70; N, 5.94. MS (HR-ESI, m/z): 533.22 [M-4PF6-2PTA)]4+. 
 
Orange solid. Yield = 0.0300 g (53%). IR: (KBr pellets), ν/cm-1: 1604 (C=N), 843 (s, P–F). 
1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.30 (m, 4H, Hcore); 1.75 (s, 60H, Cp*); 2.20 (br 
m, 8H, H4); 3.66 (br m, 12H, Hcore,H3); 4.04 (br m, 8H, H5); 4.25, 4.49, 4.64 (d, 48H, PTA); 
7.51 (br m, 4H, H8); 7.61 (br m, 4H, H7); 7.92 (br m, 8H, H9,H10); 8.13 (br m, 8H, H11); 8.38 
(br m, 4H, H12); 8.81 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.81 (Cp*); 9.32 (Ccore); 28.01 (C4); 48.88, 
49.28 (Ccore,C3); 50.91 (C5); 51.47 (PTA); 72.40 (PTA); 124.93 (C8); 122.34 (C16); 126.38 
(C11); 127.73 (C15); 128.55 (C7); 129.27 (C10); 129.55 (C9); 131.09 (C13); 133.66 (C12); 
136.27 (C14); 177.50 (C6). Melting point: 233-235oC. 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -79.09 (PTA); septet; -144.12 (PF6). 
Elemental Analysis (%): Calc. For C124H168F24Ir4N18P8 (3383.44): C, 44.02; H, 5.00; N, 
7.45; Found: C, 41.38; H, 5.61; N, 5.84. MS (HR-ESI, m/z): 1391.44 [M-2PF6-2PTA)]4+. 
 
5.3.3 General synthesis of the cationic ruthenium(II), rhodium(III) and iridium(III) 
naphthaldimine G2 metallodendrimers 3.7, 3.8 & 3.9. 
The G2 naphthaldimine dendritic ligand (3.7: 0.0773 g, 0.0412 mmol; 3.8: 0.103 g, 0.0550 
mmol; 3.9: 0.110 g, 0.0584 mmol) and sodium acetate (3.7: 0.0271 g, 0.330 mmol; 3.8: 
0.0371 g, 0.452 mmol; 3.9: 0.0385 g, 0.469 mmol) was suspended in methanol or ethanol 




(20.0 mL) followed by the addition of the [Ru(p-cymene)Cl2]2 (0.101 g, 0.165 mmol), [Rh(η-
C5Me5)Cl2]2 (0.135 g, 0.219 mmol) or  [Ir(η-C5Me5)Cl2]2 (0.186 g, 0.234 mmol) dimer. The 
reaction mixture was allowed to stir for 24-48 hours after which it was filtered through Celite. 
PTA (3.7: 0.0518 g, 0.330 mmol; 3.8: 0.0716 g, 0.456 mmol; 3.9: 0.0739 g, 0.470 mmol) 
was added to the reaction mixture and allowed to stir for a further 30-40 minutes. The solvent 
was removed, the residue dissolved in a minimum amount of acetone and filtered through 
Celite. The solvent was removed once again, a minimum amount of methanol was added 
followed by the addition of NaPF6 (3.7: 0.0554 g, 0.330 mmol; 3.8: 0.0775 g, 0.461 mmol; 
3.9: 0.0792 g, 0.472 mmol). This was stirred at 0oC for about 30-40 minutes, whereby a solid 
precipitated out, which was then filtered under vacuum, washing with cold methanol and 
diethyl ether. The crude product was dissolved in acetone, filtered through Celite and 
repeated with DCM. The DCM was then reduced and an excess of diethyl ether was added 
whereby a solid precipitated out and filtered under vacuum to yield a golden brown (3.7), 
orange-yellow (3.8) or yellow (3.9) solid. 
 
3.7: Golden brown solid. Yield = 0.100 g (39%). IR: (KBr pellets), ν/cm-1: 1603 (C=N), 835 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 0.71 (br m, 4H, Hcore); 0.99 (br m, 32H, 
H4,H16); 1.46 (br m, 48H, H19); 1.84 (br m, 16H, H7); 2.10 (br m, 8H, H18); 2.44 (br m, 32H, 
Hcore ,H3, H5, H6); 4.13 (br m, 16H, H8); 4.32, 4.43, 4.57 (d, 96H, PTA); 4.95 (br m, 8H, 
H17); 5.19 (br m, 8H, H17); 5.86 (br m, 16H, H17); 7.54 (br m, 8H, H12,H13); 7.78 (br m, 4H, 
H14); 7.94 (br m, 8H, H10,H11); 8.32 (br m, 4H, H15); 8.57 (br s, 8H, H9). 




13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 18.42 (C16); 20.42 (Ccore); 21.38 (C19); 
22.88 (C4); 30.78 (C7); 42.17 (C18); 51.42 (Ccore); 51.89 (C3); 52.19 (C5); 52.72 (C6); 58.60-
72.86 (PTA, C8); 90.12, 92.03, 94.72 (C17); 123.60 (C12); 123.75 (C13); 126.21 (C14); 126.34 
(C25); 127.26 (C10); 127.73 (C11); 128.84 (C15); 124.80 (C23); 130.38 (C21); 133.67 (C22); 
134.75 (C20); 136.51 (C24); 175.90 (C9). Melting point: 190-193oC. 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -36.68 (PTA); septet; -144.11 (PF6). 
Elemental Analysis (%): Calc. For C256H344F48N38P16Ru8 (6169.85): C, 49.84; H, 5.62; N, 
8.63; Found: C, 51.96; H, 6.46; N, 8.58. MS (HR-ESI, m/z): 585.14 [M-8PF6-2PTA]8+. 
 
3.8: Orange-yellow solid. Yield = 0.158 g (50%). IR: (KBr pellets), ν/cm-1: 1609 (C=N), 843 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.58 (br m, 4H, Hcore); 1.70 (s, 120H, 
Cp*); 2.10 (br m, 24H, H4,H7); 3.00 (br m, 28H, Hcore,H3,H6); 3.66 (br d, 32H, PTA); 3.72 
(br m, 8H, H5); 4.03 (br m, 16H, H8); 4.10, 4.28, 4.31 (d, 64H, PTA); 7.45 (br m, 8H, H12); 
7.61 (br m, 8H, H13); 7.88 (br m, 8H, H11); 7.98 (m, 8H, H14); 8.02 (br m, 8H, H10); 8.33 (br 
m, 8H, H15); 8.71 (br s, 8H, H9). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.66 (Ccore); 9.12 (Cp*); 27.29-27.63 
(C4,C7); 49.83, 49.92 (PTA); 50.69 (C5); 52.35 (Ccore); 54.03 (C3); 60.21 (C8); 72.33 (PTA); 




123.24 (C15); 125.30 (C13); 126.44 (C14); 127.17 (C18); 128.04 (C19); 128.47 (C12); 129.12 
(C11); 131.01 (C16); 135.49 (C17); 174.70 (C9). Melting point: 211-214oC. 
31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = doublet; -44.34 (PTA); septet; -144.15 (PF6). 
Elemental Analysis (%): Calc. For C256H352F48N38P16Rh8 (6192.63): C, 49.65; H, 5.73; N, 
8.60; Found: C, 48.70; H, 6.56.; N, 6.45. MS (HR-ESI, m/z): 587.15 [M-8PF6-2PTA]8+. 
 
3.9: Yellow solid. Yield = 0.117 g (30%). IR: (KBr pellets), ν/cm-1: 1602 (C=N), 843 (s, P–
F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.64 (m, 4H, Hcore); 1.96 (s, 120H, Cp*); 2.39 
(br m, 20H, Hcore,H3,H4); 3.09 (br m, 32H, H6,H7); 3.58 (br m, 24H, PTA); 3.66 (br m, 8H, 
H5); 4.01 (br m, 16H, H8); 4.33, 4.40 (br m, 72H, PTA); 7.45 (br m, 8H, H14); 7.58 (br m, 
8H, H11); 7.86 (br m, 8H, H13); 7.96 (br m, 8H, H12); 8.03 (br m, 8H, H10); 8.37 (br m, 8H, 
H15); 8.84 (br s, 8H, H9). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.81 (Cp*); 9.32 (Ccore); 22.64 (Ccore); 
23.86 (C3); 25.61 (C4); 48.64, 48.84 (PTA); 50.37 (C5); 51.36 (C6); 51.47 (C7); 62.35 (C8); 
72.36 (PTA); 124.91 (C14); 126.38 (C12); 128.53 (C11); 129.26 (C13); 130.43 (C16); 131.17 
(C15); 133.69 (C10); 137.25 (C17); 177.45 (C9). Melting point: 247-250oC. 




31P{1H}-NMR (MHz, acetone-d6) δ (ppm) = singlet; -79.09 (PTA); septet; -144.09 (PF6). 
Elemental Analysis (%): Calc. For C256H352F48Ir8N38P16 (6907.11): C, 44.52; H, 5.14; N, 
7.71; Found: C, 41.81; H, 5.22; N, 5.85. MS (HR-ESI, m/z): 1215.49 [M-4PF6-PTA]4+. 
 
5.4 Synthesis of the cationic ferrocenyl-pyridine heteronuclear complexes  
 
5.4.1 General synthesis of the cationic rhodium(III) & iridium(III)-ferrocenyl 
naphthaldimine mononuclear complexes 3.10 & 3.11. 
The naphthaldimine monomeric ligand (3.10: 0.0224 g, 0.114 mmol; 3.11: 0.0259 g, 0.131 
mmol) and sodium acetate (3.10: 0.0095 g, 0.116 mmol; 3.11: 0.0110 g, 0.134 mmol) were 
suspended in methanol (15.0 mL) followed by the addition of the [Rh(η-C5Me5)Cl2]2 (0.0359 
g, 0.0581 mmol) or [Ir(η-C5Me5)Cl2]2 (0.0525 g, 0.0659 mmol) dimer. The reaction mixture 
was allowed to stir for 2 hours, after which it was filtered through Celite. The 4-
ferrocenylpyridine (3.10: 0.0306 g, 0.116 mmol; 3.11: 0.0347 g, 0.132 mmol) was added to 
the reaction mixture and allowed to stir for a further 30 minutes. The solvent was removed, 
the residue dissolved in acetone and filtered through Celite. The solvent was once again 
removed and the residue dissolved in a minimum amount of methanol, followed by the 
addition of the NaPF6 (3.10: 0.0197 g, 0.117 mmol; 3.11: 0.0229 g, 0.136 mmol). This was 
stirred at 0oC for about 30-60 minutes, whereby a solid precipitated out, which was then 
filtered under vacuum, washing with cold methanol and diethyl ether to yield the desired 
product as dark red solids. 
 




3.10: Dark red solid. Yield = 0.0273 g (28%). IR: (KBr pellets), ν/cm-1: 1611 (C=N), 841 (s, 
P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.11 (t, 3H, H1); 1.77 (s, 15H, Cp*); 2.07 
(m, 2H, H2); 4.00 (s, 5H, H15); 4.36 (t, 2H, H3); 4.55 (m, 2H, H14); 4.89 (m, 2H, H13); 7.49 (t, 
1H, H7); 7.52 (d, 2H, H12); 7.64 (t, 1H,  H8); 7.92 (d, 1H,  H6); 8.09 (d, 1H,  H9); 8.17 (s, 1H, 
H5); 8.36 (d, 2H,  H11); 8.47 (s, 1H,  H10); 8.74 (s, 1H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.44 (Cp*); 10.49 (C1); 23.00 (C2); 61.35 
(C3); 67.35, 67.61 (C13); 70.15 (C15); 71.54 (C14); 122.53 (C12); 124.95 (C7); 125.10 (C11); 
126.79 (C9); 127.98 (C8); 129.02 (C6); 129.44 (C5); 131.06 (C16); 133.00 (C10); 136.29 (C17); 
147.30 (C19); 148.23 (C18); 152.04 (C20); 152.81 (C21); 175.30 (C4). Melting point: 239-
243oC. 
Elemental Analysis (%): Calc. For C39H42F6FeN2PRh (842.49): C, 55.60; H, 5.02; N, 3.33; 
Found: C, 55.00; H, 5.96; N, 2.72. MS (EI, m/z): 295.05 [M-PF6-(Fc-py)-Cp*]2+. 
 
3.11: Dark red solid. Yield = 0.0455 g (38%). IR: (KBr pellets), ν/cm-1: 1611 (C=N), 841 (s, 
P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.11 (t, 3H, H1); 1.79 (s, 15H, Cp*); 2.05 
(m, 2H, H2); 3.98 (s, 5H, H15); 4.43 (t, 2H, H3); 4.55 (s, 2H, H14); 4.88 (s, 2H, H13); 7.43 (d, 
2H, H12); 7.47 (t, 1H, H7); 7.60 (t, 1H,  H8); 7.88 (d, 1H,  H6); 8.04 (d, 1H,  H9); 8.21 (s, 1H, 
H5); 8.35 (s, 1H,  H10); 8.38 (d, 2H,  H11); 8.91 (s, 1H, H6). 
13C NMR (100 MHz, acetone-d6) δ (ppm) = 8.16 (Cp*); 10.38 (C1); 23.01 (C2); 62.79 (C3); 
67.38, 67.68 (C13); 70.20 (C15); 71.70, 71.73 (C14); 122.88 (C12); 124.66 (C7); 125.00 (C11); 
126.72 (C9); 128.08 (C8); 129.13 (C6); 129.75 (C5); 130.71 (C16); 131.95 (C10); 137.06 (C17); 
147.88 (C19); 149.00 (C18); 152.94 (C4); 153.54 (C20); 177.46 (C21). Melting point: 267-
268oC. 




Elemental Analysis (%): Calc. for C39H42F6FeIrN2P (931.80 g/mol): C, 50.27; H, 4.54; N, 
3.01; Found: C, 50.00; H, 4.59; N, 2.65. MS (EI, m/z): 519.10 [M-PF6-(Fc-py)]+.  
 
5.4.2 General synthesis of the cationic rhodium(III) and iridium(III)-ferrocenyl 
naphthaldimine G1 metallodendrimers 3.12 & 3.13 
The naphthaldimine G1 dendritic ligand (3.12: 0.0106 g, 0.0122 mmol; 3.13: 0.0137 g, 
0.0158 mmol) and sodium acetate (3.12: 0.0044 g, 0.0536 mmol; 3.13: 0.0052 g, 0.0634 
mmol) were suspended in methanol (10.0 mL) followed by the addition of the [Rh(η-
C5Me5)Cl2]2 (0.0155 g, 0.0251 mmol) or [Ir(η-C5Me5)Cl2]2 (0.0253 g, 0.0318 mmol). The 
reaction mixture was allowed to stir overnight, after which it was filtered through Celite. The 
4-ferrocenylpyridine (3.12: 0.0130 g, 0.0494 mmol; 3.13: 0.0165 g, 0.0627 mmol) was added 
to the reaction mixture and allowed to stir for a further 30-60 minutes. The solvent was 
removed, the residue dissolved in acetone and filtered through Celite. The solvent was once 
again removed and the residue dissolved in a minimum amount of methanol, followed by the 
addition of the NaPF6 (3.12: 0.00840 g, 0.0500 mmol; 3.13: 0.0112 g, 0.0667 mmol). This 
was stirred at 0oC for about 1 hour, whereby a solid precipitated out, which was then filtered 
under vacuum, washing with cold methanol and diethyl ether to yield the desired products as 
orange-red solids. 
 
3.12: Orange-red solid. Yield = 0.0100 g (24%). IR: (KBr pellets), ν/cm-1: 1608 (C=N), 831 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.11 (m, 4H, Hcore); 1.68 (s, 60H, Cp*); 
1.82 (m, 8H, H4); 3.77, 3.85 (m, 12H, Hcore,H3); 3.94 (m, 20H, H17); 4.46 (m, 16H, H5,H16); 




4.80 (m, 8H, H15); 7.40 (m, 12H, H9,H14); 7.57 (m, 4H, H10); 7.76 (m, 8H,  H8,H11); 8.02 (m, 
8H,  H7,H12); 8.29 (m, 8H,  H13); 8.74 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.42 (Cp*); 8.84 (Ccore); 25.60 (C4); 51.26 
(Ccore); 52.57 (C3); 67.82 (C15); 70.46 (C17); 71.78 (C16); 71.94 (C5); 122.30-124.02 (C20, 
C21, C22 C23); 125.09 (C9); 126.92 (C14); 127.95 (C7); 128.15 (C10); 129.20 (C12); 129.58 
(C11); 129.85 (C8); 131.18 (C18); 133.06 (C13); 136.40 (C19); 174.99 (C6). Melting point: 
204-206oC. 
Elemental Analysis (%): Calc. For C160H172F24Fe4N10P4Rh4 (3450.06): C, 55.70; H, 5.02; N, 
4.06; Found: C, 53.40; H, 5.89; N, 3.56. MS (ESI-HR, m/z): 653.85 [M-4PF6-(Fc-py)]4+. 
 
3.13: Orange-red solid. Yield = 0.0266 g (44%). IR: (KBr pellets), ν/cm-1: 1610 (C=N), 835 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.46 (m, 4H, Hcore); 1.68 (s, 60H, Cp*); 
2.25 (m, 8H, H4); 3.80, 3.86 (m, 12H, Hcore,H3); 3.97 (m, 20H, H17); 4.44, 4.53 (m, 16H, 
H5,H16); 4.83 (m, 8H, H15); 7.47 (m, 12H, H9,H14); 7.62 (m, 4H, H10); 7.80, 7.88 (m, 8H,  
H8,H11); 8.07 (m, 8H,  H7,H12); 8.28 (m, 8H,  H13); 8.55 (br s, 4H, H6). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.30 (Cp*); 8.81 (Ccore); 25.57 (C4); 51.28 
(Ccore); 51.41 (C3); 67.30 (C15); 71.03 (C17); 71.54 (C16); 71.80 (C5); 121.48-122.78 (C20, 
C21, C22 C23); 123.23 (C9); 124.41 (C14); 126.08 (C10); 126.51 (C12); 127.98 (C11); 128.72 
(C8); 129.08 (C7); 129.914 (C13); 132.14 (C18); 152.65 (C6); 177.18 (C19). Melting point: 
215-217oC. 




Elemental Analysis (%): Calc. For C160H172F24Fe4Ir4N10P4 (3807.30): C, 50.48; H, 4.55; N, 
3.68; Found: C, 47.28; H, 5.31; N, 3.02. MS (ESI-HR, m/z): 1058.37 [M-3PF6+MeOH]3+. 
5.4.3 General synthesis of the cationic rhodium(III) and iridium(III)-ferrocenyl 
naphthaldimine G2 metallodendrimers 3.14 & 3.15. 
The naphthaldimine G2 dendritic ligand (3.14: 0.0250 g, 0.0133 mmol; 3.15: 0.0466 g, 
0.0248 mmol) and sodium acetate (3.14: 0.0090 g, 0.110 mmol; 3.15: 0.0165 g, 0.201 mmol) 
was suspended in methanol (20.0 mL) followed by the addition of the [Rh(η-C5Me5)Cl2]2 
(0.0333 g, 0.0539 mmol) or [Ir(η-C5Me5)Cl2]2 (0.0798 g, 0.0100 mmol) dimer. The reaction 
mixture was allowed to stir for 24-48 hours, after which it was filtered through Celite. The 4-
ferrocenylpyridine (3.14: 0.0280 g, 0.106 mmol; 3.15: 0.0532 g, 0.0202 mmol) was added to 
the reaction mixture and allowed to stir for a further 30-60 minutes. The solvent was 
removed, the residue dissolved in acetone and filtered by gravity. The solvent was once again 
removed and the residue dissolved in a minimum amount of methanol, followed by the 
addition of the NaPF6 (3.14: 0.0186 g, 0.111 mmol; 3.15: 0.0343 g, 0.204 mmol). This was 
stirred at 0oC for about 1 hour, whereby a solid precipitated out, which was then filtered 
under vacuum, washing with cold methanol and diethyl ether to yield the desired products as 
dark orange solids. 
 




3.14: Dark orange solid. Yield = 0.0475 g (51%). IR: (KBr pellets), ν/cm-1: 1608 (C=N), 835 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.30 (m, 4H, Hcore); 1.43 (m, 8H, H4); 
1.68 (br s, 120H, Cp*); 2.09 (m, 16H, H7); 2.60-3.06 (m, 36H, Hcore,H3,H5,H6); 3.87 (m, 
16H, H8); 3.97 (m, 40H, H20); 4.54 (br d, 16H, H19); 4.81 (br d, 16H, H18); 7.18, 7.47 (m, 
24H, H11,H12); 7.72 (m, 16H, H17); 7.83 (m, 16H,  H13,H14); 8.05, 8.12 (m, 16H,  H10,H15); 
8.36 (m, 16H,  H16); 8.49 (br s, 8H, H9). 
13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 7.91 (Ccore); 8.37 (Cp*); 14.57 (C4); 29.54 
(C7); 51.11-59.48 (Ccore,C3,C5,C6); 67.27 (C18); 69.97 (C20); 70.95 (C8); 71.41 (C19); 123.76, 
123.93 (C23,C24); 124.74 (C12); 126.16 (C17); 127.81 (C10); 128.95 (C15); 130.32 (C11); 
130.86 (C21); 132.70 (C13); 133.48.25 (C16); 134.17 (C26); 135.38 (C25); 136.13 (C22); 145.92 
(C14); 174.96 (C9). Melting point: 196-198oC. 
Elemental Analysis (%): Calc. For C328H360F48Fe8N22P8Rh8 (7040.32): C, 55.96; H, 5.15; N, 
4.38; Found: C, 53.05; H, 5.02; N, 3.92. MS (ESI-HR, m/z): 782.29 [M-8PF6+HCO2H]8+.  
 
3.15: Dark orange solid. Yield = 0.0800 g (42%). IR: (KBr pellets), ν/cm-1: 1610 (C=N), 836 
(s, P–F). 1H NMR (400 MHz, acetone-d6) δ (ppm) = 1.20 (m, 4H, H\core); 1.30 (m, 8H, H4); 
1.71 (br s, 120H, Cp*); 1.82 (m, 16H, H7); 2.91 (m, 36H, Hcore,H3,H5,H6); 3.94 (m, 40H, 
H20); 4.46 (m, 32H, H8,H19); 4.80 (m, 16H, H18); 7.42 (m, 24H, H12,H17); 7.57 (m, 8H, H13); 
7.79 (m, 16H,  H11,H14); 8.02 (m, 16H,  H10,H15); 8.29 (m, 16H,  H16); 8.74 (br s, 8H, H9). 




13C{1H}-NMR (100 MHz, acetone-d6) δ (ppm) = 8.18 (Cp*); 8.62 (Ccore); 27.85 (C4); 32.70 
(C7); 51.00 (Ccore); 52.66 (C3); 57.50 (C5); 59.12 (C6); 67.71 (C18); 70.25 (C20); 71.68, 71.87 
(C8,C19); 122.90 (C12); 124.57 (C17); 126.25 (C10); 126.73 (C15); 128.13 (C11); 129.17 (C14); 
130.05 (C13); 131.80 (C21); 135.25 (C26); 137.04 (C25); 147.88 (C22); 153.21 (C9); 176.96 
(C16). Melting point: 200-202oC. 
Elemental Analysis (%): Calc. For C328H360F48Fe8Ir8N22P8 (7754.82): C, 50.86; H, 4.68; N, 






















5.5 X-ray diffraction studies 
X-ray quality crystals of 2.7, 2.8, 2.11 and 2.12 were mounted on a STOE Image Plate 
Diffraction system equipped with a ɸ circle goniometer, using Mo-Kα graphite 
monochromated radiation (λ = 0.71073 Å) with ɸ range 0–200°, increment of 1.2 and 0.8° 
respectively, 2θ range from 3.0–56°, Dmax − Dmin = 12.45–0.81 Å. The structures were 
solved by direct methods using the program SHELXS-97.4 Refinement and all further 
calculations were carried out using SHELXL-97.4 In all the structures, the H- atoms were 
included in calculated positions and treated as riding atoms using the SHELXL default 
parameters and the non H-atoms were refined anisotropically, using weighted full-matrix 
least-square on F2. Crystallographic details of complexes were drawn with ORTEP5 and/or 
MERCURY6. 
 
5.6 In vitro anticancer activity studies 
A2780 (cisplatin-sensitive human ovarian cancer cell line), A2780cisR (cisplatin-resistant 
human ovarian cancer cell line) and HEK (Human Embryonic Kidney 293) were obtained 
from the European Collection of Cell Cultures (Salisbury, U.K.). The A2780 and A2780cisR 
cells were grown routinely in two 50 mL culture flasks in regular RPMI-1640 medium 
supplemented with 10% heat-inactivated foetal bovine/calf serum (FCS) and antibiotics, 100 
µmL penicillin and 100 µm streptomycin. While HEK cells were grown with DMEM 
medium, with 10% foetal calf serum (FCS) and antibiotics at 37 °C and 5% CO2. One day 
before experiments, cells were seeded into 96-well plates as monolayers with 100 μL of cell 
solution (approximately 20 000 cells) per well and preincubated for 24 h in medium 
supplemented with 10% FCS. The compounds were prepared as DMSO solutions and then 
dissolved in the PBS buffer culture and serially diluted to the appropriate concentration, to 
give a final DMSO concentration of 0.5%.  A 100 μL portion of the drug solution was added 
to each well, and the plates were incubated for another 72 h at 37°C. Subsequently, MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (5 mg/mL solution) was 
added to the cells and the plates were incubated for a further 2 h. The MTT assay was used to 
quantify the viability of cells. The culture medium was aspirated, and the purple formazan 
crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in 
DMSO. The optical density, directly proportional to the number of surviving cells, was 
quantified at 590 nm using a multiwell plate reader, and the fraction of surviving cells was 




calculated from the absorbance of untreated control cells at 590 nm. Mean and standard 
deviation for the triplicate wells were reported. Each compound was tested at various 
maximum concentrations ranging from 30-300µM. 
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A series of monomeric, first- and second- generation end-group modified C,N-chelating 
bidentate poly(propylenimine) dendritic ligands were prepared. These monomeric and 
dendritic ligands were fully characterized using a range of spectroscopic and analytical 
techniques. These ligands were based on a naphthaldimine and benzaldimine Schiff base 
ligand.  
 
The synthesized monomeric and dendritic ligands were reacted with ruthenium(II), 
rhodium(III) and iridium(III) precursors to afford air-stable naphthaldimine and semi-air-
stable benzaldimine chelating bidentate C,N-donor ruthenium(II), rhodium(III) and 
iridium(III) cyclometalated multinuclear metallodendrimers, which were characterised using 
analytical and spectroscopic methods. 
 
The naphthaldimine neutral complexes underwent reactivity studies with PTA to afford air-
stable naphthaldimine chelating bidentate C,N-donor ruthenium(II), rhodium(III) and 
iridium(III) cyclometalated multinuclear metallodendrimers. A series of heterometallic 
complexes were synthesized by replacing the chloride ligand with a nitrogen-donor 
ferrocenyl-pyridine moiety to afford air-stable naphthaldimine chelating bidentate C,N-donor 
rhodium(III) and iridium(III) cyclometalated heterometallic metallodendrimers. These 
cationic complexes were characterised using analytical and spectroscopic methods. 
 
The molecular structures of the mononuclear neutral ruthenium(II) and rhodium(III) 
naphthaldimine and rhodium(III) and iridium(III) benzaldimine complexes were determined 
using single crystal X-ray crystallography which confirmed the pseudo-tetrahedral “piano-
stool” geometry around the metal centres. 
 
Subsequent to the synthesis of the neutral and cationic homometallic metallodendrimers, their 
cytotoxicities against A2780 and A2780cisR human ovarian cell lines, as well as the non-
cancerous HEK and KMST-6 cells, were evaluated. The second generation naphthaldimine 
cationic C,N-chelating bidentate octanuclear complexes showed the highest antiprolific 
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activity against both cell lines. Hence, this study has shown a definite correlation between the 
size of the metallodendrimer and cytotoxicity, as well as charge and cytotoxicity. 
 
6.2 Future Outlook 
 
From the obtained results, the project has shown great outcomes in the field of ruthenium(II), 
rhodium(III) and iridium(III) cyclometalated metallodendrimers as biological agents. 
Through functionalization of the poly(propylenimine) dendritic scaffold with ruthenium(II), 
rhodium(III) and iridium(III) moieties there was an increase in biological activity, as well as 
specificity. The benzaldimine complexes proved to be less stable and showed inconclusive 
antiproliferative results. Hence, the naphthaldimine complexes only underwent reactivity 
studies with PTA, as well as displacement with a ferrocenyl-pyridine moiety, to produce 
cationic complexes. Therefore incorporation of water soluble moieties, such as PTA or may 
increase the water solubility and therefore may result in lower IC50 values.1 Introducing a 
more water soluble dendritic scaffold, such as PAMAM, may also play a role in increasing 
the antiproliferative activity of these complexes.2 
Another alteration that could be changed is the ring-moieties attached to the metal centre. For 
example a more extended Cp* ring, such as (η5-C5Me4C6H4C6H5), could be incorporated into 
the rhodium(III) and iridium(III) complexes to improve IC50 values by possible DNA 
intercalation.3 In addition to this an HMB arene ring can be incorporated onto the 
ruthenium(II) complexes in order to improve lipophilicity.4 
 
In order to confirm the possible drug targets and the mode of action of these ruthenium(II), 
rhodium(III) and iridium(III) metallodendrimers, further studies need to be undertaken. These 
studies could include DNA-binding studies, imaging studies (for example fluorescent studies 
of iridium complexes) and cell uptake studies. 
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